Characterising gadofosveset for use in quantitative MRI studies by Richardson, Owen Carl
I 
Characterising gadofosveset for use  
in quantitative MRI studies 
 
 
Owen Carl Richardson 
 
Submitted in accordance with the requirements for the degree of 
Doctor of Philosophy (PhD) 
 
The University of Leeds 






The candidate confirms that the work submitted is his own, except where work 
which has formed part of jointly-authored publications has been included. The 
contribution of the candidate and the other authors to this work has been 
explicitly indicated below. The candidate confirms that appropriate credit has 
been given within the thesis where reference has been made to the work of 
others.  
 
Chapter 6 is based on the jointly authored publication:  
RICHARDSON, O. C., M. L. J. SCOTT, S. F. TANNER, J. C. WATERTON and 
D. L. BUCKLEY. 2012. Overcoming the low relaxivity of gadofosveset at high 
field with spin locking. Magnetic Resonance in Medicine, 68(4), pp.1234-1238. 
All authors contributed to the concept; OCR wrote the majority of the text, with 
some contribution from other authors; OCR acquired all data at 0.47 T and was 
assisted by MLJS in data acquisition at 4.7 T; OCR carried out all data analysis 
and generated plots; all authors contributed to conclusions. 
 
This copy has been supplied on the understanding that it is copyright material 
and that no quotation from the thesis may be published without proper 
acknowledgement. 
© 2013 The University of Leeds and Owen Carl Richardson 
III 
Acknowledgements 
This project was carried out with the aid of a BBSRC industrial CASE award 
(BB/G017220/1), in partnership with Astrazeneca. I am grateful to my sponsors 
for their financial support. For assistance with data acquisition I would also like 
to acknowledge the support of: Neil Woodhouse, José Ulloa, Hervé Barjat, and 
co-workers, AstaZeneca (Image acquisition, Chapters 4, 6, 7); Chris Smith, 
Steve Hill, AstraZeneca (ICP-MS, Chapter 5); Peter Wright (formerly of 
LMBRU), Arshad Zaman, Leeds Teaching Hospitals NHS Trust (Image 
acquisition, Chapters 4, 7); Peter Hine, Michael Ries, University of Leeds 
Department of Physics (NMR measurements, Chapters 4, 6); Octavia Bane, 
Tim Carroll, Michael Markl, Northwestern University, Chicago, imaging 
volunteers and staff at Northwestern Memorial Hospital, Chicago (Image 
acquisition, Chapter 7); Thomas Oerther, Bruker BioSpin GmbH (Spin-locking 
imaging sequence, Chapter 6). For valuable advice, support and suggestions 
throughout the project, I would like to thank John Waterton at AstraZeneca. For 
first introducing me to the wonderful world of MRI, I am grateful to Sasha 
Radjenovic, John Ridgway, Sarah Bacon and Dan Wilson. For being an 
inspirational and helpful bunch of people to work with, I’d like to thank the other 
members of Medical Physics (and support staff) at Leeds, in particular fellow 
book-clubbers John Biglands and Dave Broadbent. 
 
Above all, I extend unreserved thanks to my fantastic supervision team, David 
Buckley, Steve Tanner, Marietta Scott and Steven Sourbron. I am particularly 
indebted to David, for the dedication he has shown to this project and the 
generosity he has displayed in giving his time and lending his experience. 
 
On a personal note I would like to thank my family for their support. In 
particular, I would like to thank my partner Sharon for allowing me to turn our 
lives upside down (temporarily, I promise!), and for everything else – especially 
for our daughter, Isabel. It is to Isabel I would like to dedicate this thesis; I hope 
that one day she understands what an inspiration she is to me. 
IV 
Abstract 
Background: Gadofosveset is a clinically approved gadolinium-based MRI 
contrast agent that displays altered pharmacokinetic properties due to its high 
albumin-binding affinity (around 90% binds at low concentration), although the 
improved effectiveness due to binding reduces as field strength increases. With 
the trend for increasing clinical magnetic field strengths, it is important that 
gadofosveset is fully characterised at higher fields. It may then be possible to 
utilise the macromolecular properties of bound gadofosveset in tracer kinetic 
modelling for assessment of functional parameters. 
Aims: This study aimed to characterise gadofosveset, in vitro, at relevant field 
strengths, develop a method for acquiring blood concentration measurements, 
and assess several novel techniques utilising the agent’s binding affinity. The 
study was extended to include gadoxetate and gadobenate, gadolinium agents 
with a lower albumin-binding affinity, to provide a broader view of the influence 
of albumin binding.  
Results: Relaxivities were calculated from in vitro measurements in the 
presence and absence of albumin, including bound relaxivity values at high 
field that have not previously been published. Extending the conventional 
model assumption of a single binding site to include up to three bound 
molecules improved the model fit for gadofosveset at low fields. A technique for 
using micro-samples of blood to measure gadolinium levels was successfully 
demonstrated in vitro, which may enable improved accuracy in dynamic 
studies. A macromolecule-sensitive technique (spin locking) gave a significant 
increase in albumin-bound gadofosveset relaxation rates at high field. A 
method for using gadofosveset as a biomarker for albumin was successfully 
applied in vitro, and the feasibility of in vivo implementation was assessed. 
Conclusions: This in vitro characterisation of gadofosveset across a range of 
field strengths may inform future in vivo tracer kinetic modelling studies. 
Several novel applications for exploiting these characteristics have been 
successfully demonstrated in vitro, and warrant further in vivo investigation. 
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The field of medical imaging has expanded considerably since Roentgen’s 
discovery of X-rays at the end of the nineteenth century, with the introduction of 
alternative modalities and the implementation of improved technologies and 
methodologies. Yet despite these advances, the latest medical imaging 
techniques still present an imperfect view of the inner workings of the human 
body. There is a need to strengthen further the diagnostic and therapeutic 
potential of medical imaging, and it is this requirement that drives the large 
research community engaged in the improvement of these imaging techniques. 
 
Magnetic resonance imaging (MRI) is the imaging modality most recently 
adopted into everyday clinical life. Although MRI utilises properties of the 
simplest and most abundant atom in the human body, hydrogen, image 
generation is underpinned by a sophisticated blend of fundamental physics and 
advanced technology. In the 40 years since the feasibility of MRI was first 
demonstrated, new applications, techniques and opportunities have been 
identified and developed, with the latest peer-reviewed research setting the 
agenda for future advances.  
 
One area of MRI research, active since the early 1980s, is the improvement of 
tissue contrast through the introduction of exogenous contrast agents. Most 
clinical applications of MRI contrast agent utilise the paramagnetic properties of 
the gadolinium ion, which must be chelated to a ligand to reduce its toxicity. 
Differences in chelate design alter the characteristics of each agent, and lead 
to a range of practical applications. Amongst the clinically approved 
gadolinium-based contrast agents, gadofosveset demonstrates a unique affinity 
for serum albumin which sees it binds reversibly and in high fraction on 
injection. The bound gadofosveset molecule acquires certain macromolecular 
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properties which influence the effectiveness and pharmacokinetic behaviour of 
the contrast agent. Although gadofosveset is primarily used for imaging the 
vessels in MR angiography, its macromolecular properties may also have value 
in determining functional parameters such as tissue perfusion and capillary 
permeability.  
 
Not all gadofosveset binds to albumin and the effectiveness of the contrast 
agent (termed ‘relaxivity’) comprises contributions from both the bound and the 
free molecule. Previous studies of gadofosveset have assessed the variation in 
relaxivity across a range of magnetic field strengths, but generally do not 
extend to the higher fields now in regular clinical use (up to 3.0 T). With the 
trend for stronger clinical magnets likely to continue, it is important that 
gadofosveset is fully characterised at magnetic field strengths that are, or may 
become, clinically relevant. It is only by having a full assessment of the 
properties of gadofosveset that further applications, beyond angiography and at 
higher field strengths, can be successfully implemented. 
 
1.2 AIMS AND OBJECTIVES 
 
The initial aim of the project was to fully characterise gadofosveset and its in 
vivo kinetics prior to application of the tracer in pre-clinical and clinical 
quantitative dynamic contrast-enhanced MRI studies. Accurate tracer kinetic 
modelling requires representative input parameters, therefore there were two 
main objectives: firstly, to assess through in vitro measurement the influence of 
binding on the relaxivity of gadofosveset and the variation in this relationship 
with field strength; and secondly, to utilise this knowledge in vivo by measuring 
a vascular input function for gadofosveset and developing extended tracer 
kinetic models to account for the reversible binding of the contrast agent. Pre-
clinical in vivo assessment was to be carried out in a murine model, where high 
heart rates and low blood volumes add complexity to the measurement of a 




However, gadofosveset was withdrawn from the European market shortly after 
this project commenced, and as a result it was not possible to carry out the 
planned in vivo experiments. The emphasis of this study was shifted towards 
further in vitro gadofosveset characterisation, along with in vitro assessment of 
a method developed to measure a vascular input function in small mammals. 
Through this characterisation work, several novel opportunities to exploit the 
albumin-binding nature of the agent became apparent.  
 
This study has addressed gaps in the current gadofosveset literature and 
developed novel methods which may have clinical application. To provide a 
broader view of the influence of albumin binding on contrast agent behaviour, 
the study was extended to include two other gadolinium-based contrast agents, 
gadoxetate and gadobenate. These agents also bind to serum albumin, but 
have a much lower affinity than gadofosveset. In vitro experiments were 
designed using clinically relevant input parameters, and experimental work was 
supported by data simulations to provide a broader assessment of the ability to 
apply these methods in vivo. 
 
The specific objectives of the study were as follows: 
 
1. Determine the relaxivities of the bound and free molecules for gadofosveset, 
gadoxetate and gadobenate at a range of magnetic field strengths. 
 
2. Extend the relaxation rate model beyond the common assumption of a single 
binding site on the albumin molecule, to incorporate up to three bound 
molecules, and assess the relative merits of each approach. 
 
3. Develop a method for measuring gadolinium concentrations in micro-
samples of blood, which may be used to generate a vascular input function in 
small mammals. 
 
4. Measure the impact on relaxation rates when gadofosveset is used at high 
field in conjunction with an imaging technique, spin locking, which is sensitive 




5. Assess the feasibility of using an albumin-binding contrast agent as a 
biomarker for tissue albumin. 
 
1.3 OVERVIEW OF CHAPTERS 
 
Chapter 2 begins with an introduction to the fundamental principles of MRI, 
including signal generation and the concept of relaxation. The theory behind 
paramagnetic contrast agents is discussed, and a general overview of the 
properties of gadolinium-based and other contrast agents is provided. 
 
In Chapter 3 the primary focus is on gadofosveset, with a description of its 
albumin-binding properties and the influence of binding on relaxivity. A review 
of published literature is presented, within the context of gadofosveset 
characterisation and clinical application, to indicate the current level of 
knowledge associated with this agent. A similar review is also presented for 
gadoxetate and gadobenate, along with a brief overview of non-clinically 
approved albumin-binding agents. 
 
Chapter 4 is the first of four experimental chapters, investigating the variation of 
gadofosveset, gadoxetate and gadobenate longitudinal relaxivities with field 
strength and temperature using in vitro samples. An existing model of 
relaxation rate is extended to include up to three binding sites. 
 
In Chapter 5 a novel methodology is established for validating blood 
concentration levels of gadofosveset and determining a vascular input function, 
using a blood sampling technique that is well suited to small-animal studies. 
The feasibility of the technique is established using in vitro samples. 
 
In Chapter 6 the macromolecule-sensitive technique of spin locking is applied 
to in vitro samples of gadofosveset to assess the feasibility of enhancing the 
relaxivity of gadofosveset at high fields. This novel combination of 




Chapter 7, the final experimental chapter, explores through computer 
simulation and in vitro measurement the feasibility of a theoretical approach for 
using gadofosveset as a biomarker for albumin. The theoretical model is then 
applied to human volunteer data, using images acquired through collaboration 
with a research team in the USA.  
 
Chapter 8 contains a summary of experimental results, discusses novel 
findings and draws final conclusions. 
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CHAPTER 2: BACKGROUND 
 
2.1 INTRODUCTION TO MRI 
 
Magnetic resonance imaging (MRI) generates clinical images of high quality, 
providing excellent soft tissue contrast without exposing the patient to ionising 
radiation. MRI is routinely used for accurate treatment planning and diagnosis; 
the UK National Health Service carries out approximately 1.2 million MRI scans 
per year (2).  
 
Although MRI has notable advantages, equipment and scanning costs are 
higher and examination times may be longer than for other imaging modalities. 
Also, the strong magnetic field utilised in MRI (commonly, 1.5 T or 3.0 T) limits 
the interventional procedures that may be carried out during scanning, and 
precludes its use in patients with certain types of metal implant or pacemaker. 
In addition, the small bore of a conventional clinical scanner may be 
challenging for sufferers of claustrophobia.  
 
MRI has limitations in areas such as bone or lung imaging, and image quality is 
susceptible to the effects of cardiac and respiratory motion. However, MRI has 
become the preferred modality for brain, soft tissue and joint imaging, and an 
active international research community is ensuring the clinical utility of MRI 





2.2 BASIC PRINCIPLES OF MRI 
 
2.2.1 Spin and magnetic moments 
 
A full mathematical description of the theory behind MRI necessitates the 
inclusion of quantum mechanics. However, the fundamental principles of MRI 
may be adequately described through classical mechanics without the need to 
incorporate quantum theory (3). A classical approach is adopted here, and the 
reader is directed to other published texts for a quantum mechanical 
description (4, 5). 
 
Although MRI is a relatively recent clinical imaging tool, its principles are built 
on the foundation of experimental work published in 1946 by Purcell et al (6) 
and Bloch (7) relating to nuclear magnetic resonance (NMR). A fundamental 
aspect of this work is that a spinning charged particle, such as the positively 
charged proton constituting the hydrogen (1H) nucleus, generates an 
electromagnetic field and has a magnetic moment, μ, that is proportional to the 
spin angular momentum (with a proportionality constant, γ, known as the 
gyromagnetic ratio). This magnetic moment may be described by a vector 
pointing along the axis of rotation (Fig. 2.1a). In a sample containing many 
particles, the directions of these individual vectors at equilibrium in the absence 







Figure 2.1: (a) A spinning charged particle (such as the proton in the 1H nucleus) has a 
magnetic moment along the axis of rotation; (b) in a sample of many such 
particles, magnetic moments are randomly orientated and the net magnetic 
moment is zero 
 
If this sample is placed within an external magnetic field, B0, each magnetic 
moment begins to precess around the field, keeping a constant angle between 
the spin axis and the field (Fig. 2.2).  
 
 
Figure 2.2: An external magnetic field, B0, is applied, and individual magnetic moments 
precess around the axis of B0 
 
The rate at which these spins precess is known as the Larmor frequency, ω0, 
and is proportional to the strength of the applied magnetic field, B0. The Larmor 




      
  
 
         [2.1] 
 
where µ = magnetic dipole moment, h = Planck’s constant (6.63 x 10-34 J s),  
γ = gyromagnetic ratio. 
 
The sign of the Larmor frequency indicates the direction of spin precession. 
Most nuclei have a positive γ, so the Larmor frequency is negative and 
precession is in the clockwise direction (when viewed against the direction of 
the magnetic field). The 1H nucleus has a gyromagnetic ratio of 42.6 MHz T-1, 
which is larger than almost any other nucleus; it is the primary target for clinical 
MRI due to a combination of this high gyromagnetic ratio and its abundance in 
the body. 
 
The sum of these individual precessing magnetic moments is still very close to 
zero, as the direction of the vector is not changed by the magnetic field. 
However, small, rapidly fluctuating magnetic fields are generated on a 
microscopic scale by electrons and nuclei, and thermally generated interactions 
with these microscopic fields eventually leads to a breakdown in the isotropic 
nature of the individual magnetic moments. This leads to a slight tendency for 
the net magnetic moment to point in the direction of the applied magnetic field, 
as this is a lower energy state. 
 
The build-up of magnetisation towards its equilibrium value of M0 in the 
direction of the applied B0 field is defined by an exponential time constant, T1, 
known as the spin–lattice or longitudinal relaxation time constant. Although the 
term ‘lattice’ has its origins in early NMR experiments with the crystal lattice, 
the name is still employed when measuring liquids and gases. If the applied 
magnetic field were to be switched off, the individual magnetic moments would 
eventually revert to their isotropic nature and the longitudinal spin 
magnetisation would decay to a value approaching zero. In a three-dimensional 
plot, with orthogonal axes in the x, y and z direction, B0 and M0 conventionally 
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point in the z direction (Fig. 2.3a). The magnetisation Mz at time, t, after the B0 
field is switched on is given by Eq. 2.2 and plotted in Fig. 2.3b. 
 
   ( )    (   
  
 





Figure 2.3: When B0 is applied, magnetisation in the z direction (Mz) grows towards an 
equilibrium value, M0; (a) relative axes; (b) increase in Mz with time, according to 
Eq. 2.2 
 
This magnetisation in the z direction is generally too small to be measured. 
With the magnetic moments precessing around the B0 field (z axis) and the net 
magnetic moment pointing in this direction, there is no net magnetisation 
perpendicular to the field. However, if every single spin is rotated by 90° around 
the x axis by an additional radiofrequency (RF) pulse, the net magnetic moment 
will then point along the –y axis, perpendicular to B0 (Fig. 2.4a). The RF pulse 
that flips the net magnetisation into the x–y plane is known as the B1 field, and 
will only have an effect when operating at the resonant (Larmor) frequency of 
the precessing magnetic moments. For the 1H nucleus at a B0 value of 1.5 T 
(the most common field strength employed in clinical MRI) the Larmor 





(a) (b) (c) 
   
Figure 2.4: (a) An RF pulse rotates the magnetisation around the x axis into the –y 
direction; (b) the net magnetic moment still precesses around the z axis in the 
x–y plane; (c) the decay of magnetisation in the x–y plane and recovery in the z 
direction follows a spiral path 
 
This transverse magnetic moment still precesses around the z axis, at the 
precession frequency of the individual spins (the Larmor frequency) (Fig. 2.4b). 
In addition, the transverse component precesses around the axis of the B1 field 
at a frequency (γB1) which is much lower than the precession around the B0 
axis. The combination of both precessional motions would appear to an outside 
observer as a spiralling down from the longitudinal to the transverse plane. 
However, when the B1 field is switched off, the transverse magnetisation 
decays due to fluctuations in the local magnetic field resulting from random 
interactions with neighbouring spins, random motion through regions of 
differing magnetic field strength and variations in tissue magnetic susceptibility. 
The time constant of this decay, T2, is known as the spin–spin or transverse 
relaxation time constant, and is given (within the x–y plane) by Eq. 2.3.  
 
    ( )     
  
 
   [2.3] 
 
The decay of magnetisation in the x–y plane occurs at the same time as the 
recovery of magnetisation in the z axis, and as a result the vector 
magnetisation describes a spiral from the x–y plane up to the z axis (Fig. 2.4c). 
 
The rates of change of magnetisation with time in the x, y and z directions, Mx, 
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Any intrinsic inhomogeneity in the main magnetic field will contribute to faster 
signal loss, acting to shorten T2. The relaxation measure T2* is equivalent to T2 
plus the influence of magnetic field inhomogeneity. Both longitudinal and 
transverse relaxation occur at the same time, but transverse relaxation is 
generally quicker (T2* ≤ T2 ≤ T1). A further measure of relaxation, the spin-lock 
relaxation time, T1ρ, requires an additional locking pulse and will be discussed 
in Chapter 6. The angle to which the magnetic moment is rotated (90° in the 
above example) relates to a specific RF pulse amplitude and direction; by 
varying the properties of this pulse, any angle can be selected. The choice of 
angle will be discussed further in Section 2.2.3. 
 
The transverse magnetisation generates an oscillating magnetic field 
perpendicular to the main magnetic field, which may be detected through the 
electrical current induced in a coil detector. As Mz recovers and transverse 
magnetisation reduces, the generated signal follows a pattern of free induction 
decay. It is this detected signal that is used to create images in MRI. 
 
2.2.2 Generating clinical images 
 
The feasibility of generating images using NMR was first demonstrated in  
1973 (8), with improved techniques for reduced scan times and clearer images 




The subject is placed within a strong magnetic field (commonly, a B0 value of 
1.5 T or 3.0 T is used clinically, with higher B0 values used pre-clinically). By 
creating a linear magnetic field gradient in the B0 field, the Larmor frequency 
varies linearly along the axis of this gradient (according to Eq. 2.1), enabling 
slices to be selectively excited through the choice of B1 pulse properties. 
Additional gradients in orthogonal directions enable signal detection to be 
pinpointed to a specific location within the patient; repeated measurement with 
varying gradient parameters enables the generation of spatially encoded 
datasets in two or three dimensions. For detailed background information on 
the theory behind spatial encoding with gradients and the mathematical 
processes involved in converting detected signals to images, the reader is 
directed to other published texts (10, 11). 
 
The relaxation time associated with an individual voxel (the smallest unit of 
three-dimensional space within a computer image) of tissue is influenced by, 
and reflective of, the properties of the tissue within and around that voxel. For 
example, the compact structure of solids leads to interactions between 
neighbouring nuclei that are constant with time, resulting in a stronger 
dephasing effect (and a shorter T2) than in fluids, where nuclei are constantly 
experiencing new neighbours. The natural motional frequency of fat is close to 
the Larmor frequencies used in MRI; as a result, fat is the tissue type with the 
shortest T1 value, with solid tissue having an intermediate T1 and water having 
a long T1. As MRI targets the 
1H nucleus, proton density also plays a role, with 
the highest proton density signal coming from relatively free water molecules, 
such as those found in cerebrospinal fluid. Those tissues with relatively little 
water content, such as bone or air within the lungs, provide little or no signal.  
 
Example relaxation curves are shown in Fig. 2.5 (based on the magnetisation 
recovery and decay equations, Eq. 2.2 and 2.3) for a range of arbitrary T1 and 
T2 relaxation times. Note that at time t = T1, 63% of the signal is recovered, with 
almost the whole signal recovered at five times T1 (Fig. 2.5a). At t = T2, the 





Figure 2.5: (a) Signal recovery curves for three T1 relaxation times; (b) Signal decay 
curves for three T2 relaxation times 
 
2.2.3 Pulse sequences overview 
 
At a basic level, the pulse sequences used for image generation require a 
combination of RF excitation pulses and spatial encoding gradients, along with 
read-out echo detection. The strength of the excitation pulse (frequency, 
amplitude and duration), the repetition time (TR, time between excitation 
pulses) and the echo time (TE, time between excitation pulse and read-out) 
may be altered to generate T1- or T2-weighted images, according to the tissue 
of interest. Generally, if a short TR is chosen the variation in signal between 
tissue types results primarily from differences in T1, whereas if a long TE is 
chosen the variation in signal results from differences in T2. 
 
The two main pulse sequences used are known as spin echo (SE) and gradient 
echo (GE), although a range of variants have also been developed (12). The 
standard SE sequence uses a 90° excitation pulse followed at time TE/2 by a 
180° refocusing pulse and read-out at time TE (Fig. 2.6a), with free induction 
decay of the signal occurring between excitation and read-out. The sequence is 
repeated after time TR, with variations in spatial encoding for each repetition, in 
order to generate sufficient information for a two- or three-dimensional image. 
The advantage of the 180° refocusing pulse in the SE sequence is that it 
eliminates any dephasing caused by magnetic field inhomogeneity. A multi-
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echo variation on the SE sequence has a single 90° excitation pulse, followed 
by multiple 180° refocusing pulses (each producing a read-out echo at a 
different TE) within a single TR. A third variation, fast spin echo, is similar to the 
multi-echo approach, in that it employs a single 90° excitation pulse and 
multiple 180° refocusing pulses, but this time each echo is also phase encoded 
(and the phase encoding reset after each signal measurement) (Fig. 2.6b). The 
fast spin echo approach enables images to be acquired more rapidly, and is 
also known as turbo spin echo or rapid acquisition with relaxation  
enhancement (RARE).  
 
GE sequences generally use an excitation angle of less than 90°, then 
generate an echo with a pair of bipolar gradient pulses and repeat the cycle 
after a short TR (Fig. 2.6c). There is no 180° pulse to refocus the proton spins, 
resulting in a greater sensitivity to magnetic susceptibility effects, with the rate 
of decay given by T2*. Between cycles, any residual steady-state transverse 
magnetisation may be eliminated by applying spoiling RF pulses or gradients. 
Acquisition using GE is quicker than conventional SE as TR is generally 
shorter, but signal-to-noise ratios are often lower than for SE sequences and 






Figure 2.6: (a) Spin echo and (b) fast spin echo (RARE) sequence; horizontal 
lines in (b) correspond with labels in (a); (c) gradient echo 
 
Many of the pulse sequences applied in the clinic have been adapted for speed 
of acquisition. Although this may come at the expense of a perceived loss in 
image quality (for example, through reduced spatial resolution), faster 
acquisition times have the advantages of reducing image artefacts caused by 
movement and enabling improved temporal resolution on dynamic acquisitions. 
In addition, faster acquisition times reduce the time spent by the patient on the 
MRI scanner, minimising patient discomfort and increasing patient throughput. 
Although pulse sequences with longer acquisition times may be impractical for 
clinical purposes, these time constraints are lifted for research involving in vitro 
solutions and results acquired over longer time periods may give improved 




Inversion recovery sequences give heavy T1 weighting. Here, a 180° pulse 
inverts the magnetisation along the –z axis, and is followed by a 90° pulse to 
bring the residual magnetisation into the x–y plane where it may be detected. 
The time between the 180° pulse and the 90° pulse is known as the inversion 
time (TI). Repeated inversion recovery signal measurements at a range of TIs 
enable T1 to be calculated, using Eq. 2.5 (curve shape shown in Fig. 2.7a). 
 
             
 
  
    [2.5] 
 
where SI is the measured signal intensity and S0 is the signal intensity at time  
t = 0. The modulus is taken because images are usually magnitude 
reconstructions (without negative signal intensity values). 
 
Saturation recovery sequences are able to measure T1 more rapidly than using 
inversion recovery. Here, multiple 90° RF pulses are applied at a range of TR 
values; the first 90° RF pulse is dephased by a spoiling gradient and 
subsequent magnetisation developing along the z axis is rotated into the x–y 
plane by another 90° pulse and a gradient echo immediately acquired. Signal 
intensity is related to T1 according to Eq. 2.6, and the expected curve shape is 
shown in Fig. 2.7b.  
 
        (   
 
  
  ) [2.6] 
 
T2 values may be determined by varying the echo time and fitting signal 
intensity measurements using Eq. 2.7 (curve shape shown in Fig. 2.7c). 
 
         
 
  







Figure 2.7: Plot of signal intensity versus (a) inversion time (Eq. 2.5), (b) recovery time 
(Eq. 2.6) and (c) echo time (Eq. 2.7); (a) and (b) represent T1 recovery curves, and 
(c) represents T2 decay  
 
2.3 CONTRAST AGENTS 
 
In MRI, endogenous contrast between tissue types, resulting from differences 
in longitudinal and transverse relaxation times and proton density, may be 
selectively emphasised through the variation of pulse sequence parameters. 
However, the effectiveness of such tissue contrast is limited in scenarios where 
neighbouring tissue types have similar relaxation times or where pathology, 
such as a tumour, has comparable relaxation characteristics to its background.  
 
Several techniques have been developed to generate variations in contrast by 
manipulation of pulse sequences. Magnetisation transfer uses off-resonance 
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saturation pulses to suppress the signal from protein-bound water molecules, 
which gives a technique sensitive to macromolecular content (13). A similar 
concept, known as chemical exchange saturation transfer (CEST), utilises a 
selective pre-saturation pulse to differentiate bulk water from water bound to an 
exogenous contrast agent (14). Spin locking is another technique that is 
sensitive to the presence of macromolecules, using an additional locking pulse 
to generate relaxation at the (lower) field strength of this pulse rather than the 
strength of the main magnetic field (15). 
 
Blood oxygenation levels may be utilised to generate endogenous contrast, by 
assessing differences between signal intensities of diamagnetic 
oxyhaemoglobin and paramagnetic deoxyhaemoglobin. This technique, known 
as blood oxygenation level dependent (BOLD) contrast, is primarily used for 
functional brain imaging (16). A similar technique, arterial spin labelling (ASL), 
measures perfusion by magnetically ‘tagging’ blood before it flows into the 
region of interest (17). 
 
2.3.1 Contrast agent definition  
 
Contrast may also be enhanced through the administration of an exogenous 
contrast agent. The term ‘contrast agent’ in the context of this research refers 
to a substance that may be administered to a patient with the purpose of 
adding value to a medical image. Contrast agents are used in all imaging 
modalities, although the mode of operation for MRI agents differs to that of 
agents used in other modalities. 
 
An MRI contrast agent has magnetic properties which reduce longitudinal and 
transverse relaxation times; its influence is observed through an alteration of 
signal intensity in the vicinity of the agent. An agent that reduces longitudinal 
relaxation time produces an area of enhanced signal intensity in T1-weighted 
images, and may be defined as a positive contrast agent. An agent that 
reduces transverse relaxation time gives an area of signal loss on T2-weighted 
images, and is often described as a negative contrast agent. In reality, contrast 
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agents reduce both longitudinal and transverse relaxation times, but the extent 
to which each is affected varies according to the properties of the agent.  
 
2.3.2 Uses of contrast agents 
 
MRI contrast agents have a range of clinical applications, enabling improved 
assessment of damage, disease and response to treatment. Extending this 
range of applications, either through the introduction of new contrast agents 
with novel properties or by finding novel uses for existing contrast agents, 
represents an important area of ongoing research. 
 
Contrast agents induce changes in image signal intensity that may be used to 
map the flow of blood, highlighting blood vessels in contrast-enhanced MR 
angiography (18) or disruption to the blood–brain barrier in brain imaging (19). 
The spatial distribution of a contrast agent may have clinical value; for example, 
regions of signal alteration due to contrast agent accumulation (enhancing 
fraction) may correlate with regions of tumour growth and may be used as a 
prognostic biomarker in carcinoma (20). 
 
The rate of excretion of the agent may aid assessment of kidney (21) or liver 
(22) function. Plotting the variation of signal intensity with time provides 
parameters related to tissue properties, including onset time, mean gradient, 
maximum signal intensity and wash-out characteristics (23). The shape of such 
a curve may correlate with tumour malignancy (24), and the area under the 
curve is related to blood volume and capillary permeability (25), although 
separation of tissue perfusion and capillary permeability characteristics requires 
mathematical modelling to account for tracer kinetic behaviour (26). These 
parameters may be of particular value when assessing tumour physiology (27) 
or regions of necrosis in myocardial infarction (28), for example. Assessment of 
microvascular permeability using MRI contrast agents is sensitive to the size of 
the agent molecule (29, 30), with macromolecular agents potentially being 




2.3.3 Mode of operation 
 
MRI contrast agents have magnetic susceptibility properties which alter intrinsic 
tissue relaxation times by modifying the magnetic field in their immediate 
vicinity. Unlike other imaging modalities, it is not the contrast agent itself that is 
observed; instead, MRI detects the influence of the contrast agent on nearby 
water molecules. Paramagnetic MRI contrast agents have a small, positive 
susceptibility to magnetic fields, but do not retain their magnetic properties 
outside the magnetic field. Superparamagnetic contrast agents have higher 
magnetic susceptibility values, and thus have greater influence over the local 
magnetic field. 
 
When discussing contrast agents, it is common to use relaxation rates rather 
than relaxation times (where the relaxation rate is the inverse of the relaxation 
time). For a dilute paramagnetic solution, the observed solvent relaxation rate 
(Riobs, 1/Tiobs) is the sum of the relaxation rate of the solvent nuclei in the 
absence of the paramagnetic solute (Ri0, 1/Ti0) and the relaxation rate of the 
paramagnetic substance (Ri, 1/Ti) at a given concentration (Eq. 2.8) (32). 
 
              [2.8] 
 
where i = 1,2. 
 
The relaxation rate of a paramagnetic contrast agent is conventionally linearly 
related to its concentration (Cg), such that Eq. 2.8 can be rewritten as Eq. 2.9. 
 
                  [2.9] 
 
where i = 1,2. 
 
The relaxation rate (Ri) of a paramagnetic contrast agent consists of two 




              [2.10] 
 
where i = 1,2. 
 
Inner sphere effects result from one or more water molecules binding in the 
inner coordination sphere of the paramagnetic ion and exchanging rapidly with 
bulk water molecules. Secondary and outer sphere effects result from water 
molecules diffusing through the outer-sphere environment. These effects, and 
the correlation times associated with each, are illustrated graphically in Fig. 2.8. 
 
 
Figure 2.8: Graphical representation of the influence of a chelated Gd ion on nearby 
water molecules. Inner sphere relaxation is influenced by the correlation time of 
the coordinated water molecule (τM) and the rotational correlation time (τR); 
outer sphere relaxation is influenced by the diffusional correlation time (τD) 
 
Inner sphere relaxation 
 
Inner sphere relaxation occurs when a water molecule is associated with the 
contrast agent for a sufficient amount of time to form an identifiable chemical 
complex (33). The relaxation rate (RiIS) is influenced by the relaxation rate of 
the bound water molecule (Rim) and the number of water molecules binding in 
the inner coordination sphere, also known as the hydration number; for most 
Gd-based agents only one water molecule binds. RiIS is also influenced by the 
time spent by the water molecule in the inner sphere (τM), dictated by the 
solvent exchange rate (1/τM) (Eq. A.1 – A.2 in Appendix A). An increase in this 
correlation time (i.e. a decrease in the exchange rate of the coordinated water 
molecule) leads to a reduction in the inner sphere relaxation rate. When this 
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water molecule exchanges very rapidly (i.e. τM << T1m), the relaxation 
enhancement experienced by the bulk water is dependent on the relaxation 
rate of this coordinated molecule (R1m). An additional factor which has a small 
influence on R2IS is the chemical shift difference between the bound water and 
the bulk water (resulting from differences in resonant frequencies). 
 
Bound water relaxation rates consist of components representing dipole–dipole 
(DD) and scalar (SC, also known as contact) mechanisms of relaxation  
(Eq. 2.11). 
 
               [2.11] 
 
where i = 1,2. 
 
These components may be calculated using the Solomon–Bloembergen–
Morgan equations (34) (Eq. A.3 – A.6 in Appendix A). Scalar relaxation rates 
are influenced by the scalar coupling constant between the electron at the 
paramagnetic centre and the proton of the coordinated water molecule, as well 
as the electron Larmor frequency and the scalar correlation time (τei). Dipole–
dipole relaxation rates are strongly influenced by the electron spin–proton spin 
distance, r (to the inverse sixth power), as well as the nuclear and electron 
Larmor frequencies, and dipole–dipole correlation times (τci). These correlation 




   











   





where i = 1,2, τR is the rotational correlation time of the metal–proton vector, 
R1e and R2e are the longitudinal and transverse electron spin relaxation rates of 




Rie varies with magnetic field and is usually interpreted in terms of a zero-field-
splitting interaction (a quantum effect associated with spin energy states) (35) 
(Eq. A.7 – A.9 in Appendix A).  
 
Outer sphere relaxation 
 
As second sphere relaxivity is generally not well characterised (36), the 
separate contributions of the second and outer sphere are usually combined 
into a single relaxation rate, RiOS (34). This relaxation rate is influenced by the 
distance of closest approach of the water molecule and the complex, as well as 
the diffusion constants of the water and the complex (Eq. A.10 – A.14 in 
Appendix A). 
 
2.3.4 Contrast agent design 
 
The degree to which a contrast agent influences relaxation time is termed 
‘relaxivity’; this parameter is generally normalised to contrast agent 
concentration and expressed in units of L mmol-1 s-1 (or mM-1 s-1).  It is clear 
from contrast agent theory that the effectiveness of a contrast agent is 
governed by a range of physical and chemical molecular properties. In addition, 
relaxivity is affected by experimental and environmental factors including 
temperature, pH and B0 field. For small, low-molecular-weight paramagnetic 
contrast agents around 60% of the longitudinal and transverse relaxation 
results from inner-sphere effects, with the remainder due to outer sphere 
interaction and bulk water transfer (33). Superparamagnetic agents have no 
inner coordinating molecule and derive all their relaxivity from outer sphere 
effects (35). 
 
A linear relationship between contrast agent concentration (Cg) and change in 
R1 (ΔR1) or R2 (ΔR2) is often assumed. In this case, for a plot of Cg versus ΔR1 
the slope of a line through measured points and the origin represents 
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longitudinal relaxivity (r1); the slope of an equivalent line on a plot of Cg versus 
ΔR2 represents transverse relaxivity (r2) (Eq. 2.14).  
 
          [2.14] 
 
where i = 1,2. 
 
However, for contrast agents that bind to albumin, a nonlinear relaxation rate 
response to contrast agent concentration will be generated due to the variation 
of relaxivity with binding fraction (37). 
 
The variation in signal intensity with time (inversion time, repetition time or echo 
time) was shown in Fig. 2.7. A change in relaxation rate, induced by the 
introduction of a contrast agent, changes the shape of these curves. At low 
contrast agent concentration and at a given time point, a linear correlation 
between change in signal intensity and contrast agent concentration is often 
assumed. However, this assumption of signal linearity is not strictly correct and 
may lead to miscalculated pharmacokinetic parameters (38). Signal intensity 
enhancement nonlinearity is increased at high contrast agent concentrations 
and where T2 shortening effects are neglected (39). Water exchange rates 
between cellular and interstitial spaces (40) and solution microviscosity (41) 
may also contribute to nonlinearity.  
 
Contrast agents are conventionally categorised according to their magnetic 
susceptibility (paramagnetic or superparamagnetic), biodistribution 
(extravascular, intravascular, or tissue-specific) and image enhancement 
properties (positive or negative). Early work (42) showed the promise of 
utilising paramagnetic contrast agents such as orally administered ferric 
chloride and inhaled 100% oxygen to enhance natural tissue contrast. Other 
paramagnetic metal ion chelates, including gadolinium (Gd), were also being 
considered in the early 1980s (43).  
 
Although much research has been carried out using other agents, most 




2.4 GADOLINIUM-BASED CONTRAST AGENTS 
 
Gadolinium is a lanthanide element with an atomic number of 64 and an atomic 
mass of 158 in its most common isotope. In its ionic form (Gd3+) it has seven 
unpaired electrons in its outer shell, making it ideal for use as a contrast agent. 
However, due to similarities in size Gd can block voltage-gated calcium (Ca2+) 
channels at very low concentrations, inhibiting processes that require an influx 
of Ca2+ and limiting the activity of certain enzymes (44). To reduce its potential 
toxicity, Gd may be chelated to a ligand. Early studies of potential Gd chelates 
(45) suggested the use of ethylenediaminetetraacetic acid (EDTA) or 
diethylenetriaminepentaacetic acid (DTPA). Relaxation time was significantly 
reduced with both chelates, but dose experiments with rats found much higher 
tolerance for DTPA than EDTA. Gd-DTPA (gadopentetate dimeglumine) now 
forms the basis of several of the most commonly used, clinically approved MRI 
contrast agents. 
 
2.4.1 Overview of clinically approved agents 
 
Properties of clinically approved agents 
 
All MRI-approved Gd chelates are nine-coordinate complexes, with a ligand 
occupying eight of the available binding sites at the metal centre and the ninth 
site occupied by a coordinated water molecule (34). Gd contrast agents may be 
grouped according to their ligand properties, being either linear or macrocyclic 
in structure and ionic or non-ionic in charge. Several agents selectively bind to 
albumin, or may target specific organs. The relaxivity of the agent, its safety 
profile, pharmacokinetics and excretion pathway are all influenced by the 





Table 2.1: Selected properties of marketed Gd-based contrast agents 
 




The chelated Gd molecule is designed to be well tolerated during its journey 
through the body. Minor adverse effects, including nausea and hives, occur in a 
low number of cases following contrast agent administration, at a similar rate 
for all agents (47). Severe anaphylactoid reactions are rare, with an estimated 
incidence of 1:100,000 to 1:500,000 (48). In patients with poor renal function, 
the clearance rate of the contrast agent is compromised and the chelated 
molecule may degrade into a more toxic form, potentially resulting in increased 
Gd bone deposition. 
 
The development of nephrogenic systemic fibrosis (NSF), a hardening of 






































































administration of Gd contrast agents by Grobner (49). This link was 
strengthened with detection of Gd in the skin of patients with NSF having been 
exposed to a Gd-based contrast agent (50). Although the pathophysiology of 
NSF is still not fully known, the link to Gd has led to classification of all agents 
into high-, intermediate- and low-risk groups, with associated restrictions on 
their use (51). Unconfounded cases of NSF have so far been associated with 
just three of the Gd agents: gadodiamide, gadoversetamide and gadopentetate, 
with gadodiamide accounting for by far the greater majority (51). 
 
2.4.2 Gadofosveset, gadoxetate and gadobenate 
 
Gadofosveset trisodium (gadofosveset) is unique amongst the clinically 
approved agents in that it is the only agent which binds in high fraction to 
albumin. Through binding, gadofosveset acquires two fundamental properties 
associated with macromolecules: its speed of rotation and its extravasation rate 
are both reduced. The latter property influences the kinetic behaviour and 
excretion rate of the agent, ensuring the bound molecule remains mostly 
intravascular and prolonging the time window for imaging at steady state; the 
former property has a significant positive effect on its relaxivity, particularly at 
lower magnetic field strengths. The intravascular nature of bound gadofosveset 
leads to its indicated use in angiography. However, in a scenario of increased 
capillary permeability, such as angiogenesis, it is suggested that pathology may 
correlate with higher leakage rates and elevated levels of bound gadofosveset 
in the extravascular space. 
 
Gadoxetic acid (gadoxetate) and gadobenate dimeglumine (gadobenate) also 
bind reversibly to albumin, at a much lower fraction than gadofosveset. 
Although both agents demonstrate an increased relaxivity attributable to 
albumin binding, the lower binding affinity of these agents limits the extent to 
which their behaviour is modified in vivo.  
 
The properties of gadofosveset, gadoxetate and gadobenate will be discussed 





2.4.3 Other albumin-binding gadolinium-based agents 
 
Gd permanently bound to albumin (albumin-Gd-DTPA) has been used as a 
macromolecular agent in animal studies (for example,(39, 52)), although the 
excessive retention time of this agent makes it less suitable for human studies. 
Other attempts to create a macromolecular Gd-based agent include the 
conjugation of Gd chelates to synthetic polymers (53) or to a polyethylene 
glycol core (54). Biodegradable polydisulfide Gd complexes (55) may prove to 
be a safer alternative to some macromolecular agents. In addition to these 
synthetic macromolecular agents, a range of Gd-based contrast agents are 
being developed to target specific organs or respond to changes in pH, 
temperature or enzyme activity (56). 
 
2.5 NON-GADOLINIUM-BASED CONTRAST AGENTS 
 
Although the main focus of this research is on the Gd-based contrast agent 
gadofosveset, with a broader assessment of the other clinically approved 
albumin-binding agents gadoxetate and gadobenate, it should be noted that a 
range of alternative MRI contrast enhancement options are available. Other 
lanthanide ions such as dysprosium (Dy3+) and holmium (Ho3+) have larger 
magnetic moments than Gd3+ (57), but, due to the asymmetry of the electronic 
states of their orbiting electrons, the electronic relaxation rates of these other 
lanthanides are too high to influence proton relaxation to the same extent as 
Gd3+ (34). At higher magnetic fields, it may be possible to use lanthanide ions 
such as Dy3+ and Ho3+ effectively as negative contrast agents (58). 
 
Iron oxide, in the form of superparamagnetic iron oxide particles (SPIO) or 
ultrasmall superparamagnetic iron oxide particles (USPIO), is very effective in 
T2-weighted imaging. Iron oxide agents typically consist of a particle with a core 
of magnetic crystals embedded in a coating such as dextran. The size of the 
crystals governs relaxivity properties; the size of the particle influences 
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pharmacokinetics. As iron oxide has a lower number of unpaired electrons than 
Gd (1.33 unpaired electrons per iron atom compared to 7 for Gd), the individual 
magnetic moment of a molecule of magnetite (Fe3O4) is lower than that of a 
molecule of Gd chelate (57). However, in situ, individual magnetite molecules 
aggregate and the magnetic moments of neighbouring molecules align, 
effectively creating one large molecule with increased magnetisation (33). The 
coating of the iron oxide molecule may be chemically manipulated to target 
specific tissue, such as liver Kupffer cells (59). Biodegradable SPIOs, with a 
rate of degradation that enables effective imaging, have substantially lower 
toxicity than conventional paramagnetic contrast agents (60). An iron oxide 
molecule, ferumoxytol (marketed in Europe as Rienso, Takeda Pharmaceutical 
Company Ltd), recently gained clinical approval for intravenous treatment of 
iron deficiency anaemia and has previously been used as an MRI contrast 
agent. Manganese is part of the iron group of metals; manganese ions (Mn2+) 
may be taken up by cells via the calcium (Ca2+) channel, suggesting a possible 




In summary, clinical MRI utilises the spin properties of the hydrogen nucleus to 
generate signals, which are then converted into an image. The creation of this 
image requires selection of pulse sequence parameters to enable 
differentiation of a range of tissue properties. Exogenous contrast agents alter 
image contrast by influencing the magnetic properties of water molecules in 
their immediate vicinity, and may provide additional structural and functional 
information over non-contrast-enhanced images. The majority of contrast 
agents in the clinical setting are based on the gadolinium ion, which is chelated 
to a ligand to reduce toxicity. The chemical properties of this ligand vary for 
each contrast agent, leading to variations in contrast agent relaxivity and 
pharmacokinetic behaviour. Of the three clinically approved Gd-based contrast 
agents that bind reversibly to albumin, gadofosveset has the highest binding 
affinity, leading to higher relaxivity and lower extravasation and excretion rates 
than other clinically approved Gd agents. 
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CHAPTER 3: EXISTING LITERATURE ON GADOFOSVESET 
AND OTHER ALBUMIN-BINDING AGENTS 
 
3.1 CHARACTERISING GADOFOSVESET 
 
3.1.1 Development of gadofosveset 
 
Gadofosveset trisodium is a clinically approved gadolinium (Gd) based contrast 
agent, which binds reversibly and in high fraction to serum albumin upon 
injection. The molecule, shown in Fig. 3.1, has a gadopentetate core and a 
hydrophobic albumin-binding group (two phenyl rings attached to a cyclohexyl 
moiety) linked through a negatively charged phosphodiester bond (62). It has a 
molecular weight of 975.88 g mol-1 (with an ionic weight of approximately  
907 g mol-1), and an empirical formula of C33H40GdN3Na3O15P. The injectable 
solution is manufactured by dissolution of gadofosveset trisodium in water, 
followed by addition of the ligand fosveset, and specific gravity and pH 
adjustment using sodium hydroxide and hydrochloric acid.  
 
 




The use of gadofosveset as a contrast agent was first reported in 1996, under 
the name MS-325 (64). The agent was developed by Metasyn Inc (later Epix 
Pharmaceuticals, Cambridge, MA, USA), licensed to Mallinckrodt (St Louis, MI, 
USA) and developed under the brand name AngioMark from 1998. 
Development and discovery costs for gadofosveset were estimated at  
US$85 million over an 8-year period (65). Following phase III clinical trials  
(66, 67), gadofosveset gained marketing authorisation for human use from the 
European Medicines Agency in 2005. It was marketed in Europe by Bayer 
Schering Pharma AG (Berlin, Germany) under the name Vasovist, with 
contrast-enhanced MR angiography as its labelled indicated use. In 2008, 
gadofosveset gained approval from the US Food and Drug Administration for 
use in the USA. Lantheus Medical Imaging (N Billerica, MA, USA) acquired the 
rights for gadofosveset from Epix in 2009, and the product name was 
subsequently changed from Vasovist to Ablavar. Although the marketing 
authorisation in Europe was voluntarily withdrawn by the marketing 
authorisation holder in 2011, Ablavar continues (at the time of writing) to be 
available for use in North America. Gadofosveset ceased to be marketed in 
Europe when Lantheus acquired the marketing rights, although, due to its long 
shelf-life (approximately three years), gadofosveset in the form of Vasovist may 




Gadofosveset is unique amongst the clinically approved Gd contrast agents as 
it reversibly binds in high fraction to human serum albumin (HSA). HSA is the 
most abundant protein in blood plasma, constituting around 4.5% of plasma 
(68). Albumin is essential in regulating the flow of water between blood and 
tissue, providing around 75% of the colloid oncotic pressure (69), and also 
transports, via numerous binding sites, endogenous compounds such as long-
chain fatty acids (70) and elements including calcium and magnesium (71). 
Drugs including warfarin and ibuprofen have been designed to bind with HSA 
so they may be transported easily around the body (72). The heart-shaped 
HSA molecule consists of three homologous domains (I, II and III), each formed 




Figure 3.2: Structural diagram of human serum albumin molecule, with colours 
reflecting different domains (image from the Research Collaboratory for 
Structural Bioinformatics Protein Data Bank (www.pdb.org) of PDB 1AO6 (74))  
 
Although there are a number of binding locations on the HSA molecule, one 
binding cavity (subdomain IIIA) is more active and accommodating than the 
others (73). The binding location for gadofosveset may be identified by 
analysing the displacement of fluorescent probes which bind at known sites on 
the HSA molecule. Using this technique it has been demonstrated that, 
although gadofosveset is able to bind to several sites, site II on subdomain IIIA 
has the greatest affinity (68).  
 
The number of gadofosveset molecules binding to a single albumin molecule 
(and therefore the bound fraction) may be assessed by separative techniques 
such as equilibrium dialysis or ultrafiltration. Here, bound and unbound (free) 
molecules are separated either by forcing a chemical equilibrium or by physical 
filtration based on molecular size. Using the ultrafiltration method, it has been 
demonstrated that, at very high concentrations, up to 20 gadofosveset 
molecules may bind to a single serum albumin molecule (63). However, at 
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clinically applicable concentrations (0.1 – 1.0 mM), only one or two molecules 
of gadofosveset are likely to be bound per HSA molecule (63). Using the 
ultrafiltration technique it has been shown that, at low concentrations, 
approximately 90% of gadofosveset binds to albumin in human  
plasma (68, 75).  
 
An alternative approach for assessment of binding characteristics, known as 
proton relaxation enhancement (PRE), exploits the differences in relaxation 
rates between albumin-bound and free paramagnetic molecules. The non-
covalent binding equilibrium between a paramagnetic substrate and a protein is 
defined in Eq. 3.1 (76). 
 
                                           [3.1] 
 
The association constant, or binding affinity (Ka), involving a single equivalent 
binding site is defined in Eq. 3.2 (76). 
 
     
                   
                     
 [3.2] 
 
The overall gadofosveset (Cg) and serum albumin (Csa) concentrations may be 
defined as the sum of their bound and free components (Eq. 3.3 and 3.4).  
 
                     [3.3] 
                        [3.4] 
 
Assuming a single binding site on the albumin molecule, Csabound = Cgbound. 
Binding affinity (Eq. 3.2) may then be expressed in terms of gadofosveset and 
albumin concentrations (Eq. 3.5). 
 
     
       





Removing Csafree from Eq. 3.5 using Eq. 3.4 gives Eq. 3.6. 
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 [3.6] 
 
The observed relaxation rate, Riobs, is determined from the sum of the bound 
and free relaxation rates and the relaxation rate of the blank solution, Ri0  
(Eq. 3.7). 
 
                                           [3.7] 
 
where i = 1,2. 
 
Defining the contrast-agent induced change in relaxation rate as ΔRi, Eq. 3.7 
may be restated as Eq. 3.8. 
 
                                               [3.8] 
 
where i = 1,2. 
 
Combining Eq. 3.3, 3.6 and 3.7 gives Eq. 3.9. 
 
                  
(              ) {
(               )    [(              )
 
      
        ]
    
}





where i = 1,2.  
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where i = 1,2.  
 
For n binding sites with equivalent binding affinity, Eq. 3.9 may be adapted to 
Eq. 3.11 (37). 
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where i = 1,2.  
 
The relationship between Cg and R1obs (Eq. 3.11) is plotted in Fig. 3.3 for two Ka 
and n values, using arbitrary Csa, r1bound and r1free values. In practice, it may be 
difficult to independently evaluate n and Ka, particularly at low Cg, therefore 
binding affinity is sometimes expressed as a composite nKa term. However, 
Fig. 3.3 indicates the value of the PRE technique for analysing binding 
characteristics. The curve is approximately linear up to the point at which the 
binding sites are filled, and the point of inflection is indicative of saturation of 
the binding sites. As a result, the ratio Cg/Csa at the point of inflection 
corresponds approximately to n, assuming all binding sites have an equivalent 





Figure 3.3: Plot of variation of R1obs with contrast agent concentration (Cg) at an 
albumin concentration (Csa) of 0.6 mM, for two binding affinities (Ka) and up to  
n = 2 bound molecules (r1bound = 50 mM
-1 s-1, r1free = 5 mM
-1 s-1), using Eq. 3.11 
 
Although this approach may be useful in characterising the relaxation rates of 
certain albumin-binding molecules, a difference of approximately 102 in 
gadofosveset binding affinity between the first and second binding sites (68) 
precludes the use of the PRE technique in isolation to make assumptions about 
gadofosveset binding characteristics (34). Combining results from the 
displacement of fluorescent probes with the shape of the PRE curve, binding at 
the primary binding site (site II, subdomain IIIA) has been shown to have the 
greatest influence on gadofosveset relaxivity (68). 
 
A range of gadofosveset binding affinity values at the primary binding site have 
been reported, influenced by measurement technique and experimental factors 
such as temperature. Using the PRE technique, Ka values were reported at  
25 °C of 30 mM-1 (37), and at 37 °C of 6.1 mM-1 (77) and 11.0 mM-1 (78), 
although as previously noted the PRE technique should not be used in isolation 
for gadofosveset. Using ultrafiltration at 37 °C, a Ka value of 11.0 mM
-1 (68) and 
values in the range 8.2 – 41.5 mM-1 for several lots of HSA (75) were reported. 
Gadofosveset Ka has been shown to decrease with increasing pH in the range 
5.5 to 10, thought to be due to enhanced electrostatic interaction at acidic 




When gadofosveset concentration exceeds HSA concentration, the number of 
available albumin molecules with preferential binding sites is reduced, and 
there is a tendency for the bound fraction to decrease. In addition to varying 
with gadofosveset concentration, the bound fraction of gadofosveset, and 
therefore its effectiveness as a contrast agent, varies by species. In humans, 
serum albumin levels are around 4.5%, but this level may be as low as 2.6% for 
dogs and 3.2 – 3.3% for rats and mice (79). The bound fraction measured in 
different species, ranging from around 65% in rats to 91% in humans, is 
considered to be mostly influenced by these variations in albumin 
concentration, with some additional variance caused by differences in species’ 
binding characteristics leading to differences in exchange rates of the 
coordinated water molecule (75). Bound fraction will also vary within species 
according to individual variations in protein content, which may potentially be 




On binding to albumin, gadofosveset acquires macromolecular properties. As a 
result, the pharmacokinetic behaviour of the bound gadofosveset molecule 
differs substantially from that of the free molecule. The free molecule will 
behave as a conventional, non-binding small molecule Gd agent, readily 
passing through the vascular wall (although not an intact blood–brain barrier) to 
the extravascular extracellular space (EES), whereas the bound gadofosveset 
molecule is often assumed to remain intravascular. However, the assumption 
that bound gadofosveset remains intravascular may not be entirely valid. Of the 
four major pathways across the endothelium – tight junctions, breaks in tight 
junctions, vesicles and leaky junctions – only the tight junctions are small 
enough to prevent HSA molecules from escaping (80), and albumin is 
transported across the capillary wall with a natural transcapillary exchange rate 
of around 5% of intravascular albumin per hour (81). It is suggested through 
mathematical modelling that around 20% of albumin crossing the endothelium 
uses the vesicles, 36% may be associated with breaks in tight junctions and 





It is expected, therefore, that a small proportion of bound gadofosveset will 
escape to the EES. In addition, free gadofosveset may extravasate and then 
bind to albumin within the EES. Neither the extent to which unbound molecules 
cross into the EES before binding nor the binding characteristics within 
interstitial fluid are fully known. As albumin levels in plasma are around four 
times those in interstitial fluid (83) the likelihood of binding appears greater in 
the intravascular space, particularly at low gadofosveset concentrations. 
Increased levels of albumin in the EES, triggered by disease or damage to the 
endothelial wall, may lead to increased levels of bound gadofosveset in  
the EES. 
 
The binding process increases the retention time of gadofosveset by effectively 
‘hiding’ the molecule from the kidneys, leading to an excretion half-life in 
healthy humans of around 16 h (84). The extended half-life of gadofosveset 
enables signal enhancement for prolonged periods following administration. In 
a study of gadofosveset in the carotid artery, the signal-to-noise ratio (SNR) 
was shown to decrease by only 10% between 5 and 50 min post-contrast (85).  
 
Excretion pathway and elimination half-life also vary by species. In humans, the 
majority of gadofosveset is renally excreted, with less than 10% of the injected 
dose being excreted via the hepatobiliary pathway (86). In rats, gadofosveset is 
rapidly taken up by the liver, with around a quarter of the injected dose 
eventually appearing in faeces (87). The elimination half-life of gadofosveset in 
rats was measured at 23 min, compared to an elimination half-life of 2 – 3 h for 




As demonstrated in Chapter 2, the effectiveness of a contrast agent is 
influenced by the rate at which the coordinated water molecule exchanges with 
the bulk water, the rotational correlation time of the chelated Gd ion and the 




The binding process increases the molecular weight of gadofosveset to  
68 kDa (88) and reduces the rate of rotation of the molecule, resulting in an 
increase in the rotational correlation time (τR) from around 0.1 ns to around  
10 ns (89). This slower rotation is closer to the Larmor frequency of the 1H 
nucleus at clinical field strengths; as a result, longitudinal relaxivity is increased 
by a factor of 4 – 10 at low fields (75), peaking at a B0 value of 20 – 25 MHz 
(approximately 0.5 T) (77). Gadofosveset relaxivity is additionally enhanced by 
an increase in outer-sphere relaxivity, possibly due to a long-lived water 
molecule in the second sphere, and a reduction in the electronic relaxation rate 
(68). A reduction in the rate at which the coordinated water molecule 
exchanges with the bulk water (1/τm) when gadofosveset binds to albumin, 
slowed by a factor of 2 – 3, counteracts a proportion of the increase in relaxivity 
brought about by the increased τR (68).  
 
A study of the relationships between relaxation rate, gadofosveset 
concentration and field strength in whole blood samples (90) found that R1 
increased approximately linearly with gadofosveset concentration  
(≤ 1.6 mM), and decreased with magnetic field strength (between 1.5 T and  
7.0 T). At 0.47 T, a nonlinear increase of R1 with gadofosveset concentration  
(≤ 2.0 mM) in human and various animal plasmas was demonstrated (75). 
Comparison between observed gadofosveset relaxivity values (r1obs, r2obs) at 
low field (0.47 T) for solutions of water and plasma show an increase in r1obs 
from 6 mM-1 s-1 to 28 mM-1 s-1, respectively, and in r2obs from 7 mM
-1 s-1 to  
40 mM-1 s-1, respectively (91). Equivalent values at 3.0 T show a more modest 
increase in r1obs in plasma (5 mM
-1 s-1 in water, 10 mM-1 s-1 in plasma) but a 
large increase in r2obs (6 mM
-1 s-1 in water, 60 mM-1 s-1 in plasma); at 4.7 T there 
is little difference between r1obs in water and plasma (6 mM
-1 s-1 and 7 mM-1 s-1, 
respectively), but the difference in r2obs remains large (7 mM
-1 s-1 in water,  
60 mM-1 s-1 in plasma) (91). Although these figures are observed relaxivities, 
rather than separated bound (r1bound, r2bound) and free (r1free, r2free) values, they 
support a general pattern of low and approximately field-independent r1free and 
r2free, high r1bound declining rapidly with field, and high r2bound increasing slightly 




The addition of energy, in the form of an increase in temperature, reduces 
correlation times (τR and τm) and increases exchange rates. For conventional 
small molecule Gd agents the change in relaxivity with temperature is 
described by Curie’s law, which states that for a paramagnetic material the 
magnetisation (Mz) is proportional to the applied magnetic field (B0) and 
inversely proportional to the temperature (T) (Eq. 3.12) (35). 
 
    
   
    (   )
    
   [3.12] 
 
where N0 is the total number of spins, γ is the gyromagnetic ratio,   is the 
reduced Planck constant (1.05 x 10-34 J s), I is the spin quantum number (7/2 
for Gd), T is the absolute temperature and kB is the Boltzmann constant  
(1.38 x 10-23 J K-1). 
 
Applied generally, Curie’s law suggests that at a fixed B0 value paramagnetic 
materials become more magnetic, and therefore have a higher relaxivity, at 
lower temperature. This has been demonstrated for the longitudinal relaxivities 
of gadopentetate (93) and free gadofosveset (37). At low B0 values, where the 
macromolecular τR is close to the inverse of the Larmor frequency, the 
longitudinal relaxivity of bound gadofosveset increases with temperature (37). 
The relaxivities of the bound and free molecules of gadofosveset therefore 
have opposing relationships with temperature. At higher B0 values, where τR is 
already beyond its optimal range, an increase in temperature may be expected 
to have a more limited effect on relaxivity. 
 
For Gd agents at physiological pH, the proton and water exchange rates are 
equal, but proton exchange is accelerated in acidic or basic solutions due to H+ 
or OH- catalysis (32). The longitudinal relaxivity of bound gadofosveset 
increases as the solution pH moves from acidic to neutral, and then remains 





3.1.5 Injection protocol 
 
It has been suggested that, as the bound fraction of gadofosveset varies with 
time post-bolus, image quality may be affected by injection rate, particularly in 
examinations using first-pass enhancement. A study (94) found no significant 
relationship between maximum enhancement and injection rate, suggesting 
that, within the range of timescales analysed, gadofosveset effectively binds 





Although the binding of gadofosveset to albumin causes it to be retained within 
the body for longer, the reversible nature of this binding should enable the Gd 
chelate to be excreted from the body without complication or increased toxicity. 
A meta-analysis of pooled safety data from eight studies (phase II and phase III 
clinical trials) (95) found that the rate and severity of adverse events associated 
with gadofosveset at a dose of 0.03 mmol kg-1 were similar to those of a 
placebo, and concluded that the safety profile of gadofosveset was comparable 
with other Gd-based contrast agents.  
 
Following the discovery of a potential link between Gd contrast agents and 
nephrogenic systemic fibrosis (NSF) (49), a scientific advisory group at the 
European Medicines Agency reviewed the NSF risk for each clinically approved 
Gd agent. Gadofosveset was classified (with the other albumin-binding agents 
gadobenate dimeglumine and gadoxetic acid) as being of intermediate risk 
(96). However, no unconfounded cases of NSF have been reported for 
gadofosveset; the differentiation between intermediate- and low-risk agents is 
based on the chemical properties of the agents rather than clinical  





3.2 CLINICAL APPLICATIONS AND PREVIOUS RESEARCH 
 
The intravascular nature of the bound gadofosveset molecule leads to 
increased contrast enhancement within the vessels, and the reduced 
extravasation and excretion rates provide a longer imaging time window. 
Utilising these factors, the majority of clinical studies employ gadofosveset in its 
labelled use of contrast-enhanced MR angiography. At steady state, contrast 
enhancement in both the venous and arterial systems is observed, which may 
be advantageous but may also add complexity to image interpretation. As 
noted in Chapter 2 (Table 2.1), the standard clinical dose for gadofosveset is 
lower than for most other Gd agents, due to its high relaxivity (0.03 mmol kg-1 
for gadofosveset versus 0.1 mmol kg-1 for the majority of agents). 
 
Phase III clinical studies focused on the use of gadofosveset in MR 
angiography for assessing peripheral vascular (66), aortoilliac occlusive (67) 
and renal artery disease (97). Here the intravascular nature of gadofosveset 
and its relatively high relaxivity at 1.0 – 1.5 T were utilised. Gadofosveset has 
also been used in cardiac MRI for assessment of structural anomalies (98-100) 
and function (101, 102). Gadofosveset has been used in first-pass perfusion 
imaging in the kidneys (103, 104), and to verify vessel closure following 
treatment for choroidal melanoma (105). 
 
The increased size of the bound gadofosveset molecule limits extravasation 
from healthy vessels, but macromolecular leakage may increase in damaged or 
diseased vessels. Gadofosveset has been used to assess vascular 
permeability in mechanically damaged (106), fibrotic (107), atherosclerotic 
(108) and angiogenic vessels (109-112). Leakage of gadofosveset across the 
blood–brain barrier enables improved visualisation of brain tumours (84, 113, 
114). The high relaxivity of bound gadofosveset has also been correlated with 
albumin content in the differentiation of healthy and tumour-invaded lymph 
nodes (115-117) and in atherosclerotic plaques (118, 119). 
 
Although increased extravascular leakage of bound gadofosveset is expected 
from damaged or angiogenic vessels, this differential behaviour may be 
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masked by leakage of the unbound molecule from normal vessels in scenarios 
where the bound fraction is low (such as at high gadofosveset concentrations 
or in non-human species). With this in mind, a reduction in administered 
gadofosveset dose (or injection rate) may be doubly beneficial: ensuring the 
bound fraction remains high, and reducing the effect of contrast agent signal 
nonlinearity, discussed in section 2.3.4 (120). In quantitative studies using 
gadofosveset, the free fraction is often not fully unaccounted for ((121), for 
example). Low bound fraction may be partly responsible for the outcome of a 
study of breast tumours in rats, which found no significant correlation between 
derived MRI parameters (endothelial permeability and fractional plasma 
volume) using gadofosveset and either microvessel density or histologically 
assessed tumour grade (122). 
 
While many of the cited studies quantitatively assess changes in contrast 
based on signal intensity, no published work has attempted to apply 
pharmacokinetic models to calculate physiological parameters such as 
perfusion or permeability using gadofosveset in a clinical study of 
angiogenesis. A search for ‘gadofosveset’ on the ClinicalTrials.gov web site 
(August 2013) found 22 studies, of which nine were in progress or actively 
recruiting patients. Three of these nine active studies involve nodal staging; 
other studies include assessment of vascular or congenital heart disease, liver 
fibrosis, response to deep vein thrombosis treatment, and a longitudinal study 
assessing occurrence of nephrogenic systemic fibrosis in patients with kidney 
disease. One study of prostate cancer is comparing gadofosveset-enhanced 
images with other MRI techniques and histology, although it is unclear the 





3.3 OTHER CLINICALLY APPROVED ALBUMIN-BINDING 




Along with gadofosveset, two other clinically approved gadolinium contrast 
agents bind reversibly to albumin: gadoxetic acid (gadoxetate, Gd-EOB-DTPA, 
marketed as Primovist in Europe and Eovist in USA, Bayer Schering Pharma 
AG, Leverkusen, Germany) and gadobenate dimeglumine (gadobenate,  
Gd-BOPTA, MultiHance, Bracco Diagnostics Inc, Milan, Italy). Both molecules 
have a gadopentetate core, a hydrophobic residue which enables non-covalent 
interaction with serum albumin (123) and a benzyl group that targets 
hepatocytes (46) (Fig. 3.4). They enter hepatocytes by a specific carrier-
mediated mechanism (organic ion transporting polypeptides (124)), then 
concentrate in the liver and are excreted into bile (43). Unlike gadofosveset, it 
is noted that the weak albumin binding does not reduce plasma clearance rates 
(46); indeed, the dual excretion pathway of gadoxetate leads to a faster 




(a) Gadoxetate (b) Gadobenate 
  
 




Figure 3.4: Comparison of molecular structures of (a) gadoxetate, (b) gadobenate and 
(c) gadofosveset; all three molecules have the basic structure of  
(d) gadopentetate (46) 
 
Gadoxetate and gadobenate have a similar affinity for HSA, with association 
constants determined by ultrafiltration at the primary binding site of 0.255 mM-1 
for gadoxetate and 0.226 mM-1 for gadobenate (126), compared with 11.0 mM-1 
for gadofosveset (68). A similar binding affinity for gadoxetate has also been 
reported elsewhere using equilibrium dialysis (127). Using the proton relaxation 
enhancement technique a higher binding affinity of 0.490 mM-1 was determined 
for gadobenate (78), although as mentioned in section 3.1.2 this method may 
be less accurate where a molecule binds at multiple sites with varying affinity 
(34). The bound fraction has been measured at approximately 10% for 
gadoxetate (128) and is quoted at 1.6% for gadobenate (129), compared with a 




As with gadofosveset, binding to albumin increases the observed relaxivity of 
these agents above that of non-binding gadolinium-based agents, primarily by 
reducing the rotational correlation time (127). At 0.47 T, observed gadoxetate 
relaxivity increases in the presence of albumin (from 5.3 to 8.7 mM-1 s-1 for r1 
and from 6.2 to 13 mM-1 s-1 for r2), with gadobenate values showing a similar 
increase (91). At 3.0 T, the presence of albumin leads to a smaller increase in 
gadoxetate longitudinal relaxivity (from 4.3 to 6.2 mM-1 s-1 for r1 and from 5.5 to 
11 mM-1 s-1 for r2), again with similar gadobenate increases (91). However, 
calculations used to determine these values were based on just two data 
points. A study of gadobenate using eight concentrations (≤ 1.0 mM) at 3.0 T 
gave higher r1 and r2 values in plasma of 6.3 and 17.5 mM
-1 s-1,  
respectively (130).  
 
Separating the relaxation contributions of the bound and free molecules, it is 
suggested that the bound and free relaxivities for gadoxetate, gadobenate and 
gadofosveset are quite similar (78, 126). The difference in observed relaxivity 
(a composite of bound and free relaxivities) results from differences in bound 
fraction. This may be expected when the structures of the three molecules are 
compared (Fig. 3.4): each has a gadopentetate core with a single coordinated 
water molecule, and a hydrophobic element linking the molecule to serum 
albumin. The increase in relaxivity on binding (resulting from the reduction in 
correlation time, discussed in section 3.1.4 for gadofosveset) is applicable for 
all three agents. As mentioned in Chapter 2, inner sphere relaxivity is also 
influenced by the distance, r, between the Gd ion and the hydrogen nucleus of 
the coordinated water molecule (proportional to r-6 (34)); this distance is almost 
identical for gadofosveset and gadobenate (131). 
 
As previously discussed for gadofosveset the effectiveness of an albumin-
binding contrast agent depends on the proportion of contrast agent that is 
bound, which in turn varies according to relative concentrations of albumin and 
contrast agent. Gadobenate relaxation rates at a fixed contrast agent 
concentration have been shown to be strongly dependent on albumin 
concentration, with R1 and R2 at 1.5 T both increasing by approximately 40% 
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when albumin concentration was increased from 3.5 to 5.5 g dL-1 (132). Across 
a wider range of albumin concentrations this increase in relaxation rate was 
noted to be nonlinear, which is likely to be due to the influence of multiple  
(up to 10) potential binding sites on the albumin molecule (132). The same 
study showed a much smaller increase in R1 and R2 with albumin concentration 
for non-binding gadopentetate, thought to be attributable solely to an increase 
in solution viscosity. 
 
The changing relationship between contrast agent concentration and relaxivity 
is perhaps most clearly observed during the first pass of the bolus, where 
contrast agent concentration is initially very high and bound fraction relatively 
low. As contrast agent concentration decreases over time, an equilibrium level 
is reached and the bound fraction approaches its maximum value. In a rabbit 
model, the gadobenate bound fraction was calculated at 7% around the bolus 
peak and a maximum of 20% at post-bolus phase (78). It is unclear whether 
gadoxetate and gadobenate bound fractions are species dependent, although 
gadofosveset bound fraction is known to be strongly species dependent, 
primarily due to variations in albumin levels between species (75). 
 
3.3.2 Clinical applications 
 
The chemical composition of gadobenate and gadoxetate ensures they are 
partially excreted through the hepatobiliary pathway and enables their use as 
targeted liver imaging agents. However, the rates of liver uptake for the two 
agents are quite different. In humans, 2 – 4% of gadobenate is taken up 
hepatically compared to 50% for gadoxetate, with the remainder being renally 
excreted (46). In animals, biliary excretion is generally higher: for example, in 
rats the biliary excretion rates for gadobenate and gadoxetate are 55% (133) 
and 73% (125), respectively. 
 
These agents facilitate two distinct phases of liver imaging: an initial perfusion 
phase, leading to immediate enhancement similar to gadopentetate; and a 
subsequent hepatobiliary phase (hepatocyte uptake and biliary excretion), 
which produces a slower increase and leads to a fivefold increase in relaxivity 
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in the liver for gadoxetate over gadopentetate (22). The high uptake rate for 
gadoxetate in the liver enables it to be administered in a smaller clinical dose 
(typically a quarter of that used for most other Gd agents). Evidence suggests 
that, despite the higher liver uptake level of gadoxetate, the relaxivity of 
gadobenate within liver tissue is actually greater, possibly due to transient 
interactions with hepatocyte proteins or membranes (22).  
 
Reduced hepatic uptake of gadoxetate correlates with disruption in liver 
function due to cirrhosis (134, 135), and enables improved detection of focal 
liver lesions (136). Delayed-phase imaging may exploit differential uptake rates 
in benign and malignant liver tissue (137, 138). A dual-input model has been 
used with gadoxetate to determine both liver perfusion and hepatic uptake for 
identification of tumours and assessment of response to treatment (139). 
 
Beyond hepatobiliary imaging, the increased gadobenate relaxivity has been 
utilised in angiography (140-142) and in evaluation of disruption to the blood–
brain barrier (143). Gadobenate has been used to identify increased 
extravascular leakage in infarcted myocardium (133, 144), and in brain  
(145-147) and breast tumours (148). 
 
It has been suggested that the high hepatobiliary excretion rate for gadoxetate 
makes this agent only useful for liver imaging (133). However, gadoxetate has 
been shown to be as effective as gadopentetate in whole-body MRI (149), and 
has also been used in urography, where the lower renal excretion rate (leading 
to a lower concentration of contrast agent) reduces the effect of T2* 
susceptibility (150).  
 
Although the observed relaxivities of gadobenate and gadoxetate are 
influenced by the proportion of molecules binding to albumin, this bound 
fraction is not easily measurable in vivo. The dual kinetic profiles of the bound 
and free molecule may confound standard tracer kinetic models, and under 
certain conditions quantitative MRI parameters may be more accurately 
determined using a non-binding agent such as gadopentetate (151). In the 
kidneys, albumin-binding effects may be accommodated in the calculation of 
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physiological parameters such as plasma volume but binding may lead to 
inaccuracy when determining glomerular filtration rate (152).  
 
Despite having relatively low albumin binding affinities (compared to 
gadofosveset), both gadoxetate and gadobenate demonstrate increased 
relaxivity in the presence of serum albumin. These favourable relaxivity 
properties have been utilised for a range of clinical applications. However, the 
variation in bound fraction with relative contrast agent concentration, resulting 
in an associated change in observed relaxivity, may reduce the accuracy of 
quantitative analysis using a single fixed relaxivity value. This may be 
particularly relevant during the first pass of the bolus, or in disease states 
where albumin levels are altered or vascular albumin leakage rates are 
increased.  
 
3.4 NON-CLINICALLY APPROVED ALBUMIN-BINDING AGENTS 
 
A Gd-based contrast agent in development, gadocoletic acid trisodium salt 
(BB22956/1, Bracco Imaging SpA, Milan, Italy), has a higher bound fraction in 
HSA than gadofosveset and less variability for binding to the serum albumin of 
other species (153). The extended retention time and increased relaxivity 
resulting from binding suggest, as with gadofosveset, a primary use for 
BB22956/1 in angiography (154). Beyond angiography, a study in rats showed 
this agent to be effective at monitoring response to anti-vascular endothelial 
growth factor treatment (155). BB22956/1 also performed well in assessment of 
changes in vascular permeability in response to treatment of subcutaneous 
breast tumours in a rat model (156). 
 
The pre-clinical agent albumin-Gd-DTPA is a permanently bound intravascular 
Gd chelate, consisting of a large number (typically 30 – 35) of gadopentetate 
dimeglumine molecules attached to a single albumin molecule. Whereas 
gadofosveset has a free fraction of approximately 10%, albumin-Gd-DTPA is 
100% bound. Its prolonged retention time and potential immunologic response 
currently preclude its use in humans (52), although it has been used 
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extensively in animal studies. Derived quantitative parameters using albumin-
Gd-DTPA have correlated with histology in the assessment of microvascular 
permeability in reperfused myocardial infarction (157) and tumour angiogenesis 
(158, 159). A study comparing gadofosveset with albumin-Gd-DTPA (122) 
found correlation between microvascular permeability and histologically 
assessed tumour grade in rats for albumin-Gd-DTPA but not for gadofosveset. 
In a mouse tumour model, quantitative parameters derived using albumin-Gd-
DTPA correlated with histology (160). Albumin-Gd-DTPA has also been used to 
explore the relationship between VEGF and endothelial permeability in rat 
xenografts (161). 
 
Although macromolecular contrast agents such as BB22956/1 and albumin-Gd-
DTPA are not approved for clinical use, there is clear evidence to suggest that 
macromolecular contrast agents enable measurement of parameters not 
possible with small-molecule agents. As the only clinically-approved Gd-based 
contrast agent with a high macromolecular fraction, it may be possible to 





A search of existing literature has established that the chemical behaviour of 
gadofosveset has been comprehensively assessed in vitro and the safety and 
efficacy of gadofosveset as an MR angiography agent have been rigorously 
established in vivo. However, the vast majority of gadofosveset research to 
date has focused on its use as a high-relaxivity intravascular agent. Aspects 
such as the influence of the free fraction and the decline in longitudinal 
relaxivity with B0 are often neglected, while properties such as multiple binding 
sites and variations in bound fraction between species may be underplayed. In 
addition, factors such as the level of binding occurring after the free molecule 




As the only clinically approved Gd-based MRI contrast agent that binds in high 
fraction to albumin, gadofosveset is uniquely positioned to facilitate alternative 
calculation of in vivo perfusion and permeability characteristics. The complex 
nature of gadofosveset pharmacokinetics, resulting from the large physical 
differences between its bound and free form and the time-varying ratio of 
bound-to-free concentrations, has not been adequately modelled. Recent 
studies suggest that the potential of gadofosveset in areas such as 
atherosclerosis and angiogenesis is beginning to be realised, although for 
DCE-MRI models to work successfully, gadofosveset must first be  
fully characterised. 
 
Alternative clinically approved albumin-binding agents are available, in the form 
of gadoxetate and gadobenate. Although the albumin binding affinity is much 
lower for these agents, the level of binding is sufficiently high to modify 
observed relaxivity and tracer kinetics, and may necessitate adaptation of 
conventional DCE-MRI models to accommodate this binding behaviour. Only a 
limited assessment of the influence of contrast agent and albumin 
concentration on the observed relaxivity has previously been carried out for 
these agents; a more thorough investigation may be of benefit for improving the 
accuracy of pharmacokinetic modelling with gadoxetate and gadobenate. 
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CHAPTER 4: EXPLORING THE LONGITUDINAL RELAXIVITY OF 
GADOFOSVESET AND OTHER ALBUMIN-BINDING AGENTS AT 




As discussed in Chapter 3, gadofosveset binds reversibly with albumin in the 
blood, leading to a significantly higher longitudinal relaxivity that peaks at 
around 0.5 T and decreases substantially at higher magnetic fields. Bound 
fraction is at a maximum at very low gadofosveset concentrations, and varies 
according to relative gadofosveset and serum albumin concentrations. In 
dynamic gadofosveset-enhanced studies, the complexity of tracer kinetic 
modelling is increased due to the variation of bound fraction with time and the 
direct influence of binding on relaxivity. Rather than employing a simple linear 
relationship between relaxation rate and contrast agent concentration, with a 
single, fixed relaxivity to convert signal intensity to concentration at a given field 
strength, the concept of a ‘dynamic’ or observed relaxivity, varying as 
gadofosveset binding changes over time, has previously been suggested (78). 
In addition, the individual relaxivities of the bound and free gadofosveset 
molecule vary in response to changes in field strength, temperature  
and pH (37). 
 
Many of these factors are often not accounted for in studies using 
gadofosveset, with assumptions made to reduce model complexity. Previous 
gadofosveset relaxivity studies have generally assumed gadofosveset binding 
at a single site on the albumin molecule (77, 78), which is likely to lead to an 
underestimation of relaxivity at higher gadofosveset concentrations. It may be 
necessary to consider additional binding sites when analysing peak 
concentration levels, such as during the first pass of a bolus. Although the 
process of binding will not change with field strength, the influence on observed 
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relaxivity will be modified due to the manner in which bound and free 
relaxivities vary with field. 
 
It would be beneficial to fully characterise the in vitro properties of gadofosveset 
prior to modelling its tracer kinetics in vivo, although translation of in vitro 
gadofosveset relaxivity measurement may not be straightforward. For example, 
species differences in albumin levels and binding characteristics may create 
differences in bound fraction (75), and the response of the bound and free 
molecule to changes in temperature results in opposing variations in relaxivity 
(37). Another important factor to account for is the influence of field strength on 
bound and free relaxivity. Much of the initial gadofosveset characterisation work 
prior to clinical trials was carried out at low fields (63, 77). Although 
measurement of the relaxivity of free gadofosveset (and observed relaxivity in 
plasma) has been carried out at field strengths up to 4.7 T (91), it is difficult to 
find published values of bound gadofosveset relaxivity at field strengths of 3.0 T 
and above. As the strength of clinical magnets continues to increase, it is 
important to assess the properties of gadofosveset at field strengths that are, or 
may become, clinically relevant. 
 
Gadoxetate and gadobenate are clinically approved Gd-based MRI contrast 
agents with much lower albumin-binding affinities than gadofosveset, leading to 
a lower bound fraction and a smaller, but measurable, effect on observed 
relaxivity (see section 3.3.1). Comparing the longitudinal relaxivities of these 
low-affinity agents with those of gadofosveset, at a range of magnetic field 
strengths, may provide further evidence regarding the benefits and limitations 
of gadofosveset, and may support the successful application of these 
commonly used agents. As with gadofosveset, published values of bound 
relaxivity could not be found for gadoxetate or gadobenate at 3.0 T and above. 
 
4.2 AIMS AND OBJECTIVES 
 
The primary aim of this study was to gain a greater understanding of the 
influence of albumin binding on the longitudinal relaxivity of gadofosveset at a 
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range of field strengths and temperatures. In addition, the study aimed to 
acquire supplementary information on the influence of albumin binding on the 
relaxivities of gadoxetate and gadobenate. The following key objectives  
were set: 
 
1. Measure the longitudinal relaxation rates of in vitro gadofosveset solutions at 
a range of concentrations, in the presence and absence of serum albumin, at 
magnetic field strengths between 0.47 T and 9.4 T, at room and  
body temperature. 
 
2. Use these measured relaxation rates to determine the longitudinal 
relaxivities of bound and free gadofosveset (assuming a single binding site), 
and identify variances in relaxivity with field strength and temperature. 
 
3. Repeat the relaxation rate measurements for gadofosveset in mouse 
plasma, to assess the influence of species differences in albumin levels. 
 
4. Compare the single-binding-site relaxation rate model fits for gadofosveset in 
serum albumin with equivalent fits incorporating two and three binding sites. 
 
5. Repeat the measurements of relaxation rates and calculations of bound and 
free relaxivity for gadoxetate and gadobenate in the presence and absence of 
serum albumin. 
 
Existing literature provides an incomplete picture of the variation of bound 
relaxivity with field strength for these three agents, particularly at 3.0 T and 
above. By calculating bound and free relaxivities across a range of fields, an 
informed choice of dynamic relaxivity may be made for in vivo calculations. 
Comparing model fits with one, two or three binding sites allows an assessment 
of the adequacy of the common assumption of a single binding site. Measuring 
the relaxation rate of gadofosveset in mouse plasma gives further information 
regarding the binding of this agent, and may aid in the translation of pre-clinical 
studies. Extending relaxivity calculations to gadoxetate and gadobenate, which 
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have a much lower binding fraction than gadofosveset, should indicate the 
extent to which binding and dynamic relaxivity must be considered. 
 
By characterising the in vitro relaxation properties of these albumin-binding 
agents, across a range of field strengths and at clinically relevant 
concentrations, it is hoped that future studies may be better informed as to the 





4.3.1 Determining relaxivity 
 
The equation to determine the change in longitudinal relaxation rate, ΔR1, for 
an albumin-binding contrast agent is taken from Chapter 3 (Eq. 3.10). 
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where r1bound and r1free are the relaxivities of the bound and free 
molecules, respectively, Cg is the total contrast agent concentration, Ka 
is the binding affinity and Csa is the albumin concentration. 
 
 
In the absence of albumin, Csa = 0 and the second term in Eq. 3.10 vanishes 
(Eq. 4.1). 
 
                [4.1] 
 
Eq. 4.1 is of the form of Eq. 2.14 (Chapter 2); linearity is assumed, but may 




Bound and free relaxivities are expected to vary with field strength and 
temperature, and may be determined by measuring R1 of in vitro solutions 
containing known quantities of Cg and Csa. r1free may then be derived using a 
one-parameter linear fit (Eq. 4.1) to R1 measurements of in vitro solutions 
without albumin, and r1bound may be derived using a one-parameter nonlinear fit 
(Eq. 3.10) to R1 measurements of solutions containing albumin at a fixed Csa 
concentration (with a literature Ka value). This process can be repeated at a 
range of relevant field strengths and temperatures. 
 
4.3.2 Assessing binding sites 
 
Although it is often assumed that only one gadofosveset molecule binds per 
albumin molecule (77, 78), several molecules are expected to bind at high Cg 
values (63). Eq. 3.11 (Chapter 3) provides an approach for accommodating 
additional binding sites where binding affinities at these additional sites are 
equal, which is not the case for gadofosveset. To allow for the influence of 
binding at second and third sites with different binding affinities and relaxivities, 
an adaptation of Eq. 3.10 is suggested.  
 
The observed change in relaxation rate (ΔR1) may be considered as the sum of 
changes in relaxation rate induced by the free gadofosveset molecule (ΔR1free) 
and changes in relaxation rate induced by the first, second and third bound 
molecules (ΔR1bound1, ΔR1bound2 and ΔR1bound3, respectively) (Eq. 4.2). 
 
                        
              
             
[4.2] 
 
If the assumption is made that binding sites are filled sequentially, such that 
binding will not occur at the second site until all primary binding sites are filled 
and binding will not occur at the third site until all secondary binding sites are 
filled, the bracketed ΔR1bound2 and ΔR1bound3 terms can be removed from Eq. 4.2 
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according to relative albumin–gadofosveset concentrations. Assuming the first 
binding sites are all filled at Cg = Csa, the ΔR1bound2 term should be included 
where Csa < Cg ≤ 2Csa and the ΔR1bound3 term included where Cg > 2Csa. 
 
Eq. 3.10 includes contributions from the free gadofosveset molecule (r1free.Cg) 
and the first bound molecule (the remainder of the equation). Adding 
concentration-dependent terms for the second and third bound molecules gives 
three variations of Eq. 3.10, allowing for binding affinities Ka1, Ka2, Ka3 and 
bound relaxivities r1bound1, r1bound2, r1bound3 at the first, second and third binding 
sites, respectively. (Eq. 4.3a–c). 
 
For Cg ≤ Csa: [4.3a] 
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For Csa < Cg ≤ 2Csa: 
 
[4.3b] 
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For Cg > 2Csa: 
 
[4.3c] 
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4.4.1 In vitro solutions 
 
In vitro solutions were prepared using phosphate-buffered saline (PBS, dry 
powder reconstituted with deionized water, pH 7.4, Sigma Aldrich, St Louis, 
MO) and bovine serum albumin (BSA, Cohn fraction V lyophilized powder, 
Sigma Aldrich, in PBS). Gadofosveset (Vasovist) solutions were created at the 
following concentrations: Cg = 0, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 5.0 mM  
(Csa = 0 mM and Csa = 0.67 mM (4.5% w/v BSA)). Solutions of gadofosveset in 
mouse plasma were created at Cg = 0, 0.25, 0.5, 1.0, 2.0 mM. In vitro solutions 
of gadoxetate (Primovist) and gadobenate (MultiHance) were created at Cg = 0, 
0.2, 0.5, 0.7, 1.0 mM (Csa = 0 mM and Csa =0.7 mM BSA). Approximately  
8.0 mL of each solution was decanted to borosilicate NMR tubes of external 
diameter 10.0 mm, internal diameter 8.0 mm and length 150.0 mm (supplied by 
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YORLAB, York) for use at 0.47 T. Smaller plastic tubes (external diameter  
12.0 mm, length 40.0 mm) containing approximately 1.5 mL of solution were 
used at higher fields to allow for the small bore size of the pre-clinical scanners. 
 
4.4.2 Measurements at 0.47 T 
 
Measurements were made on a Maran NMR spectrometer (Oxford 
Instruments, Abingdon) utilising a 0.47 T (20 MHz) permanent magnet attached 
to a thermocouple heating mechanism and a PC running standard system 
software. T1 was measured using an inversion recovery (IR) sequence, with 20 
log incremental inversion time (TI) recovery steps and 16 scans. The recovery 
time (TR) was set to at least five times the expected final T1 value. Receiver 
gain, frequency offset and pulse length were automatically set by the system. 
For the two solutions without contrast agent, 10 linear TI steps and four scans 
were used (to maintain practical overall scanning times), and the TR was set to 
10 s. The bore temperature was allowed to stabilise for at least five minutes 
before samples were inserted, followed by a further five minutes for solution 
temperature stabilisation. All solutions were manually agitated to ensure full 
mixing of the contrast agent. Measurements were taken at 21 – 22 ˚C and  
37 ˚C to represent room and body temperature, respectively.  
 
4.4.3 Measurements at 3.0 T 
 
For gadofosveset, tubes were placed vertically in a plastic container filled with 
PBS at room temperature (20 – 22 ˚C). This container was placed in a Siemens 
head matrix coil in a 3.0 T Siemens Magnetom Verio scanner. Images were 
acquired using a spin echo (SE) IR sequence, with two coronal (horizontal) 
slices through the short axis of the tubes. Sequence parameters: 10 inversion 
times (TI = 22, 40, 75, 110, 150, 300, 600, 1000, 2000, 4000 ms);  
TR = 10000 ms; echo time (TE) = 18 ms; field of view (FOV) = 261 x 100 mm; 




For gadoxetate and gadobenate, tubes were placed vertically within a head coil 
(SENSE-Head 8) in a 3.0 T Philips Achieva TX system at room temperature  
(18 °C). Images were acquired using an SE IR sequence with a single coronal 
(horizontal) slice. Sequence parameters: 10 inversion times (TI = 50, 83, 136, 
225, 371, 611, 1009, 1665, 2747, 4925 ms); TR = 5000 ms; TE = 6.2 ms;  
FOV = 230 x 230 mm; matrix size = 240 x 240 pixels; slice thickness = 10 mm. 
 
No heating mechanism was available on either clinical 3.0 T scanner to heat 
the samples to body temperature. 
 
4.4.4 Measurements at 4.7 T 
 
For gadofosveset, tubes were placed horizontally in a cylindrical cradle of 
diameter 6.0 cm. An additional tube containing water and a fibre optic 
temperature probe was also placed into the cradle to monitor solution 
temperature. The cradle was inserted into a 63 mm quad coil in a horizontal 
bore 4.7 T magnet with Bruker console running ParaVision 5.1 software (Bruker 
BioSpin MRI GmbH, Ettlingen, Germany). Images were acquired using a fast 
spin echo saturation recovery sequence (rapid acquisition with relaxation 
enhancement, RARE), with two sets of TRs to provide additional detail for 
those solutions with very short relaxation times. Slice direction was axial 
(vertical), through the short axis of the tubes. Measurements were made at 
approximately 19˚C and 37˚C for room and body temperature, respectively. 
Sequence parameters: Recovery time (long series) = 57.2, 103.5, 183.5, 283.5, 
583.5, 1483.5, 2983.5, 7983.5 ms; recovery time (short series) = 57.2, 68.5, 
78.5, 88.5, 103.5, 183.5, 283.5, 383.5 ms; TE = 11 ms; slice thickness = 1 mm; 
FOV = 45 x 45 mm; matrix size = 256 x 256 pixels.  
 
The experimental set-up for the gadoxetate and gadobenate samples was 
identical to that for gadofosveset, with the exception of a larger FOV  
(60 x 60 mm) and a single set of recovery times (57.2, 68.5, 78.5, 88.5, 103.5, 
183.5, 483.5, 983.5, 2983.5 ms). Measurements were made at approximately 




4.4.5 Measurements at 9.4 T 
 
Gadofosveset samples were inserted into a cylindrical cradle of diameter  
4.0 cm, and placed inside a 63 mm quad coil in a horizontal bore 9.4 T Varian 
scanner. Images were acquired using a FLASH (fast low-angle shot) gradient 
echo (GE) IR sequence, with 20 TIs, a centre-out phase encoding ordering and 
one line of k-space acquired per excitation. Slice direction was axial (vertical), 
through the short axis of the tubes. Measurements were made at approximately 
22˚C and 32 – 34˚C for room and body temperature, respectively (temperatures 
could not be increased to 37 °C due to a fault with the heating mechanism). 
Delay time prior to application of inversion = 10000 ms; TI = 6.5, 7, 8, 9, 10, 30, 
50, 100, 150, 200, 250, 500, 750, 1000, 2000, 5000, 7000, 9000, 12000,  
15000 ms; slice thickness = 1 mm; FOV = 50 x 50 mm; matrix size = 128 x 128 
pixels. Gadoxetate and gadobenate samples were not measured at this  
field strength. 
 
4.4.6 Calculating relaxation rate, R1 
 
The models used for calculating R1 are summarised in Table 4.1. All model 
fitting was carried out using a nonlinear regression function in MATLAB (v7.9, 
MathWorks, USA; ‘nlinfit’ function). Confidence intervals (CI) were calculated at 
the 95% level using a nonlinear regression parameter CI function in MATLAB 
(with the exception of gadofosveset at 0.47 T, where CIs were calculated from 




Table 4.1: Summary of sequences used for R1 measurement 
Gadofosveset 0.47 T 3.0 T 4.7 T 9.4 T 
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where SI is measured signal intensity; S0 represents the fully recovered signal 
intensity; b accounts for any deviation in angle from the ideal 180° inversion 
pulse; SE is spin echo; GE is gradient echo; IR is inversion recovery; SR is 
saturation recovery 
 
For gadofosveset at 0.47 T, the system software automatically calculated T1 
(1/R1) values by fitting an exponential curve to the plotted signal intensities at 
the full range of TI values; measurements were repeated three times for each 
solution, and the mean of these three measurements used in the analysis. For 
gadoxetate and gadobenate at 0.47 T, an equivalent model was applied offline 
using the downloaded signal intensity (SI) values at each inversion time. 
Acquisitions at higher fields were based on imaging sequences, with circular 
regions of interest (ROI) drawn within each tube image and the average SI of 
each ROI measured using ImageJ software (v1.42q, Wayne Rasband, National 
Institutes of Health, USA). For the 9.4 T images, an in-house (AstraZeneca) 
model was used to reconstruct data to take account of phase and to reduce 
image noise by k-space filtering. Circular ROIs were then drawn on these 
reconstructed SI maps as described previously. For gadofosveset at 4.7 T, both 
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sets of TR were analysed separately for each tube and the R1 with the smallest 




Relaxivity of the free molecule was calculated by applying a linear fit to the PBS 
(Csa = 0 mM) data (Eq. 4.1). Bound relaxivity was calculated by applying a 
nonlinear one-parameter fit (Eq. 3.10) to the BSA (Csa = 0.67 mM for 
gadofosveset; Csa = 0.7 mM for gadoxetate and gadobenate) data at points 
where Cg ≤ 0.75 mM. Higher concentrations were excluded to reduce the 
potential influence of multiple binding sites on the calculation of bound 
relaxivity. Ka values of 11.0, 0.255 and 0.226 mM
-1 were used for gadofosveset, 
gadoxetate and gadobenate, respectively. Overall observed relaxivity (r1obs), a 
composite of r1bound and r1free, was also calculated by applying a linear fit to low 
concentration (Cg ≤ 0.75 mM) solutions of gadofosveset, gadoxetate and 
gadobenate in BSA. 
 
4.4.8 Additional binding sites 
 
An attempt was made to incorporate up to two additional binding sites for 
gadofosveset, using Eq. 4.3a–c, with the same (calculated) bound relaxivity at 
all sites and a binding affinity at the second and third binding sites (Ka2 and Ka3) 




Fig. 4.1 shows relaxation rates at room temperature (approximately 21 °C) at 
all field strengths. Body temperature values (not shown here, but included in 








Figure 4.1: Measured relaxation rates (R1) for gadofosveset, gadoxetate and 
gadobenate in PBS (left column) and BSA (right column) at room temperature 
(approximately 21 °C) at 0.47 T and 3.0 T (all agents), and at 4.7 T and 9.4 T 





Following calculation of r1free using the PBS solutions (Eq. 4.1), the nonlinear 
model (Eq. 3.10) was applied to determine r1bound for the BSA solutions. Fig. 4.2 
(gadofosveset) and Fig. 4.3 (gadoxetate and gadobenate) show this model fit, 




Figure 4.2: Measured ΔR1 values for gadofosveset in BSA; lines represent nonlinear fit 
to Cg ≤ 0.75 mM data points (Eq. 3.10; Ka = 11.0 mM
-1); error bars represent  








Figure 4.3: Measured ΔR1 values for gadoxetate (circles) and gadobenate (squares) in 
BSA; solid (gadoxetate) and dotted (gadobenate) lines represent nonlinear fit to 
Cg ≤ 0.75 mM data points (Eq. 3.10; Ka = 0.255mM
-1 and 0.226 mM-1 for 
gadoxetate and gadobenate, respectively); error bars represent 95% CI (omitted 
where smaller than data point) 
 
Bound and free relaxivity values are shown in Fig. 4.4 and summarised in 
Table 4.2. The relaxivity of the bound gadofosveset molecule peaks at low field, 
showing a sharp decrease between 0.47 T and 3.0 T and a moderate decrease 
at higher field strengths (Fig. 4.4a). The relaxivity of the free gadofosveset 
molecule has a much lower peak, and decreases slightly with field strength 
(Fig. 4.4b). A similar pattern is displayed for gadoxetate and gadobenate. 
Above 4.7 T, the binding of gadofosveset to albumin does not benefit the 









Figure 4.4: Calculated bound (left column) and free (right column) relaxivity values for 
all three agents, split by temperature (labelled 21 °C and 37 °C, but actual 
temperatures may differ slightly – see Table 4.1); error bars represent 95% CI 




Table 4.2: Summary of calculated relaxivity values and 95% confidence intervals  
(mM-1 s-1) 
 
The influence of additional binding sites is illustrated for gadofosveset in  
Fig. 4.5, where the original model is adapted to include second and third 
binding sites (Eq. 4.3a–c). Model fitting results are shown at room temperature 
only; body temperature model fits (Appendix B (Fig. B.2)) display a very  
similar pattern. 
  
Gadofosveset 21 °C 37 °C 21 °C 37 °C 19 °C 37 °C 22 °C 33 °C
r1bound 33.4 (1.2) 42.4 (2.9) 12.0 (1.4) 8.4 (0.5) 7.4 (0.6) 5.3 (0.4) 4.6 (0.8)
r1free 8.9 (0.3) 6.6 (0.2) 8.7 (0.2) 7.1 (0.5) 5.1 (0.3) 6.5 (0.2) 5.3 (0.1)
r1obs 26.1 (4.2) 31.8 (4.6) 11.0 (0.4) 8.0 (0.2) 6.7 (0.1) 5.7 (0.5) 4.8 (0.5)
Gadoxetate 21 °C 37 °C 18 °C 36 °C
r1bound 27.2 (1.5) 30.9 (0.7) 11.8 (2.9) 4.6 (1.0)
r1free 7.2 (0.2) 5.5 (0.1) 7.4 (0.2) 5.2 (0.3)
r1obs 9.9 (0.4) 9.0 (0.3) 8.0 (0.4) 5.1 (0.1)
Gadobenate 21 °C 37 °C 18 °C 36 °C
r1bound 33.9 (1.2) 39.5 (1.2) 13.7 (0.4) 5.6 (9.0)
r1free 5.7 (0.1) 4.3 (0.1) 5.7 (0.1) 3.6 (0.1)
r1obs 9.2 (0.1) 8.7 (0.1) 6.7 (0.1) 3.8 (1.1)





Figure 4.5: Modelling n = 1 – 3 binding sites at all field strengths at room 
temperature, using Eq. 4.3a–c. Circles represent measured gadofosveset data 
points; solid line is original model (single binding site, Eq. 4.3a, Ka1 = 11.0 mM
-1); 
dotted line also includes a second binding site (Eq. 4.3b, Ka2 = 0.86 mM
-1); 
dashed line also includes a third binding site (Eq. 4.3c, Ka3 = 0.26 mM
-1); the 
same relaxivity values (from Table 4.2) were used at all three binding sites 
 
A comparison of measured R1 values for gadofosveset in BSA (at  





Figure 4.6: Comparison of R1 values at 37 °C for gadofosveset in BSA (circles,  








The relationship between R1 and Cg for gadofosveset in the absence of 
albumin is approximately linear, with any differences caused by field strength 
only being observed at very high Cg (Fig. 4.1a). For gadofosveset in the 
presence of albumin, a nonlinear relationship between R1 and Cg is observed 
(Fig. 4.1b). 
 
Applying the nonlinear ΔR1 model (Eq. 3.10) to the BSA measurements at low 
Cg (≤ 0.75 mM), it is clear that the model underestimates ΔR1 at high Cg at  
0.47 T (Fig. 4.2a). This underestimation at high Cg is likely to be due to the 
assumption of a single binding site. Once this binding site is filled for all 
albumin molecules (at Cg = Csa), additional gadofosveset is assumed to remain 
free. However, if gadofosveset also binds to other sites on the albumin 
molecule, this may lead to a greater contribution to observed ΔR1. The 
underestimation is not observed at higher fields (Fig. 4.2b to 4.2d), where the 
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differences between relaxivities of the bound and free molecule are expected to 
be small. As can be seen from Eq. 3.10, when r1bound approaches r1free the ΔR1 
calculation is dominated by the product of r1free and Cg and the model becomes 
approximately linear. 
 
Gadoxetate and gadobenate 
 
For both gadoxetate and gadobenate in PBS, there is no difference between R1 
at 0.47 T and 3.0 T (Fig. 4.1c and 4.1e). In the presence of albumin, 
gadoxetate ΔR1 values are slightly higher than equivalent gadobenate values 
(Fig. 4.3); there is some evidence of nonlinearity in these plots at 0.47 T, but 






At 0.47 T, the r1free, r1bound and r1obs values at 37 °C in this study (6.6, 42.4 and 
31.8 mM-1 s-1, respectively) are close to those found in the literature  
(r1free = 6.8 mM
-1 s-1 (162), r1bound = 42 mM
-1 s-1 (approximately, below  
Cg = 1 mM) (68) and r1obs = 28.0 mM
-1 s-1 (91)). r1free and r1obs values at 4.7 T at 
37 °C are also close to literature values (5.1 and 6.7 mM-1 s-1, respectively, in 
this study versus 5.5 and 6.9 mM-1 s-1, respectively, in the literature (91)). Due 
to variations in experimental set-up, it is difficult to find directly equivalent r1bound 
literature values for comparison at field strengths of 3.0 T and above. 
 
Bound (and observed) gadofosveset relaxivity at 0.47 T has previously been 
shown to increase with temperature, with free relaxivity decreasing with 
temperature (37). This pattern is also demonstrated at 0.47 T in this study  
(Fig. 4.4). At high field, r1free remains consistently lower at 37 °C than at 21° C 
(Fig. 4.4b), but r1bound values at high field are very similar for both temperatures 
(Fig. 4.4a). Although the heating mechanism used at 9.4 T was unable to heat 
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the samples above 34 °C, it is likely the results would have been very similar  
at 37 °C. 
 
Gadoxetate and gadobenate 
 
Calculated free relaxivity values at 0.47 T and 4.7 T for gadoxetate and 
gadobenate (Fig. 4.4d and 4.4f; Table 4.2) closely match those published 
elsewhere (91), although comparative bound relaxivity values are more difficult 
to find in the literature. Studies of gadobenate at 0.47 T and 37 °C have 
calculated r1bound at 36 mM
-1 s-1 in rabbit plasma (78), and 32 mM-1 s-1 (163) 
and 42.9 mM-1 s-1 (126) in human serum albumin. These values are close to 
the equivalent gadobenate r1bound value of 39.5 mM
-1 s-1 in this study. Also at 
0.47 T and 37 °C, r1bound for gadoxetate in human serum albumin has been 
calculated at 37.3 mM-1 s-1 (126), compared with a value of 30.9 mM-1 s-1 in this 
study. 
 
Calculated r1bound values are lower, and r1free and r1obs values are slightly higher, 
for gadoxetate than gadobenate across all fields and temperatures. This is 
generally consistent with values reported elsewhere (91). 
 
4.6.3 Multiple binding sites 
 
As illustrated in Fig. 4.2a, at low field the nonlinear model underestimates 
gadofosveset ΔR1 at high Cg. This is likely to be due to the influence of 
additional binding sites on the albumin molecule not accounted for by the 
model. Eq. 3.10 is derived based on the assumption of a single bound 
gadofosveset molecule per serum albumin molecule, with a saturation point at 
Cg = Csa. If gadofosveset were to bind at multiple sites on the albumin 
molecule, saturation would occur at a higher Cg (> Csa). A modified version of 
Eq. 3.10 accommodating n binding sites of equivalent affinity (Eq. 3.11 in 
Chapter 3) has previously been presented in the context of gadofosveset 
relaxation rates (37, 77). However, the primary binding site has been shown to 
have a substantially higher binding affinity than other sites (11.0 mM-1 at the 
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primary site, compared to 0.84 and 0.26 mM-1 at the second and third binding 
sites, respectively (68)), therefore this approach may not be applicable. It is 
unclear to what extent these additional bound molecules influence the overall 
relaxivity. A similar relaxivity at all binding sites has previously been assumed 
(164), although it is suggested that the primary binding site is one of higher 
relaxivity (68).  
 
An alternative model to accommodate up to three binding sites is suggested 
(Eq. 4.3). Three versions of the model are plotted in Fig. 4.5 to assess 
differences between inclusion of one, two and three binding sites, along with 
measured gadofosveset data points at all field strengths and temperatures. All 
models use the appropriate r1free value from Table 4.2. As bound relaxivities at 
the second and third sites are not known, all bound relaxivities were set to the 
same value (r1bound1 = r1bound2 = r1bound3 = r1bound from Table 4.2).  
 
At 0.47 T, the underestimation of ΔR1 at high Cg noted in the original model 
(solid line, Fig. 4.5a) is improved by the inclusion of a second binding site 
(dotted line), but values at high Cg are overestimated by the inclusion of a third 
binding site (dashed line). This overestimation for n = 3 is likely to be due to the 
same r1bound value being used for all three sites; in reality, it may be that r1bound1 
> r1bound2 > r1bound3. Additional binding sites provide minimal improvement to the 
model fit at 3.0 T; at higher fields the difference is negligible and the 
consideration of additional binding sites may be unnecessary. In vivo, the 
consideration of additional binding sites is unlikely to be a factor during the 
post-bolus equilibrium phase (where Cg values are lower). The requirement to 
consider multiple binding sites may be eliminated altogether if the peak Cg 
value is sufficiently low, which may be achieved by reducing the dose or 
injection rate, for example.  
 
A previous study using ultrafiltration showed that gadoxetate and gadobenate 
interacted with albumin at a single site (126), and no published binding affinity 
values can be found for a second binding site. The model fits well with a single 
site (Fig. 4.3); adding a second binding site (with an equal affinity to the first 




4.6.4 Species differences: gadofosveset 
 
All measurements of bound relaxivity for gadofosveset were made using bovine 
serum albumin at a concentration of 0.67 mM (4.5% w/v). As mentioned in 
section 3.1.2, the variation in the bound fraction of gadofosveset between 
species is thought to be mostly attributable to differences in albumin level, 
therefore assessing in vitro gadofosveset samples containing albumin at a level 
corresponding with that found in humans should ensure the results are relevant 
for potential clinical translation.  
 
Confirmation of the dominant influence of bound fraction is found not only in the 
comparison of observed relaxivity between gadofosveset and gadoxetate or 
gadobenate, but also in the measurements of gadofosveset in mouse plasma. 
Here, relaxation rates for gadofosveset in mouse plasma at Cg ≤ 2 mM were 
compared with values using BSA at Csa = 0.67 mM at low (0.47 T) and high 
(4.7 T) field (Fig. 4.6). The difference in R1 between BSA and mouse plasma is 
significant at 0.47 T (Fig. 4.6a), where bound fraction has a much greater 
influence over the observed relaxivity due to the large difference between 
r1bound and r1free (Table 4.2). At 4.7 T, there is little difference between BSA and 
mouse plasma R1 measurements (Fig. 4.6b), reflective of the small difference 
between r1bound and r1free at high field, resulting in a lower influence of bound 




The one-parameter model used to determine r1bound by fitting to experimental 
ΔR1 values (Eq. 3.10) assumes a fixed literature value for Ka. An attempt was 
made to derive Ka rather than take a literature value, by fitting Eq. 3.10 for two 
unknown parameters. However, this revised model could not be satisfactorily 
resolved (returning Ka and r1bound values beyond the range that might 
reasonably be expected). The influence of Ka may be explored by comparing 
the model fit at additional Ka values; doubling or halving the assumed Ka value 
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of 11.0 mM-1 does not significantly alter the model fit at 0.47 T in this study  
(Fig. 4.7), and would have even less effect at higher fields. Although some 
difference in binding affinity may be expected between room and body 
temperature, a constant Ka value was used at both temperatures as only 
relevant literature Ka values at 37 °C could be found.  
 
  
Figure 4.7: Effect of Ka on gadofosveset model fit at 0.47 T at (a) 21 °C and  
(b) 37 °C; data points and solid lines match those in Fig. 4.2a and 4.2b 
 
A second potential limitation of this study is that bovine serum albumin was 
used as a surrogate for human serum albumin. Although the binding 
characteristics of BSA may differ slightly from those of HSA, albumin solutions 
were created at a typical concentration expected in healthy humans, therefore 
bound fractions and the proportional influence of the bound and free 
gadofosveset molecule on observed relaxivity would still be expected to be 
applicable. Bovine plasma has previously been used as the solvent for 
assessing the relaxivities of a range of contrast agents (91). BSA has been 
shown to be similar in structure to HSA, with some differences in binding 
pockets (165). 
 
As noted in Chapter 2 (Table 2.1) the standard clinical dose for gadobenate is 
0.1 mmol kg-1, which is higher than gadoxetate (0.025 mmol kg-1) or 
gadofosveset (0.03 mmol kg-1). In this study like-for-like concentration 
comparisons were made (up to 1 mM), and no account was taken of the 
variation in clinical dose between agents. The physiologically applicable 
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concentration range could have been extended for gadobenate, although the 
results as presented remain valid.  
 
For various reasons (time constraints, faulty or unavailable heating 
mechanisms) it was not possible to acquire data for all contrast agents at all 
fields at room and body temperature. As gadofosveset is the main focus of this 
research, priority was given to acquiring data for this agent. Although the 
dataset is incomplete, the influence of temperature on the relaxivity of the 
bound and free molecule is clearly observed. Any small variation in ‘room’ or 
‘body’ temperature between agents is unlikely to have a significant impact on 




In summary, this study provides information regarding gadofosveset 
longitudinal relaxivity not currently available elsewhere, particularly in relation to 
bound relaxivity values at field strengths of 3.0 T and above. Differences 
between the longitudinal relaxivities of the bound and free gadofosveset 
molecule are large at low field but small at high field. Factors influencing the 
bound fraction, such as relative concentrations of gadofosveset and serum 
albumin, will therefore have a significant impact on the observed relaxivity at 
low field but will have limited impact at high field. Consideration should be given 
to incorporating a dynamic relaxivity, which changes with bound fraction, when 
applying tracer kinetic models at low field. The influence of species differences 
in albumin levels and binding properties is demonstrated to have a much 
greater effect at low field, and may markedly alter the outcome of pre-clinical 
studies using gadofosveset. The common assumption that a single 
gadofosveset molecule binds per albumin molecule may lead to an 
underestimation of relaxation rate at low field at high gadofosveset 
concentration, although this model simplification has little influence at  
high fields.  
 
As expected from the literature, bound and free longitudinal relaxivities for 
gadoxetate and gadobenate are generally similar to those for gadofosveset. 
78 
 
However, due to a much lower binding affinity, the observed relaxivity is 
significantly lower for these agents than for gadofosveset at low field. As with 
gadofosveset, bound relaxivity values calculated here for gadoxetate and 
gadobenate at field strengths of 3.0 T and above have not previously been 
published. As field strength increases, r1bound approaches r1free at high field and 
the influence of binding on observed relaxivity reduces, although even at low 
fields the change in relaxation rate with contrast agent concentration is 
approximately linear. The use of any contrast agent in quantitative MRI studies 
requires an accurate relaxivity value to precisely monitor contrast agent 
kinetics. The in vivo relaxivity of an albumin-binding contrast agent is dynamic 
rather than fixed, varying particularly during the first bolus pass when the bound 
fraction is changing rapidly. The data presented here for gadoxetate and 
gadobenate suggests that, unlike gadofosveset, a single relaxivity value may 
still adequately represent this situation due to the relatively low binding affinity 
of these agents.  
 
It should be noted that only the longitudinal relaxivity properties of these 
albumin-binding agents have been explored in this chapter. Transverse 
relaxivity measurements are discussed in Chapter 7, and may provide an 





CHAPTER 5: A THEORETICAL APPPROACH TO IN VIVO 




5.1.1 Contrast agent blood concentration 
 
Establishing the blood concentration of a contrast agent is a fundamental step 
in calculating many quantitative parameters in dynamic contrast-enhanced 
(DCE) MRI. DCE-MRI enables functional tissue parameters to be assessed by 
monitoring the transit of a contrast agent over time. Amongst its many areas of 
application, DCE-MRI has been used in the quantitative assessment of 
myocardial (166) and pulmonary (167) perfusion. DCE-MRI may also be used 
to assess angiogenesis, a process that is fundamental to the progress and 
metastasis of tumours, along with other biomarkers in oncology (168). 
Quantification may be based on a simple, non-model-based approach such as 
measuring enhancing fraction (20). Charting signal intensity against time 
provides tissue-related parameters including onset time, maximum signal 
intensity and wash-out characteristics (23).  
 
Alternatively, parameters such as tissue perfusion and micro-vessel 
permeability may be determined through the application of tracer kinetic 
models. Commonly, these models consist of two compartments representing 
intravascular and extravascular extracellular spaces, with the rate of transfer 
between the compartments determined through mathematical modelling (169). 
The conventional starting point for such models is the intravascular contrast 
agent concentration prior to extravasation, known as the vascular input function 
(VIF), which can be measured in a nearby vessel (170). In such models, 
quantitative parameters are derived by separating changes in contrast agent 
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concentration within the tissue of interest from those in a feeding artery using 
deconvolution (171). 
 
The VIF following bolus injection of a gadolinium (Gd) contrast agent is 
characterised by a high initial peak in contrast agent concentration during the 
wash-in phase, of very short duration, followed by a decrease in concentration 
during the wash-out and clearance phases. Often, the VIF is modelled as either 
an instantaneous peak or a sharp linear rise to peak concentration, followed by 
a bi-exponential decay representing extravasation and excretion rates  
(Fig. 5.1). This simplified approach neglects potential recirculation effects; more 
complex models attempt to correct for this (172). 
 
 
Figure 5.1: Example of a VIF, showing linear rise to peak and bi-exponential decay (not 
accounting for recirculation effects) ((173), using parameters from (172)) 
 
The robustness of tracer kinetic models may be compromised by practical 
difficulties associated with accurate VIF measurement. Potential errors in 
converting measured signal intensity to contrast agent concentration may be 
further complicated when using gadofosveset, due to its binding to albumin, 
and may be exacerbated by acquisition limitations including temporal 
resolution, signal saturation, partial volume effects and flow artefacts (174), and 
by delay and dispersion of the bolus in the tissue of interest (26). In small 
animals, the requirement for improved spatial resolution due to smaller vessel 
size must compete with an increased temporal resolution requirement due to a 
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higher heart rate (175-177). Using a population average VIF, rather than one 
acquired from an individual subject, may improve model robustness (178), 
particularly in small animals (179). An alternative approach to measuring 
vascular signal intensity changes may be to take measurements in a reference 
tissue within the field of view (180). 
 
Laboratory analysis of ex vivo blood samples eliminates the requirement for 
signal intensity conversion, and may be considered the gold standard measure 
of contrast agent concentration in the blood. In humans, good agreement has 
been shown between VIF curves plotted from blood sample measurements and 
those using MRI signal intensities following injection of gadopentetate (181). 
However, using blood sampling techniques to capture the first pass of a bolus 
injection of contrast agent can be challenging due to the requirement for 
multiple blood samples in a short time-frame. Limitations regarding permissible 
sampling volumes add further difficulty in studies using small animals, although 
a recent study in rats found a good correlation between VIF descriptors 
calculated from measurement of Gd concentration in blood samples with those 
determined using imaging techniques (182).  
 
5.1.2 Blood sampling 
 
Blood sampling is one of the most commonly performed procedures in animal 
studies (183), and is fundamental to the success of pharmacokinetic and 
toxicology studies. Blood should always be collected in the manner that gives 
least pain and stress (184), and the amount of blood taken on a single occasion 
should not exceed 10% of circulating blood volume to prevent hypovolaemic 
shock (185). In a small mammal such as a mouse, this blood sampling volume 
limit may be less than 200 μL (79).  
 
Micro-sampling, the removal of less than 100 μL, causes less subject 
interference than conventional sampling (186). Blood micro-samples are often 
acquired with capillary tubes, and are then either centrifuged to produce 
plasma or analysed directly as whole blood. Direct analysis requires an 
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accurate blood sample volume and precise, low-temperature storage 
conditions, and may occasionally result in clotting within the micro-tube 
(although using EDTA-coated tubes avoids clotting). Preparation of plasma 
samples also requires an accurate volume and restrictive storage conditions, 
with additional handling steps to remove the red blood cells. 
 
An alternative micro-sampling technique, dried blood spotting (DBS), removes 
the requirements for accurate blood sample volume and low-temperature 
storage. It is a widely accepted blood sampling technique for individual testing 
and population screening. A DBS card usually consists of four circular regions 
(each 10 mm in diameter), within which blood volumes of around 10 – 30 μL 
are spotted (Fig. 5.2). The cards are dried at room temperature for two hours 
before being sealed in an airtight bag with desiccant sachets and stored at 
room temperature until required. A punched core of 3 – 6 mm diameter from 
each spot, equating to a blood volume of approximately 3 – 12 μL (187), is then 
placed in an extraction solution prior to spectral analysis. 
 
 
Figure 5.2: Transferring blood to DBS card (image from Whatman web site (188)) 
 
The DBS technique has been actively used since Robert Guthrie’s pioneering 
work in the 1960s for screening new-born babies for metabolic anomalies such 
as phenylketonuria  and congenital hypothyroidism (189). More recently, it has 
also been used for early detection of a range of diseases including cystic 
fibrosis (190) and the hepatitis C virus (191). DBS is considered a stable, 
inexpensive method of collecting and storing DNA for epidemiological  




Advantages of DBS over conventional blood sampling techniques include ease 
of collection and economical storage (samples are stored at room temperature, 
rather than in a freezer). As the samples remain stable at room temperature, 
they can be collected at remote locations and posted to a central laboratory for 
analysis. DBS also requires smaller collection volumes, which increases the 
number of potential data points per experimental animal and facilitates the 
reduction in animal numbers required for preclinical studies (193). Serial 
sampling from a small number of animals also has the advantage of reducing 
the influence of inter-animal variability.  
 
5.1.3 Measuring Gd content 
 
Inductively-coupled plasma mass spectrometry (ICP-MS) is one of a range of 
spectrometry techniques available to analyse blood samples. It is a highly 
sensitive element-detection technique, commonly used by the pharmaceutical 
industry for identification of inorganic impurities at levels as low as parts per 
trillion (194) and with many applications in a wide variety of industries including 
food quality assessment and environmental monitoring (195). ICP-MS has 
been utilised as a means of monitoring environmental Gd levels and measuring 
tissue Gd accumulation, resulting directly from the use of MRI contrast agents 
(196). It has also been adopted as the gold standard for measurement of Gd 
content in several in vitro studies characterising gadofosveset (for example, 
(68, 75)). 
 
A schematic diagram of the ICP-MS process is shown in Fig. 5.3, and an 
illustration of the key components is given in Fig. 5.4. The process begins with 
a liquid sample, pumped into the mass spectrometer and nebulised into an 
aerosol by a stream of argon gas within the spray chamber. Large drops are 
drained by gravitational force, with only small drops (up to a diameter of 10 μm) 
continuing to the sample injector. Utilising pressure gradients, the aerosol is fed 
into a plasma torch, where argon gas is converted to a plasma discharge and 
heated to a maximum of 7000 K by a radiofrequency (RF) coil. As the liquid 
aerosol travels through different temperature zones within the plasma, it dries 
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and becomes a solid, and is vaporised into molecular and then atomic form. 
When the sample reaches the extremely hot centre of the plasma, there is 
sufficient energy in the plasma electrons to knock an electron from the outer 
orbit of the sample atoms. The resulting positively charged ions are driven into 
the analyser through a sample and skimmer cone, which are maintained within 
a vacuum, and then focused and steered by ion lenses through to a quadrupole 
mass separation device. This device consists of two pairs of rods, one pair with 
a direct current (DC) field and the other pair with an RF field. Selecting the 
appropriate RF–DC voltage enables the operator to tune the device to allow 
only ions of a specific mass-to-charge ratio to pass down the middle of the 
rods, with other ions falling through gaps between the rods and being ejected. 
The selected ions finally reach the ion detector, where they are counted and a 
mass spectrum is created. 
 
 



















Figure 5.4: Key components in an inductively-coupled plasma mass spectrometer (not 
to scale); sample movement in diagram is from right to left 
 
To prevent signal saturation and accumulation of particulate matter, it is 
important that samples are diluted and large molecules broken down prior to 
being pumped into the spectrometer. Whole blood samples containing Gd-
based MRI contrast agents have previously been analysed with ICP-MS, using 
20% v/v nitric acid as the digestion agent. An acid content at this level is very 
effective at releasing Gd, and nitric acid is noted to be the best acid medium for 
ICP-MS (197). Concentrations should be above the detection limit, i.e. 
sufficiently high to be distinguishable from system noise, but should not be so 
high as to saturate the ion counter. A detection limit has previously been 
measured for Gd at 1 ng mL-1 (198). 
 
Pilot studies have been carried out to assess the validity of combining DBS with 
ICP-MS to screen for heavy metal environmental pollutants such as lead, 
mercury and cadmium in new-born babies (199). The study concluded that this 
was a useful screening method, and also found that samples remained stable 
when stored over an 8.5 month period. Another study on levels of lead in the 
blood was carried out using laser ablation to create particulates directly from 
DBS cores, followed by ICP-MS analysis (200). 
 
A literature search (May 2013) found no previous studies using DBS to 
measure Gd concentration. Although a similar technique to ICP-MS, 
inductively-coupled plasma atomic emission spectroscopy (ICP-AES), has 
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previously been used to measure blood concentrations of gadofosveset in 
rabbits following bolus injection (78), the blood sampling volumes used would 
be inappropriate for smaller animals. An aforementioned study in rats (182) 
used ICP-MS to measure the Gd content of blood samples following injection of 
gadopentetate, although blood sampling volumes are not stated. To 
successfully measure the gadofosveset time course in a mouse model, the 
novel combination of micro-sampling mouse blood using DBS followed by Gd 




The aim of this study was to combine the established techniques of DBS and 
ICP-MS to develop a method for accurate measurement of the Gd content of 
blood samples at a temporal rate suitable for characterising a VIF in small 
mammals. This would be achieved in three steps: 
 
1. Demonstrate in a proof-of-concept study that Gd levels could be accurately 
measured using ICP-MS with gadofosveset-spiked mouse blood samples on 
DBS cards. By plotting Gd counts against known Gd concentrations, calibration 
curves could then be created to enable conversion of Gd counts back to Gd 
concentrations. Applying a linear fit to these plotted data points enables 
assessment of the accuracy of the calibration method. 
 
2. The method developed in vitro could then be applied in a benchtop 
experiment by injecting several mice with a standard dose of gadofosveset, 
collecting blood samples on DBS cards at specific, interleaved time points and 
analysing these samples for Gd using ICP-MS. These Gd counts would be 
converted to Gd concentrations using the calibration curves generated from the 
in vitro data, and Gd concentrations could be plotted as a VIF. 
 
3. Using the same injection protocol as the benchtop experiment, MR images of 
mice would be acquired at corresponding time points. The measured variation 
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in signal intensity within a major vessel as the injected bolus makes its first 
pass through the animal could then be compared with the previously  
acquired VIF.  
 
There are two novel aspects to this study: firstly, the use of DBS in conjunction 
with ICP-MS to facilitate accurate Gd measurement in low-volume blood 
samples; and secondly, the application of this combined technique to determine 
a VIF for gadofosveset in a murine model. As gadofosveset was withdrawn 
from the European market before the animal studies commenced, only the in 
vitro method development stage could be completed. Although it would have 
been feasible to use an alternative Gd-based contrast agent to assess the 
method in vivo, the primary research purpose of this project is characterisation 
of gadofosveset. As gadofosveset has unique properties not found in other 
clinically approved agents, the option to complete the in vivo assessment with 




To separately validate the accuracy of Gd measurement using ICP-MS and the 
method for releasing Gd from DBS card, three sets of ICP-MS calibration 
curves were created. The first set of curves used gadofosveset in mouse 
plasma, directly prepared in solution form (without being transferred to DBS 
cards), to verify that Gd content could be accurately measured with the chosen 
diluent and dilution levels. The second set of curves used solutions of 
gadofosveset in phosphate-buffered saline (PBS), transferred to DBS cards 
and prepared for ICP-MS, to confirm that unbound gadofosveset would be 
released from the card and Gd content could be accurately measured. The 
third set of curves used mouse blood samples spiked with gadofosveset, 
transferred to DBS cards and prepared for ICP-MS, to confirm that bound 
gadofosveset would be released from the card and Gd content could be 
accurately measured at low blood volumes. This final set of curves would have 
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been used to convert Gd counts in ex vivo blood samples to Gd concentrations 
if an animal benchtop experiment had been carried out. 
 
5.3.1 Sample preparation 
 
Gadofosveset (Vasovist) at an initial concentration of 250 mM (244 mg mL-1) 
was added to lyophilised mouse plasma (reconstituted with deionised water) to 
give a concentration of 5.0 mM. This was serially diluted to give additional 
concentrations of gadovosveset in mouse plasma of 2.0, 1.0, 0.5 and 0.25 mM 
(a range of 0.24 – 4.88 mg mL-1), along with a sample of mouse plasma without 
gadofosveset. 10 μL of each solution was then diluted by a factor of 104 in nitric 
acid (20% v/v) to give final sample concentrations in the range  
24 – 488 ng mL-1. 
 
To generate the DBS samples, gadofosveset was diluted in phosphate-buffered 
saline (PBS, as used in Chapter 4 experiments) to a concentration of 15 mM, 
followed by serial dilutions in PBS to give concentrations of 6, 3, 1.5 and  
0.75 mM. 50 μL of each of these solutions was added to 100 μL mouse blood 
(CD-1 mouse type) to give final concentrations of 5, 2, 1, 0.5 and 0.25 mM 
(0.24 – 4.88 mg mL-1). An equivalent set of concentrations for gadofosveset in 
PBS (without blood) was also created. EDTA-coated 20 μL capillary tubes 
(Starstedt AG, Germany) were used to draw samples from each gadofosveset–
blood and gadofosveset–PBS solution and spot onto Whatman FTA DMPK-C 
cards (GE Healthcare). An additional card containing spots of plain mouse 
blood was also created. The cards were stacked horizontally in a drying rack 
for 2 h at room temperature (approximately 22°C, with a measured relative 
humidity of 36%). Each card was then sealed in an airtight bag containing two 
desiccant sachets and stored at room temperature until use. 
 
To prepare the DBS samples for ICP-MS analysis, a single 3 mm diameter 
punched core from the centre of each spot was placed into a plastic Eppendorff 
tube (0.5 mL) and 200 μL nitric acid (20% v/v) added. The tubes were vortexed 
for 20 s, left to stand for 40 min and then centrifuged at 5000 rpm for 5 min.  
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200 μL of supernate was extracted to a plastic Corning tube (15 mL), 1980 μL 
of nitric acid (20% v/v) added and the combined solution vortexed for 5 s prior 
to ICP-MS. Assuming a blood volume in the core of approximately 3 μL, this 
overall process amounts to a dilution from the original blood concentration 
levels of approximately 1 in 6,800, giving final concentrations in the range  
37 –732 ng mL-1. Coring took place four days after samples were spotted on 




ICP-MS was carried out on an Elan DRC-e spectrometer (Perkin Elmer, 
Waltham, MA) with quadrupole mass analyzer, peristaltic pump and pneumatic 
concentric nebulizer, using argon gas. Counts were determined for the four 
most commonly occurring isotopes of Gd (mass/charge values of 156, 157, 158 
and 160), which account for around 83% of the stable element (201). A sample 
flush of 35 s at 24 rpm was followed by a read delay of 35 s at 20 rpm and a 




Figures 5.5, 5.6, and 5.7 show the calibration curves for gadofosveset in mouse 
plasma (solution form), gadofosveset in PBS (DBS core extraction) and 
gadofosveset in mouse blood (DBS core extraction), respectively. All three sets 
of plots show a high degree of linearity between gadofosveset concentration 






Figure 5.5: Calibration curves showing Gd counts (mass/charge values of 156, 157, 158 
and 160, and the total count for all four) for a range of gadofosveset 
concentrations in mouse plasma, using samples taken from in vitro solutions; 
error bars indicate standard deviation of four measurements. R2 values for all 






Figure 5.6: Calibration curves showing Gd counts (mass/charge values of 156, 157, 158 
and 160, and the total count for all four) for a range of gadofosveset 
concentrations in PBS, using DBS collection method. R2 values for all  





Figure 5.7: Calibration curves showing Gd counts (mass/charge values of 156, 157, 158 
and 160, and the total count for all four) for a range of gadofosveset 
concentrations in mouse blood, using DBS collection method. R2 values for all 







5.5.1 Method validation 
 
The high degree of linearity between gadofosveset concentration and Gd count 
for the in vitro solutions of gadofosveset in mouse plasma (Fig. 5.5), diluted by 
a factor of 104, confirms that ICP-MS is a very sensitive method for measuring 
Gd concentration. These results also show that the extraction solution and 
dilution methodology are valid preparation for ICP-MS measurement. The 
additional methodology for releasing samples from DBS cores and creating 
liquid solutions is validated initially for gadofosveset in PBS (Fig. 5.6), where no 
gadofosveset binding will occur, and subsequently for gadofosveset in mouse 
blood (Fig. 5.7), where the majority of the gadofosveset will be bound to 
albumin. The linearity of both sets of plots suggests that this method 
adequately releases Gd from the DBS core, regardless of albumin-binding 
state. The consistency between samples prepared in solution form and those 
prepared from DBS cores demonstrates that the preparation method used to 
generate solutions from blood samples on DBS cards was appropriate for  
ICP-MS analysis. Overall, the results demonstrate the viability of using blood 
samples acquired and stored on DBS cards in conjunction with ICP-MS to 
measure Gd levels. This suggests the method may be a viable, accurate 
means of monitoring Gd concentrations in the blood (ex vivo) following contrast 
agent administration.  
 
ICP-MS has previously been used to measure Gd from MRI contrast agents in 
tissue and environmental samples (196). The technique was found to be highly 
sensitive to Gd in rat tissue, with a detection limit of approximately  
6 x 10-6 μmol of Gd per g of tissue (197). Concern around the build-up of Gd in 
tissue has increased with the establishment of a link between Gd contrast 
agent administration and nephrogenic systemic fibrosis (NSF) (49); a study 
using ICP-MS to measure Gd in hair, fingernail and blood samples of an NSF 
patient previously exposed to Gd contrast agents (202) found substantially 
higher Gd levels than in healthy control subjects. ICP-MS has also been used 
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to study the elimination time course of Gd from the skin in rats in the days 
following administration of a range of contrast agents (203, 204). Recently, the 
VIF in a rat model was captured using ICP-MS by blood sampling after injection 
of gadopentetate, and was reproduced with an MRI sequence (182). Tissue 
distribution for gadopentetate has also been assessed in rats using laser 
ablation ICP-MS on histological samples (205). ICP-MS has been used to 
assess levels of Gd passing through hospital sewage systems into rivers 
following excretion by patients injected with Gd-based contrast agents during 
MRI procedures  (198, 206). The potential to differentiate specific Gd chelates 
has been demonstrated using ICP-MS in conjunction with size-exclusion 
chromatography (207) and hydrophilic interaction chromatography (208).  
ICP-MS was used in a murine study to correlate histological tissue Gd 
concentration in cardiac slices with change in relaxation rate (ΔR1) (209). A 
study combining MRI, ICP-MS and histology assessed the clearance rate of a 
macromolecular contrast agent (albumin-Gd-DTPA) in mice following avadin 
chase (210), although the sampling intervals were insufficient to capture the 
first bolus pass. 
 
Several studies characterising gadofosveset in vitro (for example, (68, 75)) 
have used ICP-MS Gd measurements following solution filtration to determine 
the binding fraction for physiologically relevant gadofosveset concentrations 
across selected animal species. A study in rabbits (78) used ICP-AES to 
analyse acquired blood samples at multiple time points immediately following 
injection of gadofosveset. A total of 44 samples, each of volume 300 μL, were 
acquired for a single animal, amounting to a total blood sample volume of 
approximately 13 mL (around 8% of the total circulating blood volume of a  
2.5 kg rabbit); these blood sample volumes would be unsuitable for a smaller 
animal.  
 
Blood sampling using DBS cards requires smaller blood volumes and has 
practical advantages over other micro-sampling techniques (including ease of 
sample handling, room-temperature transportation and storage of samples, and 
the ability to store samples for several months without degradation). DBS may 
be considered particularly useful for collection of blood samples in small 
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animals, where low circulating blood volumes prohibit multiple sampling at 
conventional volumes. In line with the commitment to the welfare of animals 
used in scientific experimentation (the ‘3Rs’ approach: replacement, reduction, 
refinement, (211)), smaller individual blood sampling volumes facilitate the use 
of fewer animals. In addition, acquiring multiple samples from the same animal 
reduces the experimental risk of inter-animal variability. 
 
5.5.2 Proposed in vivo validation methodology 
 
Due to its withdrawal from the European market in 2011 (see Chapter 3, 
section 3.1.1), it was not possible to validate the proposed method in vivo using 
gadofosveset. As the primary research aim was characterisation of this contrast 
agent, it was not considered ethical to carry out in vivo animal experiments 
using another contrast agent. A suggested protocol for in vivo validation in a 
murine model would involve two parallel experiments, subject to necessary 
ethical approval and Home Office personal and project licence authorisation at 
a designated establishment, in accordance with the Animals (Scientific 
Procedures) Act 1986. In the first experiment, anaesthetised mice would be 
injected with gadofosveset at the clinical dose (0.03 mmol kg-1), and blood 
would be extracted to DBS cards at specific time points following injection. 
Using the same injection protocol, the second experiment would involve 
acquiring MR images at time points corresponding with those used for  
blood sampling. 
 
Assuming the animal is anaesthetised with isoflurane or an isoflurane/oxygen 
mix, and gadofosveset is administered using a cannula in one of the tail veins, 
the following blood extraction methodology is suggested. The first blood sample 
is taken by needle pricking the non-cannulated tail vein, placing an EDTA-
coated 20 μL capillary tube on the site and allowing the blood to be drawn up 
using capillary action. Although injection and sampling both use veins, this 
should not be an issue due to the rapid rate at which blood circulates in small 
mammals. Subsequent blood samples are taken from the same site; if 
necessary, the flow of blood is stemmed between samples by applying 
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pressure to the sampling site. The capillary tubes are placed temporarily into 
labelled Eppendorf tubes until all samples are collected for the animal. Taking 
six blood samples per animal, the total captured blood volume per animal is no 
more than 120 μL (approximately 7% of the total blood volume of a 20 g 
mouse). The actual volume drawn into each tube by capillary action is likely to 
be around 10 – 12 μL (60 – 72 μL total for six samples), plus a small amount of 
wastage between samples. When all samples are collected for one animal, the 
full volume of blood from each capillary tube is transferred to a DBS card. The 
process is repeated for additional animals, using a range of time points, to build 
up a full picture of the variation of contrast agent concentration with time. 
Although laboratory mice are bred to give a similar physiological response, the 
potential influence of inter-animal variability may be assessed by choosing a 
combination of coincident and interleaved time points. DBS cards are allowed 
to dry for two hours and then stored in airtight plastic bags with desiccant 
sachets. The DBS core extraction method described in section 5.3 is then used 
to prepare each sample for ICP-MS. 
 
A log spacing of blood sample acquisition times is suggested, to provide a 
greater number of data points soon after injection, where concentrations are 
changing more rapidly. Fig. 5.8 gives a suggested distribution of sample times, 
with 8 animals and 6 samples per animal. The total number of animals required 
and the timing of blood sample acquisitions may be confirmed following a small 






Figure 5.8: Proposed blood sampling times (6 time points for 8 animals), with the first 
time point immediately after a 30 s infusion; each symbol represents a different 
animal, with the same initial time point used for each animal  
 
The MR imaging sequence should use cardiac and respiratory gating where 
possible, and images should include a plane incorporating the aorta, vena cava 
or ventricles, to enable accurate blood T1 measurement (175). As 
deoxygenated haemoglobin is slightly paramagnetic, and the degree of 
deoxygenation is 1 – 2% in arteries and 30 – 40% in veins (212), differences in 
the vascular input function would be observed depending on whether the region 
of interest incorporates venous or arterial blood. 
 
5.5.3 Potential limitations 
 
A potential limitation of the DBS method is the ability to acquire blood samples 
rapidly enough to capture the first-pass peak contrast agent concentration. 
There is also a requirement to generate consistent blood spot cores. The 
volume of blood in a DBS core has been shown to vary with haematocrit levels 
(213), overall volume of the blood spot (187) and with the relative positioning of 
the core within the spot (214).  
 
For ICP-MS, it is essential at very low Gd concentrations that measurements 
exceed the limit of detection, the level above which a signal may be 
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distinguished from background noise, and the limit of quantification, the level 
above which accurate measurement is possible. These levels may be 
determined from the standard deviation of ion counts of solutions prepared 
from blank cores.  Although Gd concentrations in this study were well above 
the expected detection and quantification limits, it may be of value in a 
repeated experiment if Gd ion counts of blank solutions were recorded. False-
positive counts are possible when oxides matching the mass-to-charge ratio of 
the isotope of interest are created during the ionisation process (from 
combinations of elements within the sample solution and input gas), or as a 
result of interference from other spectra. For example, isotopes of dysprosium 
occur naturally (although rarely) at atomic masses of 156, 158 and 160.
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CHAPTER 6: OVERCOMING THE LOW RELAXIVITY OF 




The albumin-binding nature of gadofosveset, discussed in Chapter 3, leads to 
reduced extravasation and excretion rates and potentially favourable relaxation 
properties. Results from Chapter 4 (Table 4.2) confirm that the longitudinal 
relaxivity of the bound gadofosveset molecule (r1bound) is significantly higher 
than the relaxivity of the free molecule (r1free) at low fields. However, r1bound 
decreases rapidly with field strength and the two relaxivities are comparable at 
4.7 T (Chapter 4, Fig. 4.4). Where these relaxivities converge, observed 
relaxivity (r1obs) is similar to that for a non-binding contrast agent and the high-
relaxivity advantage of gadofosveset is lost. Regardless of the reduction in 
relaxivity, the unique kinetic properties of gadofosveset resulting from its 
binding to albumin are displayed at all field strengths. An alternative contrast 
mechanism that provides high gadofosveset relaxivity at high fields may be 
required to fully exploit these properties.  
 
Spin locking (SL), first described as an imaging technique in 1985 (15) but 
investigated in NMR prior to this (215), involves the application of a 90° 
excitation pulse followed by a radio frequency (RF) pulse (phase shifted by 90° 
to the excitation pulse), applied for a duration of time (spin-lock time, TSL), 





Figure 6.1: (a) Magnetisation M0 is tilted 90
° around x’ axis of rotating frame of 
reference x’y’z’ by excitatory pulse B1; (b) spin locking pulse B1L is applied along 
y’ axis 
 
Relaxation of the magnetisation in the presence of this SL field (B1L) is 
characterised by the time constant T1ρ, with free induction decay (FID) only 
occurring once the spin-locking pulse has been switched off (Fig. 6.2a). The SL 
pulse may be followed by a 90° pulse (phase shifted by 180° to the original 
excitation pulse) and an imaging sequence (Fig. 6.2b) (216), or a 180° pulse 







Figure 6.2: (a) Free induction decay follows the cessation of the spin-locking pulse;  
(b) an example of how an imaging sequence may be applied following spin 
locking (216); (c) a pulse sequence diagram showing spin-locking pulse followed 
by a selective 180° pulse and readout (15) 
 
T1ρ is influenced by the strength of the SL field, which is commonly in the μT 
(low kHz) range, rather than the main magnetic field (B0). As a result, the image 
contrast generated by SL is equivalent to image contrast obtained at low 
magnetic fields, with the advantage that a high signal-to-noise ratio, a 
characteristic of high B0, may be maintained (217). It should be noted that the 
SL RF pulse may contribute significantly to patient specific absorption rate 
(SAR), particularly at high B0 as SAR is proportional to the product of B0
2, B1L
2 
and the ratio of TSL to TR (within a practical range for TR) (Eq. 6.1) (15).  
 
         
     
  







The interaction times associated with SL at very low field strengths give this 
technique an increased sensitivity to proteins and other macromolecules (218). 
This correlation between signal intensity and tissue protein has been utilised as 
a potential biomarker for response to tumour therapy, including treatment 
designed to reduce protein synthesis (219) and gene therapy resulting in 
reduced protein content due to cell death (220). The clinical potential of SL has 
also been highlighted in a study of injured myocardium (221) and in the 
assessment of brain plaque composition in early-onset Alzheimer’s  
disease (222).  
 
Small-molecule Gd-based contrast agents have been used in combination with 
SL to provide improved myocardium–blood contrast (221, 223) and in the 
assessment of articular cartilage (224). SL after injection of gadopentetate has 
also been shown to improve tumour contrast in glioma patients (218). A 
literature search for published studies assessing the effect of gadofosveset on 
T1ρ (July 2013) found only the paper on which this thesis chapter is  
based (1). 
 
Tissue T1ρ values fall between T1 and T2, with T1ρ → T2 as B1L → 0 (225). 
Conventionally B1L << B0, therefore T1ρ may be expected to be close to T2. The 
transverse relaxivity of bound gadofosveset is known to remain high at all 
relevant field strengths (89), and T2 values are known to be sensitive to tissue 
macromolecules (226). A secondary consideration in this study is whether the 
potential benefits of T1ρ contrast could also be achieved using T2 contrast, 
without the complication of adding a spin-locking pulse and without the 
requirement to consider additional SAR factors. 
 
6.2 AIMS AND OBJECTIVES 
 
The primary aim of this study was to test the hypothesis that by combining the 
macromolecular sensitivity of SL with the albumin-binding affinity of 
gadofosveset a large contrast shift may be achieved at field strengths where 
the T1 effects of gadofosveset are very similar to those of conventional Gd-
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based agents. In addition, the influence of species’ differences in binding on 
spin-lock relaxation was investigated, along with the influence of spin-lock field 
strength on image quality. A further aspect of the study was to investigate 
whether the potential benefits of T1ρ contrast could also be achieved using T2 
contrast. The following objectives were set: 
 
1. Measure spin-lock relaxation rates (R1ρ, 1/T1ρ) for in vitro gadofosveset 
solutions, in the presence and absence of serum albumin, at a B0 value of 4.7 T 
and B1L values of 5, 25 and 90 µT.  
 
2. Repeat R1ρ measurements for solutions of the non-binding contrast agent 
gadopentetate dimeglumine, to act as a control and to separate the influence of 
the macromolecular solution from that of Gd. 
 
3. Repeat R1ρ measurements for gadofosveset in mouse plasma, to identify 
differences between albumin species. This may be informative for translating 
the outcome of pre-clinical studies utilising gadofosveset with spin locking. 
 
4. Compare gadofosveset R1ρ measurements with equivalent R1 
measurements presented in Chapter 4. 
 
5. Measure R2 for gadofosveset in the presence and absence of albumin, at 
low (0.47 T) and high (4.7 T) B0, to determine whether transverse relaxation 




6.3.1 In vitro solutions 
 
In vitro solutions of gadofosveset in phosphate-buffered saline (PBS), with and 
without bovine serum albumin (BSA), were prepared as described in Chapter 4 
(section 4.4.1). An equivalent set of solutions of the non-binding contrast agent 
gadopentetate dimeglumine (Magnevist, Bayer Healthcare Pharmaceuticals, 
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Germany) in BSA (4.5% w/v) was also created, along with samples of 
gadofosveset in mouse plasma. Prior to scanning at 4.7 T, all solutions were 
heated to 37°C in a water bath; this temperature was maintained during 
scanning with warm air flow and verified with a fibre optic temperature probe in 
an adjacent water tube. At 0.47 T, samples were heated to 37°C and the 
temperature monitored with an integral heating system. 
 
6.3.2 Data acquisition: R1ρ 
 
Tubes were placed vertically in a cylindrical cradle of diameter 60 mm and 
inserted into a 63 mm quad coil in a horizontal bore 4.7 T magnet with Bruker 
console running ParaVision 5.1 software (Bruker BioSpin MRI GmbH, Ettlingen, 
Germany). Spin locking was achieved using a B1L pulse value of 90 μT  
(3.8 kHz), applied for 14 durations (TSL): 0.01, 0.05, 0.1, 0.5, 1.0, 5.0, 12.5, 
25.0, 50.0, 75.0, 100.0, 125.0, 150.0 and 200.0 ms. This was followed by a 
rapid acquisition with relaxation enhancement (RARE) readout, using a coronal 
(horizontal) slice of thickness 1 mm. The acquisition parameters were:   
TR = 2000 ms; TE = 10 ms; field of view = 60 x 60 mm; matrix size = 128 x 128 
pixels; RARE factor = 2; averages = 1; centric encoding. No spoiler gradients 
were applied between repetitions. In addition to the B1L pulse value of 90 μT, 
images were also acquired using spin-lock pulse strengths of 5 and 25 μT  
(0.2 and 1.1 kHz, respectively). 
 
6.3.3 Data acquisition: R1 and R2  
 
R1 measurements at 0.47 T and 4.7 T were made using the instrumentation 
and techniques described in Chapter 4 (sections 4.4.2 and 4.4.4, respectively). 
 
R2 values at 4.7 T were measured using a RARE saturation recovery imaging 
sequence without the preparatory SL pulse. Tubes were placed horizontally in 
the cradle and coil described previously and a single axial (vertical) slice used. 
TE ranged between 11 and 66 ms; TR (BSA) = 2000 ms; TR (PBS) = 8000 ms; 
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field of view = 60 x 60 mm; matrix size = 256 x 256 pixels; RARE factor = 2; 
averages = 1; centric encoding; slice thickness = 1 mm. 
 
R2 measurements at 0.47 T were made on a 20 MHz Maran NMR spectrometer 
(Oxford Instruments, Abingdon, UK), using a standard Carr–Purcell–Meiboom–
Gill (CPMG) sequence, with 1000 TE values.  
 
6.3.4 Calculating relaxation rates 
 
R1 relaxation rates were calculated using the methods described in Chapter 4 
(section 4.4.6). For R1ρ and R2 at 4.7 T, circular regions of interest (ROI) were 
drawn on the images within each tube and the mean signal intensity (SI) of 
each ROI measured using ImageJ software (v1.42q, Rasband, W.S., ImageJ, 
U. S. National Institutes of Health, Bethesda, Maryland, USA, 
http://imagej.nih.gov/ij/, 1997-2011). SI values were adjusted for noise bias 
using a simple Rician correction (227), based on mean standard deviations of 
four background regions in each image. Fitting of  R1ρ followed a nonlinear 
three-parameter fit suggested by Engelhart & Johnson (228) using MATLAB 
(v7.9, MathWorks, Natick, Ma) to determine the fully recovered SI (S0) values 
and relaxation rates (R1ρ), along with a parameter (a) to account for residual 
magnetisation in the y axis due to the SL pulse (Eq. 6.2). R2 (1/T2) was 
determined using a two-parameter nonlinear fit (Eq. 6.3).  
 
         
          [6.2] 
 
         
      [6.3] 
 
Confidence intervals (CI) were calculated at the 95% level. Datasets were 
compared for statistical significance at α = 0.05 using a paired t-test in SPSS  






Results are shown in Figs. 6.3 – 6.8, with error bars representing 95% 
confidence intervals. R1 results for gadofosveset have previously been 
presented in a different format (Chapter 4, Fig. 4.1); in Fig. 6.3 PBS and BSA 
results are presented together to enable direct comparison. The overall R1 
values for solutions of gadofosveset in BSA and in PBS were significantly 
different at B0 = 0.47 T (P = 0.003, Fig. 6.3a) but not different at 4.7 T  
(P = 0.757, Fig. 6.3b), confirming the lack of influence of albumin binding on 




Figure 6.3: R1 values for gadofosveset in BSA (circles) and in PBS (crosses) at (a) 0.47 T 
and (b) 4.7 T. Error bars in (a) are smaller than data points 
 
The R1ρ relaxation rates for solutions of gadofosveset in BSA at 4.7 T were 
significantly higher than for gadofosveset in PBS (P = 0.001, Fig. 6.4). PBS R1ρ 
values (Fig. 6.4) were similar to R1 values at 4.7 T (BSA and PBS solutions, 
Fig. 6.3b). The R1ρ values for solutions of gadopentetate in BSA were similar to 





Figure 6.4: R1ρ values for gadofosveset in BSA (circles) and in PBS (crosses) and 
gadopentetate in BSA (squares) at B0 = 4.7 T, B1L = 90 μT 
 
R2 values for solutions of gadofosveset in BSA and in PBS at 0.47 T displayed 
a similar pattern to R1 values at this field strength, with significantly higher R2 
values for the BSA solutions (P = 0.032, Fig. 6.5a). R2 values for equivalent 
solutions at 4.7 T were comparable to the R2 values at 0.47 T and the R1ρ 
values at 4.7 T, with the BSA R2 values being significantly higher than the PBS 
R2 values (P < 0.001, Fig. 6.5b). 
 
  
Figure 6.5: R2 values for gadofosveset in BSA (circles) and in PBS (crosses) at (a) 0.47 T 
and (b) 4.7 T. Error bars in (a) are smaller than data points 
 
Measurement of R1, R1ρ and R2 for gadofosveset in mouse plasma at  
B0 = 4.7 T and B1L = 90 μT (Fig. 6.6) shows that R1ρ and R2 are similar and 
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significantly higher than R1, complementing the findings for gadofosveset in 
BSA. However, when R1ρ values for gadofosveset in mouse plasma are directly 
compared with those for gadofosveset in BSA, the mouse plasma values are 
much lower (Fig. 6.7). 
 
 
Figure 6.6: R1 (crosses), R1ρ (circles) and R2 (squares) for gadofosveset in mouse 
plasma at B0 = 4.7 T, B1L = 90 μT; data points presented with a slight offset in Cg 




Figure 6.7: Comparison of R1ρ values for gadofosveset in BSA (diamonds), mouse 
plasma (circles) and PBS (crosses) at B0 = 4.7 T, B1L = 90 μT 
 
A comparison of R1ρ measurements at three B1L values (Fig. 6.8a) shows that 
although R1ρ values are generally similar at all three spin-lock field strengths, 
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the confidence intervals are generally much larger at lower B1L. Image quality is 
noticeably poorer at 5 μT when sample images from each of the three spin-lock 
fields are visually compared (Fig. 6.8 (b – d)). 
 
 
(b) TSL  = 1.0 ms, B1L = 90 μT  
 
(c) TSL  = 1.0 ms, B1L = 25 μT 
 
(d) TSL  = 1.0 ms, B1L = 5 μT  
 
Figure 6.8: (a) Plot of calculated R1ρ at three B1L values for gadofosveset in BSA (data 
points presented with a slight offset in Cg to improve clarity); sample images at 




6.5.1 Spin locking 
 
The high albumin-binding affinity of gadofosveset differentiates it from other 
clinically approved Gd-based contrast agents. The influence of binding on 
gadofosveset R1 is clear at 0.47 T (Fig. 6.3a), but is not observed at 4.7 T  
(Fig. 6.3b). Most clinical scanners operate at 3.0 T or lower, where the 
longitudinal relaxivity of gadofosveset in the presence of albumin is still higher 
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than other Gd agents (91). However, as clinical field strengths continue to 
increase, this advantage of high relaxivity diminishes and an alternative method 
for exploiting gadofosveset characteristics would be of benefit. This study 
demonstrates the feasibility of a previously unpublished method for combining 
the albumin-binding properties of gadofosveset with the macromolecular 
sensitivity of spin locking to generate improved contrast modification at high 
field strengths. R1ρ values at 4.7 T for BSA solutions containing mostly bound 
gadofosveset were found to be significantly greater than R1ρ values for PBS 
solutions containing unbound gadofosveset at the same concentration  
(Fig. 6.4).  
 
Because of the sensitivity of the SL technique to macromolecules, it is not clear 
from these findings alone the extent to which the difference in R1ρ is attributable 
to the binding of gadofosveset or the presence of serum albumin 
macromolecules. Comparison of R1ρ values for BSA and PBS solutions in the 
absence of contrast agent (0 mM) should give an indication of the influence of 
the albumin molecules on SL relaxation. However, the lengthy relaxation times 
of these blank solutions led to poor model fits to signal intensity data. Instead, 
the influence of albumin is better illustrated here by measurements using the 
non-binding contrast agent gadopentetate in BSA. A previous study at contrast 
agent concentrations ≤ 0.5 mM (91) showed longitudinal relaxivity values at  
4.7 T to be higher for gadofosveset in water than for gadopentetate in plasma 
(5.5 versus 3.7 mM-1 s-1, respectively). If the SL relaxivity of gadopentetate in 
BSA is found to be higher than that of gadofosveset in PBS, this may be 
attributable to the BSA solution macromolecules. The R1ρ values for solutions 
of gadopentetate in BSA and gadofosveset in PBS (Fig. 6.4), and their 
associated relaxivity values, were not significantly different. The similarity of R1ρ 
values for gadofosveset in PBS and gadopentetate in BSA together with the 
observation of relatively large R1ρ values for gadofosveset in BSA all suggest, 
firstly, that the gadolinium has a greater effect on R1ρ than the mere presence 
of the macromolecule and, secondly, that it is the binding rather than any non-




Further evidence for the influence of binding on R1ρ is provided by the R1ρ 
measurements of gadofosveset in mouse plasma. Gadofosveset binds at a 
lower fraction in mouse plasma (approximately 67% versus 91% in human 
plasma (75)), primarily due to a lower albumin concentration (3.3% in mice (79) 
compared to around 4.5% in humans (68)). A comparison of R1ρ for 
gadofosveset in mouse plasma and for gadofosveset in BSA at a concentration 
equivalent to that found in human serum albumin (Fig. 6.7) clearly shows that 
although mouse plasma R1ρ values are higher than those recorded in PBS, 
they are still significantly lower than values recorded in BSA, as would be 
expected from the differences in bound fraction. This mouse plasma data 
shows a potential problem with translating the outcome of pre-clinical studies 
with this technique. 
 
Although the SL contrast alteration observed with gadofosveset is not seen to 
the same extent with a small Gd-based non-binding contrast agent in an 
equivalent macromolecular solution (Fig. 6.4), SL has previously been 
successfully utilised in combination with non-binding agents (218, 221, 223, 
224). The outcome of this study suggests that additional contrast may be 
generated by exploiting the albumin-binding characteristics of an agent such as 
gadofosveset, although the reduced extravasation of the bound molecule may 
limit the extent of any increases in tissue contrast. Although it is not possible to 
use R1 measurements to differentiate signal alteration from bound and free 
gadofosveset at high field, due to their equivalent relaxivities (see Chapter 4, 
Table 4.2), it may be possible to differentiate bound and free gadofosveset 
through spin locking as R1ρ is substantially altered by binding. 
 
It should be noted that for this in vitro study it was not necessary to optimise SL 
imaging parameters to take into account potential tissue heating issues 
resulting from high SAR. For the majority of measurements a relatively high B1L 
value of 90 µT was chosen to give improved image quality. Although R1ρ 
increases as B1L decreases, images become increasingly susceptible to 
artefacts caused by magnetic field inhomogeneities at very low B1L values 
(216). This finding is confirmed by the large error bars at low B1L in Fig. 6.8a 
and the prominent image artefacts at 5 µT in Fig. 6.8d, although artefacts at a 
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B1L of 25 µT were less obvious. A range of patient and volunteer studies have 
successfully applied spin locking in vivo  with a B1L value of 500 Hz (11.7 µT) at 
B0 values of 1.5 T (216, 222, 229) and at 3.0 T (230-232). Other methods for 
reducing SAR, such as off-resonance spin locking (233), were not explored in 
this study.  
 
6.5.2 Transverse relaxation rates 
 
To avoid SAR-related constraints when carrying out in vivo measurements, an 
alternative, more practical solution may be to exploit the differences between 
bound and free gadofosveset transverse relaxation rates (R2). T2 values are 
regularly acquired on clinical scanners, and the effect of gadofosveset is clearly 
shown by R2 values in the presence and absence of albumin at 4.7 T  
(Fig. 6.5b). For these in vitro solutions, both R2 and R1ρ demonstrate greater 
relaxation for bound gadofosveset than R1. Transverse relaxation rates for 
gadofosveset will be explored further in Chapter 7. 
 
Although measurement of T2 is more easily achieved in practice than T1ρ, T1ρ is 
less influenced by the effect of diffusion from microscopic susceptibility 
gradients. As a result several studies, in particular those looking at tumour 
response to cytotoxic treatment, have suggested that T1ρ may be a more 
responsive early indicator of physiological change than T2 (219, 220). It has 
also been suggested that improved (qualitative) tumour boundary definition 
may be achieved utilising T1ρ rather than T2 (234). A study of brain images in 
healthy volunteers at 1.5 T (235) found that T1ρ-weighted images displayed 
improved spatial resolution over T2-weighted images and in vivo T1ρ maps had 
a greater dynamic range than equivalent T2 maps, due to the tissue T1ρ signal 




The scanning parameters at 4.7 T were optimised for physiological contrast 
agent concentrations. As a result, model fitting was less precise for the 
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solutions containing the lowest and highest concentrations. The long T1 values 
on the 0 mM solutions caused particular problems with model fitting and were 
excluded from this analysis. In addition, the PBS R2 values at 4.7 T were based 
on a model fit to just three TE points, rather than the six points used for the 
BSA solutions, leading to greater imprecision in the calculated PBS R2 values. 
 
For the purpose of this study gadopentetate was assumed to be a non-binding 
contrast agent, although there is some evidence to suggest that the chelate 
displays a weak tendency for binding to albumin (41). At the comparatively low 
serum albumin concentration used here, however, the measured relaxation 
rates suggested little influence of albumin binding for gadopentetate and it may 




In summary, this study has shown the R1ρ response to gadofosveset in serum 
albumin at high fields to be significantly larger than to a conventional small-
molecule Gd-based contrast agent. This suggests that spin locking may be a 
viable method for regaining the longitudinal relaxivity lost by gadofosveset at 
high fields, and may also provide an opportunity for additional tissue 
characterisation through the differentiation of bound and free gadofosveset 
molecules. Despite offering potential benefits, implementation of this method in 
a SAR-limited clinical setting would require further investigation of optimal SL 
parameters prior to assessment in humans. If pre-clinical evaluation of spin 
locking with gadofosveset is undertaken, species differences in albumin levels 
must also be considered. 
 
Note: A reduced version of this chapter appeared in the October 2012 edition 
of Magnetic Resonance in Medicine (1). 
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CHAPTER 7: A GADOFOSVESET-BASED BIOMARKER OF 




Albumin is the most abundant protein in human plasma, accounting for half of 
all serum proteins (69); its role within the body was discussed in Chapter 3 
(section 3.1.2). Albumin is not stored, but continuously synthesized by the liver 
and broken down by most organs in the body. The distribution of albumin may 
be described by a single intravascular and two extravascular compartments, 
one easily mobilised and exchangeable with the intravascular compartment and 
the other remote (particularly in the skin, (236)). Around 33% of albumin is 
found in the intravascular compartment, with 49% and 18% in the 
exchangeable and remote extravascular compartments, respectively (71). The 
normal level of serum albumin in plasma is approximately 3.5 – 5.0 g per  
100 ml (237), equating to a concentration of approximately 0.52 – 0.74 mM. 
 
Albumin concentrations may be accurately measured in urine or blood 
samples, with altered levels caused by changes in rates of synthesis, 
catabolism or extravascular leakage. Low levels of albumin have been linked to 
critical illness (238) and may be a risk factor for myocardial infarction (239). 
The body’s natural transcapillary exchange rate of around 5% of intravascular 
albumin per hour (81) may increase in damaged or angiogenic vessels. 
Localised increases in extravascular macromolecular content may be 
symptomatic of, for example, reperfused myocardial infarction (157) or tumour 
angiogenesis (240). 
 
Although albumin concentrations in blood and urine are valuable indicators of 
albumin imbalance, they do not fully describe its biodistribution. Direct 
measurement of interstitial albumin concentration is not straightforward, with 
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varying results found using invasive techniques such as wick implantation 
(241), blister suction (242) or double lumen catheterization (243). It is 
suggested that a non-invasive biomarker (244) of localised extravascular 
albumin may facilitate quantitative assessment of extravascular leakage. This 
technique may have prognostic and/or diagnostic value in assessment of 
tumour angiogenesis and response to treatment, as an increase in the leakage 
of macromolecules from the vasculature of tumours has been demonstrated 
(245). Although conventional small-molecule gadolinium (Gd) contrast agents 
are frequently used in MRI to assess microvascular permeability, 
macromolecular Gd agents have shown increased sensitivity to malignancy 
(159) and response to anti-angiogenic treatment (246). Increased albumin 
leakage may also be expected in myocardial infarction (247), where the use of 
macromolecular agents may aid assessment of ischaemic microvascular 
damage (248). 
 
The general properties of the albumin-binding MRI contrast agent gadofosveset 
have been discussed in Chapter 3, with longitudinal relaxivity (r1) assessed in 
Chapter 4. In the presence of albumin, gadofosveset r1 is high at low fields but 
decreases rapidly as field strength increases (Chapter 4, Fig. 4.4). Conversely, 
the transverse relaxivity of the bound molecule is expected to be high at low 
field and increase slightly with field strength (89). Results from Chapter 6 show 
that, unlike longitudinal relaxation rates (R1, Fig. 6.3), transverse relaxation 
rates (R2) are significantly higher for gadofosveset in BSA than in PBS at both 
0.47 T and 4.7 T (Fig. 6.5). 
 
The decline in the bound fraction of gadofosveset as contrast agent 
concentration increases above a specific value (related to the albumin 
concentration, and based on the assumption of a single binding site on the 
albumin molecule) suggests that bound fraction may be used as a biomarker 
for albumin concentration. Through manipulation of equations presented in 
earlier chapters, it is possible to calculate bound and free gadofosveset 
concentrations and serum albumin concentration directly from measured R1 
and R2 values (with assumed Ka and relaxivity values). This theory holds for 
other albumin-binding contrast agents, such as gadoxetate and gadobenate, 
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although these agents have much lower binding affinities (and lower peak 
bound fractions). The accuracy of the albumin calculation model is dependent 
on accurate R1 and R2 measurements; for agents with low binding affinity, 
results may be increasingly susceptible to experimental imprecision in the 
measurement of R1 and R2. 
 
7.2 AIMS AND OBJECTIVES 
 
This study aims to assess the viability of utilising measured relaxation rates in 
solutions with and without gadofosveset to develop a biomarker of albumin 
concentration in vitro. The viability of this method is also assessed in vitro using 
gadoxetate and gadobenate, and the feasibility of applying the method in a 
clinical setting is tested in vivo using gadofosveset-enhanced images from a 
small (n = 7) volunteer study. The following objectives were set: 
 
1. Carry out simulation studies to assess the potential influence on albumin 
calculation of realistic experimental imprecision in R1 and R2. 
 
2. Measure R1 and R2 at two field strengths for in vitro solutions of 
gadofosveset, gadoxetate and gadobenate, along with the non-binding agent 
gadopentetate. 
 
3. Calculate bound and free relaxivities based on measured relaxation rates, 
and use these results to determine bound fractions and albumin concentrations 
for each solution. 
 
4. Use the relaxivity values derived in vitro, along with measured in vivo R1 and 
R2 values, to determine gadofosveset and albumin concentrations in left 
ventricular blood and myocardial tissue of healthy human volunteers at 3.0 T. 
 
If the method is successful, it may be applied to generate a spatially located 
measure of tissue albumin which could be used as an alternative to current 
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invasive techniques. Identification of abnormal extravascular albumin 
distribution correlating with increased capillary leakage may have a number of 
applications, including early indication of disease progression or treatment 





7.3.1 Bound fraction 
 
Basic theory relating to albumin-binding contrast agents is covered in  
Chapter 3; key equations are repeated here with their original numbering. The 
overall contrast agent (Cg) and serum albumin (Csa) concentrations equal the 
sum of their bound and free components (Eq. 3.3 and 3.4). 
 
                     [3.3] 
                        [3.4] 
 
Assuming gadofosveset binds at a single site on the albumin molecule,  
Cgbound = Csabound; binding affinity (Ka) is then defined by Eq. 3.6. 
 
     
       
       (           )
 [3.6] 
 
Bound fraction (fb, Cgbound/Cg) decreases as Cg increases, with the highest fb 
occurring when Cg (and therefore Cgbound) is very low. As Cgbound approaches 0, 
a first order Taylor expansion of Eq. 3.6 provides a theoretical maximum bound 
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Assuming gadofosveset, gadoxetate and gadobenate Ka values of 11.0 mM
-1 , 
0.255 mM-1 and 0.226 mM-1, respectively, fbmax in human plasma (with an 
assumed Csa value of 0.7 mM) at very low Cg would be 0.89 (gadofosveset), 
0.15 (gadoxetate) and 0.14 (gadobenate). 
 
Replacing Cgfree in Eq. 3.6 using Eq. 3.3, the quadratic may be solved to give 
an expression for Cgbound if total contrast agent concentration, albumin 
concentration and binding affinity are known (Eq. 7.2). 
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Only the negative form of the quadratic solution is applicable as the positive 
form would give a non-zero solution for Cgbound at Cg = 0. Fig. 7.1a shows the 
variation of Cgbound with Cg using Eq. 7.2, with Csa = 0.7 mM and Ka = 11.0, 
0.255 and 0.226 mM-1 (for gadofosveset, gadoxetate and gadobenate, 
respectively). With the assumption of a 1:1 binding ratio of the contrast agent to 
albumin, the plot shows that Cgbound approaches a maximum value equivalent to 
Csa at high Cg. The variation of bound fraction with Cg (using the same fixed 





Figure 7.1: Modelled variation of (a) bound concentration and (b) bound fraction with 
total gadofosveset concentration, for  Csa = 0.7 mM and Ka = 11.0 mM
-1 
(gadofosveset), 0.255 mM-1 (gadoxetate) and 0.226 mM-1 (gadobenate); note 
semi log scale on (b) 
 
7.3.2 Measuring albumin binding fraction 
 
As represented in Chapter 4, the contrast-agent induced change in relaxation 
rate Ri (ΔRi) for non-binding Gd-based contrast agents, or albumin-binding 
agents in the absence of albumin, is conventionally represented by a linear 
relationship, defined by the free relaxivity (rifree) (Eq. 4.1). 
 
                [4.1] 
 
where i = 1,2.  
 
For an albumin-binding agent composite relaxivities are observed, comprising 
contributions from both the bound (ribound) and free molecule, and variations of 
Eq. 3.8 (Chapter 3) may be used (Eq. 7.3 and 7.4). 
 
                                     [7.3] 




Assuming ΔR1 and ΔR2 may be measured and r1bound, r1free, r2bound and r2free are 
known, it is possible to rearrange Eqs. 7.3 and 7.4 to give expressions for 
bound and free contrast agent concentrations (Eqs. 7.5 and 7.6). 
 
          
                      




         
                        
                             
 [7.6] 
 
Total contrast agent concentration is then defined by Eq. 7.7.  
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 [7.7] 
 
Bound, free and overall contrast agent concentrations can therefore be derived 
from measurement of ΔR1 and ΔR2. 
 
7.3.3 Measuring albumin concentration 
 
In a second step, contrast agent concentration is related to albumin 
concentration by assuming a chemical equilibrium between free and bound 
substances. Eq. 3.6 can be rearranged for Csa (Eq. 7.8). 
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Inserting Eqs. 7.5 and 7.6 into Eq. 7.8 gives an expression for total albumin 
concentration (Eq. 7.9). 
 
     
                      





                      





Eq. 7.9 therefore provides a method for deriving albumin concentration through 
measurement of ΔR1 and ΔR2, assuming fixed relaxivity and binding  
affinity values.  
 
7.3.4 Measuring bound relaxivity 
 
It remains to derive a method for measuring the relaxivity values from in vitro 
samples with known contrast agent concentrations. Free relaxivity is derived 
using Eq. 4.1, applied to a solution without albumin. An equation for bound 
relaxivity is provided in Chapter 3 (Eq. 3.10). 
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where i = 1,2.  
 
Eq. 3.10 has been represented in a similar form in a number of papers (for 
example, (37, 77, 78)). This model describes a gradual transition of binding 
fraction, from a maximum at low Cg, where observed relaxivity is dominated by 
r1,2bound, towards a minimum at high Cg, where r1,2free has the greater influence. 
As the model assumes a single binding site, the shift in emphasis from r1,2bound 
to r1,2free occurs at around Cg = Csa. 
 
Accepting that r2bound > r2free and Cgfree > 0, it follows from Eq. 3.3 and Eq. 7.4 
that, in all cases: 
 
                 [7.10] 
 
It should be noted that experimental imprecision in R2 measurement (and R1 
measurement, as Cg is calculated using Eq. 7.7) may violate this inequality, 
and may lead to calculated values of Csa ≤ 0 mM. For transverse relaxivity, 
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r2bound is much higher than r2free at all B0 values; for longitudinal relaxivity, r1bound 
is much higher than r1free at low B0 but both are effectively equivalent at very 
high B0 (89). This variation with field strength means that at low B0 any 
imprecision in R2 measurement has a much greater influence on calculated Cg 
(Eq. 7.7), therefore it is expected that the albumin-calculation model may not be 
applicable at low B0 values. 
 




The influence of experimental imprecision in the measurement of ΔR1 and ΔR2 
on calculated Csa was assessed through simulation. Estimated 3.0 T relaxivity 
values for gadofosveset and gadoxetate were applied to Eq. 3.10 with fixed Ka 
values of 11.0 mM-1 (gadofosveset) and 0.255 mM-1 (gadoxetate) to determine 
‘true’ ΔR1 and ΔR2 values within the Csa range 0.1 – 1.0 mM and at Cg = 0.1 
and 1.0 mM. These ΔR1 and ΔR2 values were then independently adjusted by 
± 10% and inserted into Eq. 7.9 in order to determine a calculated Csa. Results 
from Chapter 4 suggest that 95% confidence intervals of around ± 10% are 
realistic for measurement of relaxation rates. 
 
A further simulated study incorporated a randomly fluctuating variance in both 
ΔR1 and ΔR2 (rather than a fixed ± 10%), limited to a Gaussian distribution with 
a 5% standard deviation. Csa was calculated for each random variance and the 
process repeated 1000 times. 
 
7.4.2 In vitro validation 
 
Model validation was carried out by calculating Csa (using Eq. 7.9) for a range 
of in vitro solutions. This requires values of Ka, ΔR1, ΔR2, r2bound, r2free, r1bound 
and r1free. ΔR1 and ΔR2 were measured within the study, fixed Ka values of 
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11.0, 0.255 and 0.226 mM-1 for gadofosveset, gadoxetate and gadobenate, 
respectively, were assumed, and relaxivity values were derived from the data 
(as values for matching experimental conditions could not be found in the 
literature). 
 
In vitro solutions of gadofosveset (Vasovist), gadopentetate (Magnevist), 
gadoxetate (Primovist) and gadobenate (MultiHance) were prepared in 
phosphate-buffered saline (PBS) and bovine serum albumin (BSA) using the 
method described in Chapter 4, at concentrations shown in Table 7.1. In total, 
28 combinations of gadofosveset and BSA were prepared, along with 12 
combinations of contrast agent and BSA for gadoxetate and gadobenate. 
 





Contrast agent concentration, Cg
Contrast agent mM % (w/v) (mM)
0.0 - 0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0
0.15 1.0% 0, 0.1, 0.2, 0.3, 0.4 
0.3 2.0% 0, 0.1, 0.2, 0.3, 0.4, 0.6, 0.8, 1.0 
0.45 3.0% 0, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.9 
0.6 4.0% 0, 0.2, 0.5
0.7 4.7% 0, 0.2, 0.4, 0.6, 0.7, 0.8, 1.0 
1.0 6.7% 0,0.6, 1.0 
0.3 2.0% 0, 0.1, 0.2, 0.3, 0.4, 0.6, 0.8, 1.0 
0.45 3.0% 0, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.9 
0.7 4.7% 0, 0.2, 0.4, 0.6, 0.7, 0.8, 1.0 
0.0 - 0, 0.2, 0.5, 0.7, 1.0 
0.45 3.0% 0, 0.2, 0.5, 0.7, 1.0 
0.7 4.7% 0, 0.2, 0.5, 0.7, 1.0 
1.0 6.7% 0, 0.2, 0.5, 0.7, 1.0 
0.0 - 0, 0.2, 0.5, 0.7, 1.0 
0.45 3.0% 0, 0.2, 0.5, 0.7, 1.0 
0.7 4.7% 0, 0.2, 0.5, 0.7, 1.0 
1.0 6.7% 0, 0.2, 0.5, 0.7, 1.0 







7.4.3 In vitro data acquisition: 3.0 T 
 
Tubes were placed vertically within a head coil (SENSE-Head 8) in a 3.0 T 
Philips Achieva TX system at room temperature (approximately 21 °C). R1 
values were measured using a spin echo inversion recovery sequence with 10 
inversion times (TI = 50, 83, 136, 225, 371, 611, 1009, 1665, 2747, 4925 ms), 
TR = 5000 ms, TE = 6.2 ms. R2 values were measured using a multi-echo 
sequence with eight echo times (TE = 10, 20, 30, 40, 50, 60, 70, 80 ms),  
TR = 1000 ms. Even echoes only were used for model fitting. Additional 
parameters common to both R1 and R2 measurement: FOV = 231 x 231 mm; 
matrix size = 240 x 240 pixels; single coronal (horizontal) slice; slice  
thickness = 10 mm.  
 
7.4.4 In vitro data acquisition: 4.7 T 
 
Tubes were placed vertically in a cylindrical cradle of diameter 60 mm and 
inserted into a 63 mm quad coil in a horizontal bore 4.7 T magnet with Bruker 
console running ParaVision 5.1 software (Bruker BioSpin MRI GmbH, Ettlingen, 
Germany). Solutions were maintained at a temperature of 37 °C with warm air 
flow, verified with a fibre optic temperature probe in an adjacent water tube. R1 
values were measured using a RARE saturation recovery imaging sequence, 
with nine recovery times (57.2, 68.5, 78.5, 88.5, 103.5, 183.5, 283.5, 383.5, 
983.5 ms for gadofosveset and gadopentetate; 57.2, 68.5, 78.5, 88.5, 103.5, 
183.5, 483.5, 983.5, 2983.5 ms for gadoxetate and gadobenate) and a TE of  
11 ms. R2 values were measured using a multi-slice multi-echo (MSME) 
sequence, with 20 equally spaced TE values from 11 to 220 ms and a TR of 
1000 ms. Additional parameters common to both R1 and R2 measurement:  
FOV = 60 x 60 mm; matrix size = 256 x 256 pixels; RARE factor = 2;  
averages = 1; centric encoding; single coronal (horizontal) slice; slice  




7.4.5 Relaxation rates 
 
A circular region of interest (ROI) was drawn within each tube and the mean 
signal intensity (SI) of each ROI measured using ImageJ software (v1.42q, 
Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, 
Maryland, USA, http://imagej.nih.gov/ij/, 1997-2011). SI values at 4.7 T were 
adjusted for noise bias using a simple Rician correction (227), based on mean 
standard deviations of four background regions in each image. R1 values at  
4.7 T and R2 values at 3.0 T and 4.7 T, along with 95% confidence intervals, 
were determined from two-parameter nonlinear fits to Eqs. 7.11 and 7.12, 
respectively, using MATLAB (v 7.9, MathWorks, Natick, MA). R1 calculation at 
3.0 T included an extra term for TR (Eq. 7.13). 
 
        (        ) [7.11] 
               [7.12] 
                            [7.13] 
 
where S0 represents the fully recovered SI value and b is a factor accounting for 
imprecision in the 180° inversion pulse, applied to each ROI. 
 
Contrast agent-induced changes in relaxation rate (ΔR1,2) were calculated by 
subtracting R1,2 values for each non-Gd Csa solution (Cg = 0) from equivalent 
Gd-containing Csa solutions (Cg > 0). 
 
7.4.6 Calculating relaxivity and Csa 
 
Once ΔR1 and ΔR2 values were established, Csa calculation was a three-step 
process. In the first step, r1free and r2free were calculated by applying the linear 
model in Eq. 4.1 to the ΔR1 and ΔR2 values for the contrast agent–PBS 
samples (Csa = 0 mM), where no binding was assumed. The second step then 
used these free relaxivities and ΔR1 and ΔR2 values to calculate bound 
relaxivities. To prevent bias, bound relaxivities were calculated separately for 
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each sample by adopting a leave-one-out approach. For example, for the 
gadofosveset Csa = 0.15 mM, Cg = 0.1 mM sample, r1bound and r2bound were 
calculated using Eq. 3.10 by applying one-parameter fits to the ΔR1 and ΔR2 
values for all the other gadofosveset samples. In this way, a unique set of 
relaxivity values were calculated for each sample. 
 
The final step in the process then used the calculated relaxivities and 
measured ΔR1 and ΔR2 values for a given sample (for example, for the  
Csa = 0.15, Cg = 0.1 mM sample) and applied Eq. 7.9 to determine a calculated 
Csa value for that sample. This process was repeated for each sample until an 
individual Csa value was calculated for each sample.  
 
In addition, an overall, observed relaxivity (r1obs, r2obs) was calculated for each 
set of Csa > 0 mM samples by applying a linear fit to the contrast agent–BSA 
ΔR1 and ΔR2 values. 
 
7.4.7 Temperature adjustment 
 
Although measurements at 3.0 T were made at room temperature 
(approximately 21 °C), equivalent relaxivity values at body temperature were 
also required. To determine a method for adjusting 3.0 T relaxivities at 21 °C to 
37 °C equivalents, temperature-related relaxivity values from published studies 
were reviewed and supplemented by data acquired at other B0 values as part 
of this project.  
 
Relaxivity of the free gadofosveset molecule is expected to decrease as 
temperature increases (37). At 3.0 T, a decrease in r1free of around 25% from 
room to body temperature has been shown (77); calculated values at 4.7 T in 
Chapter 4 (Table 4.2) show a similar decrease. Measurement of gadopentetate 
r2 at 1.5 T showed a decrease between room and body temperature of 35% 
(93); assuming the free gadofosveset molecule has similar attributes to the 
non-binding gadopentetate molecule, this gives an indication of the likely 




Studies of r1bound at low field demonstrate an opposite temperature 
dependence, increasing between room and body temperature (37). However, 
this relationship alters as field strength increases (75). Data collected here at a 
range of field strengths (Chapter 4, Table 4.2) demonstrate this variation, with 
r1bound being 27% higher at 37 °C than at 21 °C at 0.47 T, but 12% lower and 
13% lower at 37 °C at 4.7 T and 9.4 T, respectively. It was not possible to find 
direct indication of the likely change in r2bound at 3.0 T. However, r2bound (unlike 
r1bound) increases with field strength (89), therefore it is suggested that if a 
similar increase in r2bound with temperature to r1bound is shown at low field (27% 
increase between 21 °C and 37 °C, Table 4.2), a larger increase may be 
expected at higher fields. 
 
On the basis of these findings, the following conversions were used to adjust 
3.0 T relaxivities from 21 °C to 37 °C: r1free = -25%; r1bound = -10%; r2free = -30%; 
r2bound = +40%. 
 
7.4.8 In vivo feasibility assessment: 3.0 T 
 
A total of seven healthy volunteers (five male, mean age 36 ± 10 years, mean 
weight 81 ± 15 kg) underwent pre- and post-contrast short-axis cardiac scans 
on a 3.0 T Siemens Skyra system at Northwestern Memorial Hospital, Chicago. 
The study was approved by the Institutional Review Board (IRB) at 
Northwestern University (IRB project number STU00061779, IRB Office, 
Northwestern University, Chicago, Illinois), with informed consent obtained from 
all participants. IRB approval did not include provision for taking blood samples, 
therefore per-volunteer measures of haematocrit and blood albumin were not 
available. 
 
Images were acquired as part of a larger study mapping flow patterns in 
thoracic aortic aneurisms (TAA) in different progression stages. Myocardial T1 
and T2 values with administration of an MR contrast agent were also acquired 
to study changes of these parameters associated with inflammatory and 
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connective tissue diseases that are in turn associated with the progression of 
TAA. A small timing bolus of 1.0 – 2.0 ml of gadofosveset (Ablavar) was used 
to establish arrival time and was followed by a main bolus of 6.2 – 8.8 ml, 
giving a total dose of 0.12 ml kg-1 (0.03 mmol kg-1). A modified Look-Locker 
inversion recovery (MOLLI) sequence (249) with motion correction (250) (field 
of view = 270 x 360 mm, matrix size = 144 x 256 pixels, flip angle = 35°,  
TR = 313.45 ms, TE = 1.13 ms, bandwidth/pixel = 975 Hz) was used for T1, 
with T1 maps created inline by the system software. This version of the MOLLI 
sequence consisted of two inversions, with three images acquired after the first 
inversion (initial effective TI of 120 ms, and RR interval added to the other two 
acquisitions), and five images acquired after the second inversion (first effective 
TI of 200 ms; 200 ms + RR for subsequent acquisitions). Images were acquired 
with a specific trigger delay to select for end diastole.  MOLLI acquisition was 
followed by a T2 mapping sequence using a single-shot T2-prepared steady-
state free precession (SSFP) acquisition with three T2-preparation echo times: 
0, 24, and 55 ms (field of view = 337 x 450 mm, matrix size = 144 x192 pixels, 
TR = 201.88 ms, TE = 1.07 ms, flip angle = 40°, bandwidth/pixel = 930 Hz). For 
all sequences, 8 mm slices were acquired at cardiac short axis base, mid and 
apex locations. Post-contrast images were acquired at up to three time points 
for each volunteer, with T2 image acquisition occurring 1 – 2 min after T1 
acquisition (Table 7.2). The mid-point between T1 and T2 image acquisitions 
was used as the post-contrast reference time.  
 
Table 7.2: Main bolus and image acquisition times for volunteers (time from first 
administration of contrast agent (timing bolus), MM:SS) 
 
Main
Volunteer bolus T1 [1] T2 [1] T1 [2] T2 [2] T1 [3] T2 [3]
#1 07:08 14:31 16:47 – – – –
#2 03:52 08:57 11:19 38:34 39:35 54:06 55:53
#3 02:35 07:10 08:10 29:12 30:15 – –
#4 04:15 29:17 31:44 – – – –
#5 08:24 41:43 43:25 – – – –
#6 03:24 23:45 25:02 28:09 29:29 39:23 40:38





ROIs were drawn within the left ventricle and within the myocardium on each 
pre- and post-contrast T1 and T2 map at the middle of the short axis view, and 
median and standard deviation values derived using MATLAB. Relaxation 
times were converted to relaxation rates and Eq. 7.7 and 7.9 used to determine 
gadofosveset and albumin concentrations, respectively. A Ka value of  
11.0 mM-1 was assumed and the temperature-adjusted 3.0 T in vitro bound and 
free relaxivities used. For albumin calculation each ROI is considered as a 
single well-mixed compartment, which is a valid assumption for the left 
ventricle, where gadofosveset is entirely intravascular, but is a simplification of 
conditions in the myocardium, where ΔR1 and ΔR2 are influenced by 






Simulated data are shown in Fig. 7.2 and 7.3. The influence on calculated Csa 
of a ± 10% variance in ΔR1 or ΔR2 is illustrated by a plot of percentage 
difference between calculated and actual Csa for gadofosveset and gadoxetate, 
at contrast agent concentrations of 0.1 mM and 1.0 mM (Fig. 7.2). A boxplot of 
percentage error in calculated Csa is shown at a gadofosveset concentration of 







Figure 7.2: Simulated effect of error in measured relaxation rate (± 10%) on calculated 
Csa at Cg = 0.1 mM (left) and 1.0 mM (right) for gadofosveset (top) and 









Figure 7.3: (a) Simulated spread of error in calculated Csa for gadofosveset when 
applying a 5% standard deviation on ΔR1,2 variability using a Gaussian 
distribution (1000 repetitions; Cg = 0.5 mM, Ka = 11.0 mM
-1, representative 
relaxivity values). Red lines represent median value, box limits are 25th and 75th 
percentiles, whiskers cover 99.3% of data points and red ‘+’ signs are outliers 
beyond this range; (b) as (a), with reduced vertical scale to highlight detail 
 
7.5.2 In vitro data at 3.0 T and 4.7 T 
 
Mean individual gadofosveset, gadoxetate and gadobenate relaxivity values 
measured at 3.0 T and 4.7 T for the range of Csa – Cg combinations are given 
in Table 7.3; standard deviations in brackets indicate the variance in calculated 
relaxivity. Calculated 3.0 T relaxivity values were acquired at approximately  
21 °C and the values adjusted to 37 °C using the method described in  




Table 7.3: Calculated relaxivity values and standard deviations (mM-1 s-1) 
 
* Temperature adjustment for 3.0 T data as described in methods (section 7.4.7) 
 
Figs. 7.4 and 7.5 show gadofosveset, gadoxetate and gadobenate model fits 
(Eq. 3.10) plotted against actual ΔR1 and ΔR2 data points for three 
(gadofosveset) or two (gadoxetate and gadobenate) Csa values at 3.0 T  
(Fig. 7.4) and 4.7 T (Fig. 7.5), using the mean individual relaxivities in  
Table 7.3, along with a linear fit to the gadopentetate data. 
 
The bound relaxivity values in Table 7.3 were based on a range of Csa values. 
Observed relaxivity values (r1obs and r2obs) were not included in this table as it 
was expected there may be an underlying relationship between observed 
relaxivity and Csa. Fig. 7.6 shows the variation in observed relaxivity with Csa at 
3.0 T and 4.7 T, based on a linear fit to ΔR1 and ΔR2 data points for the BSA 
solutions. 
 
Fig. 7.7 shows calculated bound fractions derived from ΔR1 and ΔR2 
measurements (Eqs. 7.5 and 7.7) for gadofosveset, gadoxetate and 
gadobenate, at all albumin concentrations and at 3.0 T and 4.7 T, along with 
theoretical bound fractions for each albumin concentration (Eq. 7.2). 
 
In Fig. 7.8 calculated Csa values (using Eq. 7.9) are compared to actual values 
for each solution using individually derived relaxivity values at 3.0 T and 4.7 T. 
Two data points for gadofosveset at 4.7 T, one point for gadobenate at 3.0 T 





















































































r1bound 12.2 (0.3) 11.6 (0.6) 13.9 (1.5) -10% 11.0 10.4 12.5 6.5 (0.0) 5.5 (1.4) 8.6 (4.6)
r1free 8.1 (0.3) 7.4 (0.2) 5.7 (0.1) -25% 6.0 5.6 4.3 4.5 (0.1) 5.2 (0.3) 3.6 (0.1)
r2bound 43.8 (1.0) 28.4 (2.1) 32.9 (2.8) +40% 61.3 39.7 46.1 60 (1.4) 45.8 (2.4) 54.4 (5.4)
r2free 9.7 (0.2) 8.7 (0.2) 7.6 (1.1) -30% 6.8 6.1 5.3 10.7 (1.7) 6.4 (0.1) 4.4 (0.4)




















were outside the range shown (calculated Csa more than double actual Csa). 
Four gadofosveset data points at 4.7 T violated the inequality described in  
Eq. 7.10 and gave negative values of calculated Csa, and were therefore also 
excluded. For gadofosveset, the model-derived Csa values correlate with actual 
Csa at a statistically significant level at both field strengths (Pearson correlation 
coefficients of 0.95 and 0.88 for 3.0 T and 4.7 T, respectively). If the two points 
not shown in Fig 7.8b for gadofosveset are excluded from the calculation, the 
Pearson correlation at 4.7 T increases to 0.95. For gadoxetate, a significant 
correlation between actual and calculated Csa is seen at 4.7 T, but not at 3.0 T 
(Pearson correlations of 0.89 and 0.33, respectively). For gadobenate, no 
correlation was seen between actual and calculated Csa at either field (-0.13 at 
3.0 T and -0.03 at 4.7 T); even excluding the two data points not shown in  






Figure 7.4: ΔR1 (left column) and ΔR2 (right column) values at 3.0 T (at room 
temperature) for gadofosveset (circles) and gadopentetate (squares) at Csa = 0.3, 
0.45 and 0.7 mM, and gadoxetate (diamonds) and gadobenate (stars) at  
Csa = 0.45 and 0.7 mM; error bars indicate 95% confidence intervals. 
Gadofosveset, gadoxetate and gadobenate model fits (Eq. 3.10, solid, dotted and 
dot-dash lines, respectively) are represented using mean relaxivity values  






Figure 7.5: ΔR1 (left column) and ΔR2 (right column) values at 4.7 T (at body 
temperature) for gadofosveset (circles) and gadopentetate (squares) at Csa = 0.3, 
0.45 and 0.7 mM, and gadoxetate (diamonds) and gadobenate (stars) at  
Csa = 0.45 and 0.7 mM; error bars indicate 95% confidence intervals. 
Gadofosveset, gadoxetate and gadobenate model fits (Eq. 3.10, solid, dotted and 
dot-dash lines, respectively) are represented using mean relaxivity values  







Figure 7.6: Variation of observed relaxivity (r1obs, left column; r2obs, right column) with 









Figure 7.7: Calculated bound fraction (Cgbound/Cg) based on measured data using  
Eq. 7.5 and 7.7 at Csa = 0.15 (circles), 0.3 (diamonds), 0.45 (stars), 0.7 (squares) 
and 1.0 mM (crosses); lines represent theoretical bound fraction using Eq. 7.2 
and literature binding affinity values quoted previously at Csa = 0.15 (black solid 








Figure 7.8: Spread of calculated Csa values (represented as a percentage difference to 
actual Csa) using Eq. 7.9; two data points in (b) are beyond plot scale (calculated 
Csa = 0.55 mM, actual Csa = 0.15 mM; calculated Csa = 0.63 mM, actual  
Csa = 0.3 mM); one data point in (e) is beyond plot scale (calculated  
Csa = 2.82 mM, actual Csa = 0.45 mM); two data points in (f) are beyond plot scale 
(calculated Csa = 2.41 mM, actual Csa = 0.45 mM; calculated Csa = 2.53 mM, actual 




7.5.3 Volunteer data at 3.0 T 
 
  
Figure 7.9: Example of (a) pre-contrast and (b) post-contrast T1 maps (T1 values 
calculated separately for each pixel and assigned a greyscale value) for a single 
volunteer, with left ventricle (LV) surrounded by myocardium in centre of image 
 
Examples of pre- and post-contrast T1 maps for one volunteer are shown in 
Fig. 7.9. Pre-contrast T1 values in the left ventricle and myocardium were in the 
range 1493 – 1818 ms and 1099 – 1124 ms, respectively. Pre-contrast T2 
values in the left ventricle and myocardium were in the range 117 – 158 ms and 
43 – 47 ms, respectively. 
 
Calculated gadofosveset and albumin concentrations in the left ventricle and 
myocardium are shown in Fig. 7.10, with data for all seven volunteers plotted 
against time from first bolus administration. The models for calculating 
gadofosveset (Eq. 7.7) and albumin (Eq. 7.9) concentrations used the 





Figure 7.10: Calculated (a) gadofosveset and (b) albumin concentrations in left 
ventricle (filled symbols) and myocardium (open symbols) in healthy volunteers 
at 3.0 T. Each symbol shape represents a different volunteer; values are plotted 
against time from first administration of contrast agent (to mid-point between T1 




Increased capillary leakage is symptomatic of a range of pathologies and 
healthy processes, resulting in rapid wash-in and wash-out of small molecule 
contrast agents and an increased transfer of macromolecules, including 
intravascular albumin, to the interstitial space. In vivo measurement of 
extravascular albumin content is not straightforward, although a range of 
invasive techniques are currently available. This study has explored the 
possibility of utilising albumin-binding Gd-based contrast agents to generate a 
novel and location-specific non-invasive method for measuring levels of 
albumin at moderate to high magnetic field strengths. The albumin-calculation 
model was assessed in vitro with agents binding in low and high fraction, and in 
vivo with the high-binding agent gadofosveset. Pre- and post-contrast R1 and 
R2 measurements are regularly carried out in MRI; the models presented here 
combine these changes in relaxation rate with calculated relaxivity values and a 







At low gadofosveset Cg (Fig. 7.2a), a +10% inaccuracy in ΔR1 or a -10% 
inaccuracy in ΔR2 leads to an underestimation of Csa; a -10% inaccuracy in ΔR1 
or a +10% inaccuracy in ΔR2 causes the model to behave erratically. This is 
due to the denominator in the right-hand term of Eq. 7.9 (r1bound.ΔR2 – 
r2bound.ΔR1) approaching zero at a certain combination of shifted relaxation 
rates. Results from Chapter 4 suggest that an imprecision in ΔR1 or ΔR2 of 10% 
is not unfeasible, therefore it is important that relaxation rates are measured as 
accurately as possible, particularly where low gadofosveset concentrations are 
expected. At high gadofosveset Cg (Fig. 7.2b), the model performs much more 
consistently at intermediate Csa values (0.2 – 0.8 mM): a +10% inaccuracy in 
ΔR1 or a -10% inaccuracy in ΔR2 leads to a slight underestimation of Csa; a  
-10% inaccuracy in ΔR1 or a +10% inaccuracy in ΔR2 leads to a slight 
overestimation of Csa. However, the model becomes increasingly inaccurate at 
very high or very low Csa values.  
 
For gadoxetate, an underestimation of Csa results from a +10% inaccuracy in 
ΔR1 or a -10% inaccuracy in ΔR2; an overestimation of Csa is caused by a -10% 
inaccuracy in ΔR1 or a +10% inaccuracy in ΔR2. The pattern is very similar at 
both Cg = 0.1 mM (Fig. 7.2c) and Cg = 1.0 mM (Fig. 7.2d), and shows that 
calculated Csa values using gadoxetate are more susceptible to inaccuracies in 
ΔR1 and ΔR2 at higher Cg values than gadofosveset. These simulations were 
not carried out for gadobenate, but the patterns would be expected to be very 
similar to those of gadoxetate. 
 
Although these simulations at the extreme limits of the expected range of 
imprecision in ΔR1 and ΔR2 are useful to assess model robustness, a more 
realistic simulation would incorporate a Gaussian distribution within this range 
of imprecision. Applying such a distribution to a randomly varying error in ΔR1 
or ΔR2 for gadofosveset at a concentration of 0.5 mM (Fig. 7.3), it can be seen 
that the majority of calculated Csa values have an error much less than 50%. 
142 
 
Although the median value is accurate at lower Csa values, the model begins to 
underestimate Csa at high Csa values. 
 




Calculated r1 and r2 relaxivity values at both 3.0 T and 4.7 T are in general 
agreement with previously published values (91). Using mean calculated 
relaxivity values, the model represents a good fit to gadofosveset ΔR1 and ΔR2 
data points at all Csa values (Figs. 7.4 and 7.5), suggesting that the assumption 
of a single binding site on the albumin molecule is adequate at these 
concentrations. The primary binding site is known to provide the greatest 
contribution to relaxivity (68), and it is unlikely that Cg levels would be 
sufficiently high in vivo during the post-bolus phase to necessitate inclusion of 
additional binding sites in this model (78). Although a literature Ka value of  
11.0 mM-1 was assumed for these calculations, a plot of Ka at half and double 
this value was previously shown to make very little difference to a model fit of 
similar data (Chapter 4, Fig. 4.7). It should be noted that in vitro data at 3.0 T 
were acquired at room temperature (21 °C). An increase from room to body 
temperature reduces the relaxivity of the free gadofosveset molecule slightly; 
the relationship between the relaxivity of the bound gadofosveset molecule and 
temperature is additionally influenced by field strength, and will differ for r1bound 
and r2bound. An attempt was made to adjust room temperature 3.0 T relaxivities 
to their body temperature equivalents (Table 7.3), and the resulting values are 
similar to those published elsewhere (91). r2obs shows a clear increase with 
increasing albumin concentrations at both field strengths (Fig. 7.6b), but this 
relationship is less clear for r1obs (Fig. 7.6a). 
 
The longitudinal relaxivity values presented here for gadofosveset differ slightly 
from those calculated in Chapter 4. r1free estimates are 7% and 12% lower at 
3.0 T and 4.7 T, respectively, in this chapter than estimated in Chapter 4. 
However, r1free values in Chapter 4 were based on 8 gadofosveset 
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concentrations in the range 0.25 – 5.0 mM (with four Cg values ≤ 1.0 mM); the 
r1free values in this chapter were based on 10 Cg values in the range  
0.1 – 1.0 mM. It is possible that some nonlinearity at very high Cg was 
introduced in the Chapter 4 data that may have skewed the results slightly. 
r1bound values are 2% higher and 12% lower at 3.0 T and 4.7 T, respectively, in 
this chapter than in Chapter 4. The r1bound values in Chapter 4 were calculated 
based on solutions of gadofosveset at concentrations up to 0.75 mM at a single 
fixed serum albumin concentration (Csa = 0.67 mM), whereas the r1bound values 
in this chapter are based on a range of Cg concentrations up to 1 mM at five 
Csa values between 0.15 mM and 1.0 mM. It is possible that the larger number 
of data points used for model fitting in this chapter (28 points, compared to just 
8 in Chapter 4), along with a greater range of albumin concentrations, make the 
calculated values in this chapter more precise. 
 
Gadoxetate and gadobenate relaxivity 
 
Free relaxivity values for gadoxetate and gadobenate at 3.0 T and 4.7 T are 
similar to those published elsewhere (91). It is difficult to find published 
relaxivity values for the bound molecule at these field strengths, so the 
calculated values could not be directly verified. However, observed relaxivities 
at Csa = 0.7 mM (Fig. 7.6c to 7.6f), based on a linear fit to ΔR1 and ΔR2 values 
at all Cg values, are comparable with those published elsewhere (91). 
 
r1free values for gadoxetate and gadobenate are identical in this chapter to 
those values given in Chapter 4, as the same solution combinations were used. 
At 3.0 T, there was very little difference between r1bound values in Chapter 4 and 
those given in this chapter. However, at 4.7 T, r1bound values were 20% 
(gadoxetate) and 54% (gadobenate) higher in this chapter than in Chapter 4. 
Although these differences may appear large, they are not statistically 
significant as the 95% confidence intervals overlap. The relatively large 
confidence intervals suggest it is more difficult to accurately determine bound 




As may be expected by their relative binding affinities, ΔR1 and ΔR2 values 
plotted in Fig. 7.4 and 7.5 are higher for gadoxetate and gadobenate than those 
for gadopentetate but lower than those for gadofosveset. As with gadofosveset, 
ΔR1 values decrease with field strength; however, unlike gadofosveset, where 
ΔR2 values increase between 3.0 T and 4.7 T, the ΔR2 values for both 
gadoxetate and gadobenate change very little with field strength. 
 
Bound fraction calculations 
 
Calculated bound fractions for gadofosveset are in good general agreement 
with theoretical expected values at 3.0 T (Fig. 7.7a). At 4.7 T (Fig. 7.7b), a 
consistent pattern still generally holds, although the value at Csa = 0.15 mM,  
Cg = 0.1 mM is higher than expected. For gadoxetate at 3.0 T (Fig. 7.7c), 
calculated bound fractions at Csa = 1.0 mM do not behave as expected 
(increasing, instead of decreasing, with Cg), but bound fractions at other Csa 
values are closer to their theoretical equivalents. For gadoxetate at 4.7 T  
(Fig. 7.7d), the bound fraction at Cg = 0.2 mM, Csa = 1.0 mM is higher than 
expected, but all other values are close to their expected values. For 
gadobenate at both fields (Fig. 7.7e and 7.7f), the bound fractions at the lowest 
Cg appear to be too high. This pattern of high calculated bound fraction at low 
Cg may be the result of the relative uncertainty in measured Ri0 (relaxation 
rates at Cg = 0 mM) having a greater influence on the ΔRi values at low Cg. 
 
A study which derived bound fractions from relaxation rate measurements in 
rabbits (78) found bound fractions at 300 s post-bolus of 0.77 and 0.18 for 
gadofosveset and gadobenate, respectively (at Cg values of approximately  
0.4 mM). Assuming a plasma albumin concentration of 3.9% (approximately  
0.6 mM) in rabbits (79), the points plotted in Fig. 7.7 which are closest to these 







If negative calculated Csa values resulting from measurement imprecision are 
excluded, a comparison of the remaining calculated and actual Csa values for 
gadofosveset (Fig. 7.8a and 7.6b) shows a correlation at a statistically 
significant level at both field strengths. Two further data points at 4.7 T were 
beyond the chosen scale in Fig. 7.8b, possibly as a result of imprecision in ΔR1 
and ΔR2 measurement; if these points are also excluded, the correlation at  
4.7 T is strengthened. 
 
For gadoxetate, a significant correlation between actual and calculated Csa is 
seen at 4.7 T (Fig. 7.8d), but not at 3.0 T (Fig. 7.8c). For gadobenate, no 
correlation was seen between actual and calculated Csa at either field (Fig. 7.8e 
and 7.8f); the correlation improves if the two data points not shown in Fig. 7.8f 
are excluded, but not to a statistically significant level. 
 
These results highlight the potential difficulty in applying the albumin-calculation 
model to agents such as gadoxetate or gadobenate, which bind to albumin at a 
relatively low fraction. Although the overall performance of gadofosveset in 
calculating Csa is better, there are still data points where the model is 
inaccurate or fails altogether (producing negative Csa estimates). Simulated 
errors in calculated Csa (Figs. 7.2 and 7.3) suggest the model is susceptible to 
imprecision in measured relaxation rates. 
 
Although all three albumin-binding contrast agents were assessed at the same 
contrast agent concentrations, gadobenate is used at a higher standard clinical 
dose (0.1 mmol kg-1) compared to gadofosveset (0.03 mmol kg-1) or gadoxetate 
(0.025 mmol kg-1) (Table 2.1 in Chapter 2). This higher gadobenate dose gives 
in vivo concentrations 3 – 4 times those of gadofosveset or gadoxetate, but as 
can be seen from Fig 7.1b bound fraction would only be slightly lower at these 
higher concentrations. As the albumin-calculation model was assessed here 
across a range of albumin and contrast agent concentrations, the results are 




The albumin calculation model presented here is expected to work well for 
gadofosveset at higher B0 values (3.0 T and above), where there is a large 
difference between r2bound and r2free but a small difference between r1bound and 
r1free. At low fields, r1bound is close to r2bound and the difference between ΔR1 and 
ΔR2 is small. In this case, the precision of the model input parameters would be 
insufficient to overcome the sensitivity of the model to the variability in those 
parameters. At very high B0, r1bound and r1free values for gadofosveset may be 
considered equivalent and the model may be simplified to incorporate a linear 
relationship between ΔR1 and Cg. The Cg calculation described in Eq. 7.7 may 
then be represented as Cg = ΔR1 / r1. 
 
An underlying correlation between relaxivity and protein content has been 
shown in previous studies for Gd-based contrast agents not conventionally 
described as albumin binding (41, 251). In vitro gadopentetate ΔR2 data points 
are well represented here by a linear fit (Figs. 7.4 and 7.5), suggesting no 
observable influence of weak binding on contrast agent relaxivity at the albumin 
levels used in this study. Without separate bound and free transverse 
relaxivities, gadopentetate provides no means of estimating Csa through 
application of the model presented here. The high binding affinity of 
gadofosveset makes it a much more sensitive biomarker of albumin.  
 
7.6.3 In vivo feasibility 
 
Gadofosveset-enhanced cardiovascular imaging is an area of active research 
(99, 100, 102, 106, 252), and likely to remain so in North America where the 
agent is available under the trade name Ablavar. One potential clinical 
application of the technique for calculating albumin concentration relates to 
myocardial infarction, therefore a feasibility assessment utilising human cardiac 
images was considered relevant. Cardiac imaging has the advantage of 
enabling direct comparison of calculated albumin values from blood in the left 
ventricle and from highly perfused myocardial tissue. However, before the 
147 
 
model can be assessed, motion correction and other technical challenges must 
be overcome.  
 
Pre-contrast T1 and T2 values obtained here correlate well with literature values 
in blood (253, 254) and in the myocardium (253, 255, 256). Combining data 
from seven volunteers with images acquired at a range of time points gave 
remarkably consistent values of the two model input variables ΔR1 and ΔR2, 
and supported calculation of appropriate Cg values in both the left ventricle and 
the myocardium (Fig. 7.10a). As expected, gadofosveset concentration peaks 
at the earliest time points post-bolus and decreases towards an equilibrium 
value, although this was not a dynamic acquisition therefore the temporal 
resolution is such that the bolus peak is not fully described. In the left ventricle, 
a maximum value of 0.48 mM is calculated at the earliest time points (6 – 8 min 
post-bolus), with a later calculated Cg of 0.24 mM (at 55 min post-bolus). Lower 
peak and equilibrium gadofosveset concentrations are observed in the 
myocardium (0.18 mM and 0.1 mM, respectively).  
 
At a dose of 0.03 mmol kg-1, the average blood concentration of gadofosveset 
for an 81 kg adult with a total blood volume of 6.4 L would be 0.4 mM; allowing 
for some extravasation and excretion, the gadofosveset values calculated here 
in the left ventricle appear reasonable. For a small molecule agent such as 
gadopentetate, approximately 50% may diffuse to the extravascular space from 
the blood on the first pass through the capillary bed (257). Although, as a ‘blood 
pool’ agent, gadofosveset may be expected to remain predominantly within the 
intravascular space, at high concentrations (immediately after bolus injection, 
for example) the bound fraction will be low and the extravasation rate may be 
similar to that of a conventional agent (258). A study in rabbits showed that 
61% of injected gadofosveset was still in the blood at 1 minute post-injection 
(78). Certainly, a reduction in Cg between the left ventricle and myocardium is 
expected, as noted in the relative values here. 
 
Unlike gadofosveset, albumin concentration is expected to remain consistent 
within an individual for the image acquisition duration. Although there is some 
within-subject variability (Fig. 7.10b), this variability may be representative of an 
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imprecision in the data acquisition and does not correlate with time post-bolus. 
The mean calculated albumin concentration in the left ventricle of the seven 
volunteers was 0.14 mM (range 0.10 – 0.18 mM); in the myocardium the mean 
calculated Csa was 0.03 mM (range 0.00 – 0.07 mM).  
 
A reference measure of albumin concentration was not available for 
comparison. Serum albumin levels in plasma (Csa_plasma) are expected to be 
approximately 3.5 – 5.0 g dl-1 (0.52 – 0.74 mM) (237). Assuming a haematocrit 
(Hct) of 0.42, this equates to albumin levels in whole blood of 0.30 – 0.43 mM 
(where blood concentration = Csa_plasma.(1 – Hct)). Previous studies quote 
interstitial fluid albumin concentrations (Csa_interstitial) of 0.2 – 0.4 mM (83, 241, 
242). However, the myocardium ROI contains intravascular, extravascular 
extracellular and intracellular spaces. Neglecting the intracellular space, as 
gadofosveset cannot directly access it, and assuming an extracellular volume 
fraction (EVF) of 0.25 (259), a myocardial blood volume (MBV) of 8% (260) and 
a haematocrit in capillaries (Hctcap) of 0.25, tissue albumin (Csa_tissue, 
measurable using gadofosveset) may be expected to be in the range 0.07 – 
0.11 mM (where Csa_tissue = MBV.(Csa_plasma.(1 – Hctcap)) + Csa_interstitial.(EVF – 
MBV)). This range of expected values assumes that all blood vessels in the 
myocardium are capillaries; in reality, a proportion would be larger than 
capillaries and would therefore have a higher Hct, leading to a slightly lower 
range of expected Csa_tissue values.  
 
Calculated Csa values were lower than might be expected in healthy volunteers. 
This underestimation may be partly attributable to the relative timings of the T1 
and T2 measurements used as the basis for calculating Csa. Images used for T1 
and T2 measurement were taken at different time points post-bolus, with the 
images for T2 measurement acquired 1 – 2 minutes after the images for T1 
measurement (Table 7.2). This time difference is unlikely to be an issue at the 
later time points (within the equilibrium phase). However, at earlier time points, 
where the concentration of gadofosveset is initially high and then drops rapidly, 
ΔR1 values at the T1 time point are higher than they would be at the equivalent 
T2 time point. The model is sensitive to the ratio of ΔR2 to ΔR1; if ΔR1 is 
artificially high in relation to ΔR2, the resulting calculated Csa will be lower. This 
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may account for an element of model underestimation in vivo, particularly at the 
earlier time points. Also, the gadofosveset dose was administered in the form of 
a small timing bolus followed 2 – 8 minutes later by the main bolus. Again, this 
is unlikely to have an effect at equilibrium, but could influence calculations at 
the earliest time points. 
 
Another consideration is whether the relaxivities used in Csa calculation, 
derived in vitro, were directly applicable in vivo. These relaxivities were based 
on values determined at room temperature and converted to body temperature; 
it is possible that the temperature conversion factor was slightly inaccurate. In 
addition, bovine serum albumin was used in vitro; although bovine serum 
albumin is structurally similar to human serum albumin, and BSA is often used 
as a surrogate for HSA in laboratory studies (for example, (261)), the molecules 
may display slightly different binding properties (165). There is also some 
evidence to suggest that relaxivities derived in vitro for a non-binding Gd agent 
may be higher than equivalent measurements in vivo (262), which may have 
implications for the free relaxivity measurements used in this study. 
 
It should also be noted that the bound gadofosveset fraction will be at its 
maximum in the left ventricle at equilibrium, where Csa > Cg. The model is less 
sensitive in this scenario, as confirmed by the observed underestimation of Csa 
at higher albumin concentrations in vitro at 3.0 T (Fig. 7.8a). This feature is also 
noted in the median Csa values from the simulated data (Fig. 7.3b). Although 
calculations in the left ventricle were carried out in this study, the method may 
not be appropriate or necessary here as albumin levels in blood can be readily 
measured from blood samples. The primary utility of the method may be in 
providing measurement of albumin concentration in tissue, where Cg is lower 
and Csa is conventionally difficult to acquire.  
 
A previous study using the contrast agent gadobenate (152) suggested that 
renal protein leakage could be identified by analysing tubular flow differences 
following injection of two contrast agents, one binding and one non-binding. 
Attempts have also been made to map protein levels by utilising the distinct 
field dependency of the bound and free gadofosveset molecule (termed delta 
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relaxation enhanced MR, DREMR) (263, 264), although this approach requires 
the use of additional hardware to modulate B0. The advantage of the method 
described in this study over either of these approaches is that it only requires a 
single contrast agent injection and may be readily derived from routinely 
acquired R1 and R2 measurements using conventional equipment. 
 
It should be noted that a single MRI voxel on the cardiac T1 maps represents a 
volume of tissue 1.9 x 1.4 x 8.0 mm, and on the T2 maps represents a volume 
of 2.3 x 2.3 x 8.0 mm. Each myocardial voxel will contain a combination of 
interstitial, intravascular and intracellular space, therefore it is difficult to use 
this method to isolate and measure interstitial albumin. In reality, the 
measurement of albumin will relate to tissue levels, and the interstitial 




In summary, the albumin calculation model presented here demonstrates the 
feasibility of determining in vitro serum albumin concentration using pre- and 
post-gadofosveset measurements of R1 and R2 at high B0 values. The method 
was successfully validated using in vitro samples at 3.0 T and 4.7 T. Extending 
the methodology to other albumin-binding agents, gadoxetate and gadobenate, 
was less successful, due to the low binding fraction of these agents. It was not 
possible to implement the method using the non-binding agent gadopentetate. 
 
Feasibility assessment in a small number of human volunteers was performed 
using gadofosveset, and consistent ΔR1, ΔR2 and Cg values were determined. 
Underestimation of Csa may be the result of several contributing factors, 
including the timing of the image acquisitions and translation of in vitro 
relaxivities. Due to the withdrawal of gadofosveset from the European market, it 
was not possible to complete additional in vivo experiments. However, further 
in vivo assessment is suggested, to include: simultaneous T1 and T2 
measurement; additionally acquiring images between the timing bolus and the 
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main bolus; and blood sampling to establish Hct and reference blood albumin 
levels.  
 
This novel approach may enable non-invasive assessment of extravascular 
leakage of albumin, utilising parameters acquired during routine imaging, in 
regions where implementation of invasive techniques for measurement of 
interstitial albumin is conventionally challenging. A range of potential clinical 
applications are envisaged, including assessment of myocardial infarction, 
tumour angiogenesis and response to treatment. 
152 
 




The albumin-binding affinity of gadofosveset makes this molecule unique 
amongst the gadolinium-based clinically approved MRI contrast agents. 
Binding prolongs its intravascular retention and increases the relaxivity of the 
agent, primarily through reduction of the rotational correlation time. However, 
the fraction of gadofosveset that binds varies with concentration and the 
relaxivities of the bound and free molecules display differential responses to 
variations in field strength and temperature. 
 
Although originally intended as an assessment of the in vivo use of 
gadofosveset for dynamic contrast-enhanced MRI studies, the lack of 
availability of gadofosveset due to its withdrawal from the European market 
(shortly after the project commenced) limited the extent to which in vivo studies 
could be carried out. As a result, the aims of the project were adjusted to 
incorporate further in vitro characterisation of gadofosveset and other albumin-
binding agents, along with the development of a technique that would enable 
accurate measurement of a vascular input function which may be of value in 
future tracer kinetic studies. 
 
The first aim of this study, therefore, was to address gaps in the current 
gadofosveset literature, by determining the relaxivity of the bound and free 
molecule across a range of field strengths, and at two temperatures. In 
addition, the study addressed the issue of binding sites, by comparing models 
incorporating one, two and three bound molecules at a fixed albumin 
concentration, and assessed the general influence of binding by measuring 
relaxation rates and bound fractions at a range of contrast agent and serum 




The second aim of the study was to assess several novel techniques for 
exploiting the albumin-binding nature of gadofosveset. This included 
developing a method for combining blood sampling and spectroscopic 
techniques, which may enable accurate gadofosveset concentration 
measurement in small mammals immediately following bolus injection. These 
measurements may be converted to a vascular input function for use in tracer 
kinetic modelling. In addition, the possibility of combining the albumin-binding 
properties of gadofosveset with the macromolecule-sensitive imaging technique 
of spin locking was explored, along with the feasibility of using gadofosveset as 
a biomarker for tissue albumin. 
 
A third aim of the study was to extend these in vitro experiments to two other 
albumin-binding agents, gadoxetate and gadobenate. The lower binding affinity 
of these agents gave an opportunity to compare the properties of high- and 
low-binding agents, and determine the extent to which novel techniques 
suggested for gadofosveset may also be appropriate for gadoxetate  
and gadobenate. 
 
8.1.1 Experimental results: Relaxivity 
 
Bound, free and observed longitudinal relaxivity values were calculated for 
gadofosveset at field strengths ranging from 0.47 T to 9.4 T at room and body 
temperature. The general relationship between gadofosveset relaxivity and field 
strength has been shown in previous studies and was confirmed with these 
results:  
 The longitudinal relaxivity of the free molecule is low at low field and 
reduces slightly with field strength. 
 The longitudinal relaxivity of the bound molecule is high at low field but 
reduces rapidly with field strength, and is equivalent to the relaxivity of the 
free molecule at high field.  
 The transverse relaxivity of the bound molecule increases with field 




Calculated bound and free relaxivities for gadoxetate and gadobenate are 
similar to gadofosveset (a direct result of the similarity of their core structures, 
as predicted by basic contrast agent theory) and display a similar variation with 
field strength. Differences in observed longitudinal relaxivity are due to the 
significantly higher albumin binding affinity for gadofosveset than for 
gadoxetate or gadobenate.  
 
Variations in relaxivity with temperature may have implications for translation of 
in vitro results. Measurements at room and body temperature suggest that, 
within this general temperature range:  
 Bound longitudinal relaxivity increases with temperature at low field but 
has little variation with temperature at high field.  
 Bound transverse relaxivity increases with temperature at all fields.  




 Separate relaxivities of the bound and free molecule at 3.0 T and above 
have not previously been published for gadofosveset, gadoxetate  
or gadobenate.  
 The variation of bound relaxivity with temperature has not previously 
been shown at high field. 
 
8.1.2 Experimental results: Bound fraction 
 
Binding has been shown to significantly alter observed longitudinal relaxivity at 
low field (where bound relaxivity is much higher than free relaxivity) but has 
little influence on observed relaxivity at high field (where bound and free 
longitudinal relaxivities are effectively equivalent). A comparison of measured 
gadofosveset relaxation rates at low field showed significantly higher relaxation 
rates in serum albumin (at a concentration of 0.67 mM) than in mouse plasma. 
This is a direct reflection of the difference in albumin concentration between the 
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two solutions. At high field, relaxation rates for serum albumin were similar to 
those for mouse plasma, due to the similarity of bound and free relaxivities. 
This may have implications for using the results of pre-clinical studies in small 
mammals carried out at high field to predict the outcome of human clinical 
studies at lower fields.  
 
Calculated bound fractions based on measured relaxation rates are close to the 
values predicted by theory, with bound fraction being highest at lowest contrast 
agent concentration and increasing with albumin concentration. 
 
Novel findings: 
 To the author’s knowledge, a comparison of relaxation rates for 
gadofosveset in serum albumin and mouse plasma has not previously been 
carried out at high field.   
 The method for calculating bound fraction from measured longitudinal 
and transverse relaxation rates has not previously been reported. 
 
8.1.3 Experimental results: Binding sites 
 
At low field, model-derived relaxation rates were lower than measured values at 
high gadofosveset concentration. To compensate for this potential 
underestimation it may be necessary to account for the influence of additional 
binding sites at low field, particularly at higher gadofosveset concentrations. A 
proposed method for including a second and/or third binding site, according to 
gadofosveset concentration, improved the model fit to measured relaxation 
rates at 0.47 T, but had little influence at higher fields. Inclusion of an additional 
binding site makes very little difference to the model fits for gadoxetate or 
gadobenate, due to the lower bound fraction for these agents. Although 
gadobenate has a higher approved clinical dose, it is unlikely that 







 The method for including additional binding sites is a novel variation of 
an existing model.  
 To the author’s knowledge, a relaxation rate model incorporating two 
binding sites has not previously been applied to gadoxetate or gadobenate 
measurements. 
 
8.1.4 Experimental results: Gadolinium measurement 
 
A method was developed to accurately determine gadolinium levels in micro-
samples of blood spotted onto card, using inductively-coupled plasma mass 
spectrometry. This technique requires a very small quantity of blood 
(approximately 10 – 12 μL) per sample, making it ideal for use in small 
mammals, and its accuracy was demonstrated for mouse blood samples spiked 
with gadofosveset. The proposed method has the potential to capture the first 
pass of a bolus of contrast agent in a small mammal. 
 
Novel findings: 
 The combination of acquiring blood samples using dried blood spotting 
and analysing the gadolinium content using ICP-MS is novel, although 
previous studies have used ICP-MS to measure gadolinium directly from 
blood samples. 
 
8.1.5 Experimental results: Spin locking 
 
Applying spin locking to gadofosveset samples at a high magnetic field 
produces significantly higher relaxation rates compared with longitudinal 
relaxation rates at the same field. The difference between spin-lock relaxation 
rates in the presence and absence of albumin is comparable with the difference 






 The experimental results presented here are novel and form the basis of 
the first published paper combining spin locking with gadofosveset. 
 
8.1.6 Experimental results: Albumin biomarker 
 
A suggested model for calculating albumin concentration, based on longitudinal 
and transverse relaxation rate measurements, demonstrated a significant 
correlation between calculated and actual values at 3.0 T and 4.7 T for 
gadofosveset, although supplementary simulations suggest the model may be 
vulnerable to imprecision in relaxation rate measurement at low gadofosveset 
concentrations. Extending this model to gadoxetate and gadobenate, a 
significant correlation between calculated and actual albumin concentration 
was found for gadoxetate at 4.7 T, but not at 3.0 T; no correlation was seen for 
gadobenate at either field. It is suggested that the low bound fraction for these 
two agents increases the sensitivity to imprecision in the relaxation rate 
measurements. Although albumin calculations were lower than expected when 
the model was applied to in vivo gadofosveset data from healthy volunteers, 
actual albumin concentrations were not available for comparison. 
 
Novel findings: 
 The described method for calculating albumin concentration from 
measured gadofosveset relaxation rates, and its potential application as a 
biomarker for albumin, has not previously been published. 
 
8.2 STUDY LIMITATIONS 
 
The primary limitation of this study, resulting from the withdrawal of 
gadofosveset from the European market soon after the project commenced, 
was the lack of in vivo data. Although in vitro samples were created at 
physiologically applicable concentrations, it was not possible to validate the 
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method for blood sampling (described in Chapter 5) or to assess the feasibility 
of applying spin locking (Chapter 6) in vivo. Through collaboration with a 
research team at Northwestern University, Chicago, some human volunteer 
images were acquired, enabling in vivo assessment of the albumin calculation 
model described in Chapter 7. Although calculated gadofosveset 
concentrations were within the expected range and it was possible to calculate 
albumin concentrations, comparison of these calculated values against a 
reference standard was not possible as blood samples were not taken at the 
time of imaging. 
 
A second limitation was that 3.0 T in vitro data were acquired at room 
temperature only, due to the lack of an available heating mechanism for the 
clinical scanners. A method for converting room temperature relaxivities to 
body temperature was provided (Chapter 7), but this was based partly on 
extrapolation of relaxivities at other field strengths. In general, room and body 
temperatures did not match exactly across all field strengths, although this 
variation is unlikely to have a large influence on the measured results. 
 
A third limitation was that in vitro samples were created using bovine serum 
albumin (BSA) rather than human serum albumin (HSA). Unlike in animal 
plasma, where albumin concentration may vary considerably by species, in 
vitro samples were created at fixed albumin concentrations, therefore any 
potential difference between results presented here and those acquired using 
HSA would be solely attributable to differences in binding characteristics. BSA 
is often used in laboratory experiments as a surrogate for HSA, and the two 
molecules are structurally very similar. 
 
8.3 AREAS FOR FURTHER INVESTIGATION 
 
As mentioned within the study limitations, the lack of availability of 
gadofosveset in Europe has limited the extent to which in vivo experiments 
could be carried out. A natural extension of the work presented here would be 
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to carry out these in vivo experiments in a location (such as North America) 
where gadofosveset is readily available. In Chapter 5 (section 5.5.2) a 
suggested methodology for in vivo validation of the blood sampling technique is 
provided, for use in small mammals following injection of gadofosveset. If in 
vivo validation were carried out, a vascular input function could be created and 
assessed against signal intensity measurements acquired using a dynamic MRI 
sequence. A representative vascular input function is essential in tracer kinetic 
modelling for determining accurate physiological parameters. 
 
An extension of this work may involve improved use of the kinetic 
characteristics of the bound albumin molecule. General pharmacokinetic 
models do not currently accommodate the separate contributions of the bound 
and free gadofosveset molecule, resulting in potentially inaccurate calculated 
physiological parameters. Adapting existing kinetic models to improve perfusion 
and permeability quantification may facilitate the use of gadofosveset in the 
assessment of tumour angiogenesis and the diagnosis, staging and treatment 
response monitoring of a range of tumour types, for example. In this respect, 
bound and free relaxivity values calculated in this study at field strengths of  
3.0 T and above may be of particular value. 
 
The in vivo data used in the albumin calculation model (Chapter 7) may have 
benefited from alterations in the T1 and T2 acquisition times. Collection of blood 
samples for measurement of blood albumin concentration would be useful to 
enable a direct comparison with calculated blood albumin concentrations. In 
addition, the sensitivity of the model could be assessed by repeating the study 
in other tissue, where albumin levels may be expected to be low or high. 
Applying the model to regions where images are not influenced by cardiac or 
respiratory motion may also be of benefit for model assessment. 
 
Differences in gadofosveset binding between HSA and BSA could be assessed 




8.4 CONCLUSIONS AND FINAL REMARKS 
 
This study has contributed to the existing knowledge base for gadofosveset by 
assessing the relaxivity response to changes in contrast agent and albumin 
concentration at both low and high field. In addition, novel techniques and 
potential clinical applications have been suggested and their validity assessed 
in vitro. The lower binding affinities of gadoxetate and gadobenate limit the 
extent to which these techniques may be of value for these agents. Although 
longitudinal relaxivity is increased by binding to albumin at low fields, it is 
unlikely that separate bound and free relaxivities need to be considered for 
gadoxetate or gadobenate at higher fields.  
 
Without additional in vivo studies to support the positive gadofosveset results 
seen in vitro it is difficult to estimate the clinical value of implementing such 
techniques. However, it is suggested that the unique characteristics of 
gadofosveset warrant further in vivo investigation. 
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Appendix A: Contrast agent equations 
A.1 Inner sphere relaxation 
 
Longitudinal and transverse inner sphere relaxation rates (R1IS and R2IS, 
respectively) may be determined using Eq. A.1 and A.2 (34). The parameter q 
represents the number of bound water nuclei per Gd ion (also known as the 
hydration number); for most Gd-based agents, q = 1. 
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where Pm is the mole fraction of the bound water nuclei, τm is the lifetime of a 
water molecule in the inner sphere of the complex (this is the reciprocal of 
the solvent exchange rate, kex), R1m and R2m are proton relaxation rates in 
the bound water, and Δωm is the chemical shift difference between the 
bound water and the bulk water. 
 
Dipole–dipole (DD) and scalar (SC) components of the bound water relaxation 
rates (Eq. 2.11) may be calculated using the Solomen–Bloembergen–Morgan 
equations (Eq. A.3 – A.6) (34). 
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where γI is the nuclear gyromagnetic ratio, g is the electron g-factor, μB is the 
Bohr magneton, r is the electron spin–proton distance, ωI and ωs are the 
nuclear and electron Larmor frequencies, respectively (and ω = γB), and A/  
is the scalar coupling constant between the electron at the paramagnetic 
centre and the proton of the coordinated water molecule. τc and τe represent 
the dipole–dipole and scalar correlation times, respectively. 
 
The electronic relaxation rates in Eq. 2.12 and 2.13 also vary with the magnetic 
field; for Gd3+ complexes they are usually interpreted in terms of a zero-field-
splitting (ZFS) interaction (Eq. A.7 – A.9) (35). 
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Δ2 is the mean-square ZFS energy and τv is the correlation time for the 




A.2 Outer sphere relaxation 
 
Second and outer sphere are usually combined into a single relaxation rate, 
RiOS (Eq. A.10 – A.14) (34). 
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where k = 1,2, NA is Avagadro’s constant (6.02 x 10
23), M is the concentration 
of the complex, a is the distance of closest approach of the water molecule and 
the complex (spins I and S), D is the sum of the diffusion constants of water 
and the complex, τD is diffusional correlation time (τD = a
2/D). Spectral densities 








Figure B.1: Measured relaxation rates (R1) for gadofosveset, gadoxetate and 
gadobenate in PBS (left column) and BSA (right column) at body temperature 
(approximately 37 °C) at 0.47 T and 4.7 T (all agents), and at 9.4 T (gadofosveset 







Figure B.2: Modelling n = 1 – 3 binding sites at all field strengths at body temperature, 
using Eq. 4.3a–c. Circles represent measured gadofosveset data points; solid line 
is original model (single binding site, Eq. 4.3a, Ka1 = 11.0 mM
-1); dotted line also 
includes a second binding site (Eq. 4.3b, Ka2 = 0.86 mM
-1); dashed line also 
includes a third binding site (Eq. 4.3c, Ka3 = 0.26 mM
-1); the same relaxivity 







Figure B.3: Modelling n = 1 – 2 binding sites for gadoxetate and gadobenate at body 
temperature and at 0.47 T and 4.7 T, using Eq. 4.3a–b. Circles represent 
measured data points; solid line is original model (single binding site, Eq. 4.3a, 
Ka1 = 0.255 mM
-1 (gadoxetate) and 0.226 mM-1 (gadobenate)); dotted line also 
includes a second binding site (Eq. 4.3b, Ka2 = Ka1, as no literature binding 
affinity values could be found for a second site); the same relaxivity values (from 





Appendix C: Derivation of maximum bound fraction 
 
The steps to determine the bound fraction (fb) as contrast agent concentration 
approaches zero, from Eq. 3.3 and 3.6, are shown below. 
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Replacing Cgfree in Eq. 3.6 using Eq. 3.3: 
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Multiplying out the denominator and moving terms across the equals sign: 
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Grouping the Cg and Cgbound terms: 
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fb is Cgbound/Cg, therefore dividing Eq. C.3 by Cg gives: 
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Rearranging Eq. C.4 gives: 
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The bound fraction as Cgbound approaches 0, equivalent to the maximum bound 
fraction (fbmax), is then given by: 
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